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Chapter 1 
INTRODUCTION 
For patients with symptomatic obstructive disease of peripheral arteries, 
Dotter and Judkins 1 introduced the percutaneous approach of treatment in 
1964, using coaxial catheters to enlarge the obstructed lumen. In 1974 
Gruntzig and Hopff 2 improved this technique by introducing dilatation 
balloon catheters. Since then, percutaneous transluminal angioplasty (PTA) has 
been considered the most important technique to treat patients with 
obstructive vascular disease. However, the long-term results of PTA in 
femoropopliteal arteries are disappointing with 1-year restenosis rates of 4 7% 
to81%.3' 5 
For objective evaluation of the location and severity of obstructive vascular 
disease different imaging techniques are available. The most important of these 
imaging techniques is angiography, which displays a silhouette of the lumen. 
This imaging technique is considered the gold standard, but has the 
disadvantage of being an invasive imaging technique. External ultrasound is a 
non-invasive imaging technique which, in addition to information on lumen 
dimensions, gives information on vessel wall thickness of superficially located 
arteries. Over the past decade, intravascular ultrasound (IVUS) has become an 
acknowledged technique for imaging coronary and peripheral arteries. 6'7 The 
advantage oflVUS, as compared to angiography or external ultrasound, is that 
this technique provides a cross-sectional view of the vessel with information 
on lumen, vessel and plaque area at high resolution. Serial IVUS studies have 
shown that, following successful intervention, vascular remodeling (vascular 
shrinkage) is an important factor in the development of restenosis in addition 
to plaque growth.8'9 As a consequence, treatment modalities should be 
developed that potentially might reduce vascular shrinkage in addition to other 
ways of treatment that may inhibit plaque growth. 
The aim of the IVUS studies presented in this thesis was to provide insight in 
new alternative treatment modalities including endografts, intravascular 
radiation (i.e. endovascular brachytherapy) and statin therapy on the outcome 
of peripheral intervention in patients with obstructive disease of the 
femoropopliteal artery. 
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Endografts 
To eliminate vascular shrinkage after successful vascular intervention, stents 
have been introduced. The use of stents resulted in a reduction in restenosis 
rate in coronary arteries. 10 However, stents used in femoropopliteal arteries did 
not improve restenosis rates; both plaque growth and stent area reduction 
resulted in lumen area reduction, particularly at stent edges and stent 
junctions."·" In order to diminish the vascular response to mechanical 
intervention, a polytetrafluoroethylene (ePTFE) endograftwas developed. This 
endograft covers the damaged arterial wall with an endoprosthesis after 
vascular intervention. Chapters 2 and 3 present the IVUS findings in patients 
that were treated with this endograft 6 months and 2 years after endograft 
placement, respectively. Long-term clinical follow-up data of all patients 
treated with this ePTFE endograft are presented in Chapter 4. 
Endovascular brachytherapy 
To diminish the vascular response to intervention (PTA), endovascular 
brachytherapy (EBT) was introduced. The effective use of EBT to prevent 
plaque growth in animal models after balloon arterial injury has been 
demonstrated in preclinical studies using histology as the gold standard. 13'14 
Similarly, there is clinical and angiographic evidence that EBT reduces 
restenosis following percutaneous transluminal coronary angioplasty with or 
"th I · · 15- 18 Ch 5 d "b W1 out stent p acement m coronary artenes. apter escn es a 
randomized IVUS study aimed at determining the precise effect of 
endovascular radiation as an adjunct to PTA in femoropopliteal arteries at 
6-months follow-up. 
Starin therapy 
In the early 1990s the newest class of cholesterol-lowering drugs, HMG-CoA 
reductase inhibitors (i.e. statins), became available for primary and secondary 
prevention of cardiovascular disease. 19'2° Clinical studies using angiography 
and extemal ultrasound have shown that statin therapy may reduce the 
progression of atherosclerosis or even induce regression. 21 '22 However, the 
benefits of statin therapy on the primary and secondary prevention of 
cardiovascular disease cannot be solely attributed to the reduction in 
cholesterol levels and the reduction in progression of atherosclerosis. More 
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recent studies reported that statin therapy may exert a direct antiproliferative 
effect on the arterial wall 23 and may enhance endothelial function.24 Before 
performing our first IVUS study to assess the effect of statin therapy, some 
validation studies were needed in order to test a newly developed automated 
contour analysis system. With this system three-dimensional (3-D) 
reconstructions of cross-sectionallVUS images can be obtained providing data 
on plaque, lumen and vessel volumes. Before this automated contour analysis 
system was used in a clinical setting, the reproducibility of volume 
measurements obtained with the system was determined (Chapter 6). Chapter 7 
presents a study to assess the reproducibility of circumferential arc and length 
measurements of calcified lesions seen with IVUS and the changes observed 
at 1-year follow-up. Chapter 8 presents a study using the automated contour 
analysis system to assess the progression of atherosclerosis and vascular 
remodeling of femoropopliteal arteries at 1-year follow-up. Chapters 9 and 10 
present longitudinal IVUS studies conducted to assess the effect of 1-year 
treatment with statin therapy on both plaque growth and vascular remodeling 
in femoropopliteal arteries not treated with PTA (Chapter 9) and in 
femoropopliteal arteries subjected to PTA (Chapter 10). In Chapter 11 the 
rationale and design of a future randomized IVUS study aimed at assessing the 
dose-dependent effect of statin therapy on both plaque growth and vascular 
remodeling is described. Finally, Chapters 12 and 13 present the summary of 
this thesis. 
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IVUS Study of Femoropopliteal Endograft 
ABSTRACT 
Purpose: To use intravascular ultrasound (IVUS) to document changes in 
vascular dimensions after placement of a balloon-expandable endograft. 
Methods: Thirteen patients (9 men; mean age 62 years, range 4 7-75) treated 
with an investigational polytetrafluoroethylene endograft for obstructive 
disease of the femoropopliteal segment were studied with IVUS immediately 
after endograft implantation and at follow-up. Corresponding IVUS cross 
sections were analyzed for changes in lumen, vessel, and plaque areas seen 
inside the endograft, in the anastomotic segment, and in the remote arterial 
segment. 
Results: A mean 6-month (range 1.5-9) follow-up was completed in 12 
patients. Matched IVUS cross sections derived ftom within the endograft 
(n=l2) and at the endograft edges (n=23) showed no change in lumen area 
(LA) in 17, reduction in 11, and dilatation in 7. Median changes within the 
endograft ( + 3%) were not significant (p=0.28) and no neo-intima was found. 
Cross sections obtained at the anastomotic segment revealed a significant 
increase in LA (85%, p<0.001), which was associated with a significant increase 
in both vessel area 0/A) (42%, p<0.001) and plaque area (PLA) (15%, 
p=0.003). In the remote arterial segment, the change in LA was minimal (6%, 
p=0.07), as were changes in the VA (9%, p=0.04) and PLA (10%, p=0.07). 
Conclusions: Following endograft placement, luminal changes within the 
endograft, at the endograft edges, and at the remote arterial segments were 
minimal. Intimal hyperplasia was not observed in the endograft. The distinct 
LA increase at the anastomotic segments was determined by the extent of VA 
and PLA change. 
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INTRODUCTION 
The long-term results of balloon angioplasty in femoropopliteal arteries are 
disappointing, with 1-year patency rates ranging from 47% to 81%. 1- 6 
Intravascular ultrasound (IVUS) studies performed in coronary arteries have 
shown that vascular remodeling is an impotrant factor in the development of 
restenosis, in addition to intimal hyperplasia. 7-9 By eliminating this geometrical 
remodeling, stents have reduced restenosis in coronary vessels. 10 However, 
stents used in the femoropopliteal arteries did not improve patency rates. Both 
intimal hyperplasia and stent area reduction resulted in lumen area (LA) 
reduction, particularly at stent edges and stent junctions. 11.12 To diminish the 
vascular response to intervention, a polytetrafluoroethylene (ePTFE) endografr 
was developed that covers the damaged arterial wall with an endoprosthesis. 
The aim of this study was to use angiography and IVUS to assess the vascular 
response following endovascular graft placement in the femoropopliteal 
segment. 
METHODS 
From October 1996 to August 1997, 13 patients (9 men; mean age 62 years, 
range 4 7-7 5) with obstructive disease of the femoropopliteal segment were 
selected for treatment with an endovascular graft. Patients were known to have 
disabling claudication (n=12) or critical ischemia (n=1). Five patients had a 
stenotic lesion (5.2-cm mean length) and 8 had an occlusion (7 .5-cm mean 
length). The lesion length was estimated from the angiograms. Four patients 
underwent previous vascular interventions (3 balloon angioplasties and 1 
femoropopliteal bypass). The preoperative mean ankle-brachial index was 0. 7 
at rest and 0.42 afrer exercise. Patients were included in the study afrer giving 
informed consent for the procedure and the invasive follow-up study. 
The endografr used was a balloon -expandable thin -walled ePTFE graft 
(Enduring, W.L. Gore & Associates, Flagstaff, AI., USA) with a 4-mm outer 
diameter (Figure 1). The graft wall contains ring-shaped ePTFE reinforcements 
that are integrated in the material. It can be custom cut in any length, and 
depending on the diameter of the balloon used, the graft can be expanded 
from 4 to 7 mm (inner diameter). This maneuver fixes the graft to the arterial 
wall over its entire length and provides a proper seal. The rings are 
compression resistant, comparable to self-expandable stents. 
17 
IVUS Study of Femoropopliteal Endograft 
Figure 1. Samples of the 
enduring vascular graft 
(lower example partially 
dilated). 
Procedures were performed in the operating theater under fluoroscopic, 
angiographic, and IVUS guidance. IVUS examinations used a 4.3-F 
motor-driven imaging catheter with a 30-MHz transducer (Endosonics, 
Rijswijk, The Netherlands). The IVUS transducer was advanced beyond the 
diseased arterial segment, and cross-sectional images were obtained during 
manual pullback of the catheter. The catheter position was documented using 
a displacement-sensing device13 and fluoroscopy, with a radiopaque ruler as 
reference. Images were stored on an S-VHS videotape. Arterial access was 
gained through a surgical cutdown of the common or superficial femoral 
artery. In 5 patients with a stenosis and in 5 of the 8 patients with an 
occlusion, a hydrophilic guidewire was positioned beyond the lesion. 
Predilation with a 5- to 7 -mm balloon was performed to facilitate passage of 
a 14-F sheath. In the 3 remaining occlusion patients, remote endarterectomy 
with a MollRing Cutter (Avatar, Inc., Portola Valley, CA, USA) was necessary 
before the guidewire was advanced. 14' 15 The endograft was cut to match the 
length of the entire predilated segment, or in the case of a remote 
endarterectomy, with a 1-cm overlap. The endograft was mounted on a 
dilation balloon catheter and positioned in the femoropopliteal segment under 
fluoroscopic guidance. The sheath was retracted and the endograft expanded. 
Care was taken that the adjacent arterial segments were not dilated. 
18 
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Figure 2. Matched intra-
vascular ultrasound cross 
sections of a femoropopliteal 
segment after endograft 
placement (left panel) and at 
follow-up (middle panel) 
paired with the corresponding 
follow-up angiogram (right 
panel). Note the absence of 
plaque inside d1e endograft. 
A distinct dilatation seen at 
the anastomotic segments (A, 
E, F) was absent within the 
endograft (B, proximal edge; 
C, inside endograft; and D, 
distal edge). The angiogram 
showed dilatation in the 
anastomotic segments, bur 
the change was less 
prominent. 
The follow-up protocol included single plane angiography and IVUS imaging 
6 months after intervention. In cases of graft occlusion, a control angiogram 
and IVUS were performed after successful fibrinolysis. The single plane 
angiograms obtained after placement of the endograft and at follow-up were 
compared by a radiologist blinded to the IVUS results. By visual inspection, 
the change in the endograft lumen, the adjacent arterial segments (i.e., 
anastomotic segment), and the remote arterial segment(> 2 em) was defined as 
no change, reduction, or dilatation. 
rvus cross sections obtained after endograftplacement and at follow-up were 
19 
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matched precisely using the radiopaque ruler and catheter 
displacement-sensing device. 13 The following IVUS images were selected from 
each patient for quantitative analysis: 
1. the site within the endografr with the smallest LA; 
2. the proximal and distal endograft edges; 
3. 0.5 em from the arterial segment adjacent to the endografr (i.e., 
anastomotic segment); 
4. the site with the largest change in LA in the anastomotic segment; and 
5. 2 em remote from the site in (4) (above). 
The selected cross sections were digitized and analyzed for LA, VA, and PLA. 
If no intimal hyperplasia was evident in the endograft or at the edges (PLA=O), 
LA was equal to VA. The matched IVUS cross sections were grouped 
according to the change in LA at follow-up and classified as no change 
(difference <10%), reduction(> 10% decrease), or dilatation(> 10% increase). 
Statistical analysis 
Changes in LA, VA, and PLA were expressed as median values (ranges). The 
1-sample t test was used to evaluate the null hypothesis that there was no 
change in LA, VA, and PLAin follow-up. A p value of <0.05 was considered 
statistically significant. 
RESULTS 
The mean length of the endograft used was 20 em (range 13 to 34). The 
angiographic and IVUS studies from 12 patients were acquired after a mean 
6-month follow-up (range 1.5-9.0). One endograft, which had been 
implanted subintimally, occluded within 1 week due to a dissection distal to 
the graft; imaging follow-up was not available in this patient. In 8 patients, the 
endografts remained patent during follow-up (minimum 6 months), but the 
other 4 endografts occluded at 1.5, 2, 4, and 7 months. These were successfully 
recanalized using thrombolysis; 2 remained patent, but the other 2 reoccluded 
after 3 and 5 months. 
From the 12 endografts, 20 (8 proximal, 12 distal) anastomotic segments and 
10 remote arterial segments were available for angiographic analysis. Compared 
to the postimplantation angiogram, the follow-up image showed no change in 
the endograft lumen, at the edges of the endograft, or in the arterial segments 
20 
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Table 1 Differences at Follow-up in d1e Lumen, Vessel, and Plaque Areas at 4 Endograft 
Locations as Assessed by IVUS* 
Locations n Lumen Area Vessel Area Plaque Area 
Inside endograft 12 3% (p-0.28) 
(-22% to 45%) 
No lumen change 4 0% (-5% to 5%) 
Reduction 3 -18% (-22% to -14%) 
Dilatation 5 22% (12% to 45%) 
Endograft edge 23 -6% (p=0.19) 
(-26% to 63%) 
No lumen change 13 -5% (-9% to 6%) 
Reduction 8 -18% (-26% to -12%) 
Dilatation 2 38% (13% to 63%) 
Anastomotic 22 85% (p<0.001) 42% (p<0.001) 15% (p<O.OO 1) 
segment (-56% to 339%) (-16% to 130%) (-11% to 158%) 
No lumen d1ange 1 7% 2% -8% 
Reduction 4 -41% 7% 69% 
(-56% to -28%) (-16% to 27%) (17% to 156%) 
Dilatation 17 100% 49% 13% 
(29% to 339%) (21% to 130%) (-11% to 158%) 
Remote arterial 10 6% (p·0.07) 9% (p-0.04) 10% (p-0.07) 
segment (-9% to 53%) (-6% to 46%) (-17% to 65%) 
No lumen change 6 2% (-9% to 9%) 4% (-6% to 31%) 10% (-3% to 65%) 
Reduction 0 
Dilatation 4 28% 19% 10% 
(13% to 53%) (-3% to 46%) (-17%to58%) 
* Values are expressed as median (range); n "" number of cross sections analyzed 
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Table 2 Differences at Follow-up in the Lumen, Vessel, and Plaque Areas at d1e Endograft 
Edges and Adjacent Arterial Segments as Assessed by IVUS* 
Locations n Lumen Area Vessel Area Plaque Area 
Proximal endograft 11 -6% (-26% to 13%) 
edge 
No lumen change 8 -4% ( -9% to 6%) 
Reduction 2 -20% (-26% to -14%) 
Dilatation 1 13% 
Distal endograft 12 -10% (-22% to 63%) 
edge 
No lumen change 5 -5% (-7% to 1%) 
Reduction 6 -18% (-22% to -12%) 
Dilatation 1 63% 
Proximal 10 93% 41% 26% 
anastomotic (-56% to 339%) (-16% to 100%) (-10% to 156%) 
segment 
No lumen change 1 7% 2% -8% 
Reduction 2 -51% 5% 87% 
(-56% to -45%) (-16% to 27%) (17% to 156%) 
Dilatation 7 100% 48% 10% 
(75% to 339%) (32% to 100%) (-10% to 56%) 
Distal anastomotic 12 82% 45% 25% 
segment (-38% to 188%) (-13% to 130%) (-11% to 158%) 
No lumen change 0 
Reduction 2 -33% (-28% to -38%) 7% (-13% to 27%) 69% (56% to 82%) 
Dilatation 10 90% 54% 18% 
(29% to 188%) (21% to 130%) (-11% to 158%) 
*Values are t}..1Jressed as median (range); n= number of cross sections analyzed 
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Figure 3. Changes in plaque and vessel area measurements at different locations within the endograft. 
Remodeling produced minimal change at the endograft edge and increases in plaque and vessel areas in 
the majority of the anastomotic segments. At the remote arterial segments, the changes were less 
prominent. 
remote from the endograft. Of the 20 anastomotic segments studied, no 
lumen change was encountered in 9, a reduction in 2 (<1 em), and an increase 
in 9 ( <2 em) (Figure 2). No change in LA was observed in the remote arterial 
segments. 
Changes in LA, VA, and PLA assessed with IVUS are summarized in Tables 
1 and 2 and Figure 3. LA change was minimal both inside the endografr (3%, 
p=0.28) and at the endograft edge (-6%, p=0.19). No hyperplasia was seen 
within the endografrs or at the endograft edges (Figure 2). LA showed no 
change (n=17), a reduction (n=ll), or a dilatation (n=7) (Table 1). Changes 
encountered in LA at the proximal and distal endograft edge were comparable 
(Table 2). In 1 patient, the reoccluded endovascular grafr was excised after 8 
months; histology (Figure 4) confirmed the absence of plaque, which is 
consistent with the IVUS findings. 
Of the anastomotic sites studied, 10 proximal and 12 distal anastomotic 
segments were available for IVUS analysis. The LA increase (85%, p<O.OO 1) 
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Figure 4. Histology sections (Milligan's trichrome stain) of an ePTFE endograft (left: in sim; right: 
magnified 325) excised 8 months after deployment. No neointima was observed within the endograft. 
was associated with an increase in both VA (42%, p<0.001) and PLA (15%, 
p=0.003) (Table 1, Figure 2). The increase in PLA was overcompensated by the 
increase in VA Individual cross sections showed no change in LA in 1, a 
reduction in 4, and a dilatation in 17. No significant differences were observed 
between the proximal and distal anastomotic segment (Table 2). 
Of the 10 remote arterial segments available for IVUS analysis, the minimal 
change in LA (6%) was associated with an increase in both VA (9%) and PLA 
(10%) (Table 1). Individual cross sections showed no change in LA in 6 and 
a dilatation in 4 others. 
DISCUSSION 
Endografts of many types are being investigated for treatment of both occlusive 
and aneurysmal disease. 16-zt We employed arteriography and IVUS imaging to 
evaluate a new ePTFE balloon-expandable endograft in patients with 
obstructive femoropopliteal disease. On both the angiogram and the IVUS 
images, there were only minimal luminal changes within the endograft and at 
the remote arterial segments. Distinct changes in LA were encountered at the 
anastomotic segments, however. The greater incidence of dilatation seen with 
IVUS at this level was probably due to the quantitative nature of the 
cross-sectional analysis compared to the subjective visual assessment of the 
angiographic images. 
In this study, the lumen changes seen on IVUS both within the endograft (3%) 
and at the endograft edges (-6%) were small. Intimal hyperplasia (PLA 
increase) and VA reduction (shrinkage), both of which are important 
24 
Chapter 2 
parameters in the development of postangioplasry restenosis, were likewise 
minimal. 7-9'22 Similarly, the changes in LA in the arterial segments remote from 
the endograft were modest (6%) and associated with minor increases in VA 
(9%) and PLA (10%). These data are in accordance with those of van Lmkeren 
et al., 22 who reported a 3% LA change and associated increases in both VA 
(6%) and PLA (15%) in cross sections not subjected to balloon dilation. 
The changes at the anastomotic segments adjacent to the endograft were 
significant for all area measurements, a remarkable finding for an arterial 
segment that has not been dilated. Although the mechanism for this local 
dilatation at the anastomosis is unclear, there are hypotheses that may explain 
the findings. 
First, the patency of a prosthetic vascular graft may be determined, in part, by 
the healing properties of the graft and the development of intimal hyperplasia 
at the anastomotic segment. 23- 25 Development of intimal hyperplasia is related 
to low mean and oscillating shear stress.26'27 Compared to an end-to-side 
anastomosis, wall shear stress distribution in endovascular end-to-end 
anastomosis may prevent turbulent flow and consequently intimal hyperplasia. 
Hasson et a!. 28 described an increase in arterial diameter in a 
"para-anastomotic hypercompliant" zone distal to an end-to-end 
anastomosis. They suggested that this zone might be associated with a local 
high stress induced by compliance mismatch in a direct graft-to-artery 
anastomosis.29- 31 This phenomenon may explain our findings related to the 
increase of lumen and vessel areas, but not plaque. 
Secondly, dilatation seen at the anastomotic segment might be explained by 
flow obstruction from the 14-F delivery sheath used during endograft 
implantation. At follow-up, the angiogram and IVUS were obtained using a 
7-F sheath. The higher arterial pressure could be responsible for the increase 
in both LA and VA The fact that this phenomenon was not encountered 
within the endograft and in the arterial segments remote from the endograft, 
however, does not support this argument. 
Thirdly, covering endothelial cells with an endograft may lead to local tissue 
hypoxia by interrupting the interaction between blood and the vessel wall. 
Vascular endothelial growth factor (VEGF) expression is upregulated by 
hypoxia in normal tissues that become ischemic, and receptors to VEGF are 
also upregulated in hypoxic tissues. Hence, local tissue ischemia may lead to 
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angiogenesis, necessitating remodeling without sprouting. 32 Growth factors or 
other mediators may play a role in the findings described in our study, 
although no objective evidence exists. 
Based on our observations, vascular remodeling may compensate for intimal 
hyperplasia at the anastomotic segment of an e-PTFE endograft. However, the 
small number of patients available for analysis limits our ability to make 
definitive conclusions in this regard. Only 10 remote arterial segments were 
available for angiographic and IVUS analysis because the sheath hampered 
visualization of the proximal remote arterial segment. Another limitation of 
this study was the visually estimated angiographic analysis, whereas the IVUS 
cross sections were analyzed quantitatively. 
Compared to angiography, we have shown that IVUS is more sensitive in 
demonstrating luminal changes at follow-up. Minimal changes in LA were 
found within the endograft, at the endograft edges, and in the remote arterial 
segments. Distinct LA increases encountered at the anastomotic segments were 
associated with increases in VA and PLA. Endografts may prove useful in long 
segment obstructions in the femoropopliteal segment. 
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Vascular Response after Endograft 
ABSTRACT 
Purpose: To document whether the vasodilatory response seen at the 
anastomotic segment 6 months after placement of a balloon-expandable 
endograft is progressive between 6 and 24 months follow-up. 
Methods: Patients (n= 12; median age 65 years, range 4 7 to 7 5) treated with an 
investigational polytetrafluorethylene (ePTFE) endograftfor obstructive disease 
of the femoropopliteal artery, were studied with intravascular ultrasound 
(IVUS) immediately after placement and at 6 and 24 months follow-up. 
Matched IVUS cross-sections derived from the endograft and the anastomotic 
segment were analyzed for changes in lumen (LA), vessel 0/ A) and plaque area 
(PLA). 
Results: In total 5 patients had a complete follow-up with IVUS at 8 (first 
follow-up period) and 25 months (second follow-up period). Matched IVUS 
cross-sections derived from the endograft showed no significant change in LA 
during both follow-up periods (-8% and + 1%, respectively). There was no 
evidence for intimal hyperplasia or endograft recoil. During both follow-up 
periods IVUS cross-sections derived from the anastomotic segment revealed 
a significant increase in LA(+ 37% and +8%, respectively) and VA (+26% and 
+6% respectively). The change in PLA during both follow-up periods was not 
significant ( + 13% and + 3%, respectively). 
Conclusions: The ePTFE endograft seems to inhibit both intimal hyperplasia 
and constrictive remodeling. The vascular dilatory response seen at the 
anastomotic segment at 8 months follow-up tends to stabilize at 25 months 
follow-up. Therefore, this endovascular anastomosis acts as an "ideal" 
end-to-end anastomosis. 
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INTRODUCTION 
Recently, a polytetrafluorethylene (ePTFE) endograft was developed to cover 
the damaged arterial wall after vascular intervention. In a previous 
intravascular ultrasound (IVUS) study on femoropopliteal arteries undergoing 
ePTFE endograft placement we established that at 6 months follow-up lumen 
area change within the endograft and at the en do graft edges was minimal and 
intimal hyperplasia was not observed. 1 In contrast, the arterial segment 
adjacent to the endograft (i.e. anastomotic segment) revealed a distinct increase 
in lumen area, which was due to a vasodilatory response. The purpose of the 
present rvus study is to document whether this vasodilatory response seen at 
the anastomotic segment is progressive between 6 and 24 months follow-up. 
METHODS 
Patients 
This is a follow-up study of 12 patients in whom the short-term results have 
been previously reported. 1 Patients with disabling claudication (n = 11) or 
critical ischemia (n= 1) were treated with an ePTFE endovascular graft of the 
femoropopliteal artery. A high-grade stenosis (mean length 5.2 em) was 
involved in 5 patients and an occlusion (mean length 7.5 em) in 7 patients. 
There were 9 men and 3 women, with median age of 65 (range 4 7-7 5) years. 
At baseline patients were studied with IVUS immediately after endograft 
placement. A per-protocol follow-up IVUS investigation was performed after 
6 and 24 months. Patients were included in the present study after giving 
informed consent for the procedure and the invasive follow-up study. 
Endovascular graft 
The characteristics of the endograft used have been described before.1 Briefly, 
the endograft is a balloon expandable ePTFE thin -walled graft 
(ENDURING™, W.L Gore & Associates, Flagstaff, AZ, USA) with an outer 
diameter of 4 mm; it can be custom cut in any desired length. The graft wall 
contains ring-shaped ePTFE reinforcements that are integrated in the material. 
The rings are compression resistant comparable to self-expandable stents. 
Depending on the diameter of the balloon used, the graft can be expanded 
from 4 to 7 mm inner diameter. This maneuver fixes the graft to the arterial 
wall over its entire length and provides proper seal. In 9 patients pre-dilatation 
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with a balloon (5-7 mm) was performed to allow passage of a 14 French sheath 
which included the endograft. In the 3 remaining patients, a remote 
endarterectomy with a MollRing CutterTM (Vascular Architects, Inc., Portola 
Valley, CA, USA) was performed first. 2'3 
Intravascular ultrasound 
The IVUS studies were performed using a single rotating ultrasound element 
(30 MHz) on a guidewire-tipped 4.3F catheter (Endosonics, Rijswijk, The 
Netherlands, 0.035"). The IVUS catheter was advanced beyond the endograft 
and cross-sectional images were obtained during manual pullback of the 
catheter. The information on the location of the cathetertip was documented 
using a catheter displacement sensing device and fluoroscopy, with a 
radiopaque ruler as reference. 4 This information on the cathetertip position 
was mixed with the IVUS images on the monitor and the resulting images were 
stored on an S-VHS videotape. 
Follow-up 
The follow-up protocol included IVUS at 6 and 24 months follow-up. In case 
of graft occlusion, the IVUS investigation was performed after successful 
fibrinolysis. The IVUS cross-sections obtained after endograft placement and 
at follow-up were matched using the information derived from the radiopaque 
ruler and the catheter displacement sensing device. The following matched 
IVUS cross-sections were selected for quantitative analysis (Figure 1): (1) from 
the endograft, the proximal and distal edge and the site showing the smallest 
lumen area following endograft placement; (2) ftom the anastomotic segment, 
2-4 cross-sections with an interval of 0.5 to 1 em. Subsequently, these 
matched IVUS cross-sections were digitized and analyzed for lumen area (LA), 
vessel area (VA) and plaque area (PLA). A comparison was made between area 
measurements obtained immediately after endograft placement and at 6 
months follow-up (first follow-up period) and at 6 to 24 months follow-up 
(second follow-up period). 
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Figure 1. Schematic drawing 
showing the ePTFE endograft 
and the proximal and distal 
anastomotic segments 
immediately after endograft 
placement and at follow-up. 
Intravascular ultrasound 
measurements are performed 
on corresponding intravascular 
ultrasound cross-sections 
obtained from the endograft 
and the anastomotic segments. 
Results are given as mean ± standard deviation, or as median and range. 
Comparison of the area measurements obtained at baseline and at both 
follow-up periods was performed by means of the Student's t-test for paired 
observations. A p-value <0.05 was considered statistically significant. 
RESULTS 
Clinical events and follow-up characteristics of the 12 patients included in the 
study are listed in Table 1. Occlusions of the endograft experienced during the 
first follow-up period (n=4) were successfully treated with fibrinolysis. One 
stenotic lesion (>50% diameter stenosis) observed distal to the endograftwas 
additionally treated with PTA. During the second follow-up period fibrinolysis 
was successful in 1 patient, unsuccessful in 2 patients and not performed in 2 
other patients. The occlusion of the endograft was compensated by collateral 
flow in 1 patient and bypass surgery was required in 3 patients. There were 5 
patients (4 men and 1 woman) with a complete IVUS follow-up at 8 (range 
7-9) and 25 (range 23-26) months. The remaining 7 patients were excluded 
during the second follow-up period; in 2 patients fibrinolysis was unsuccessful, 
in 2 patients fibrinolysis was not performed, in 1 patient the IVUS equipment 
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failed at 25 months follow-up and 2 patients were lost to follow-up. 
In the endograft and at the endograft edges lumen area did not change during 
both follow-up periods (Table 2, Figure 2). Intimal hyperplasia inside the 
endograft and at the endograft edges was not observed. 
Table 1 Clinical events and follow-up characteristics of 12 patients treated with an 
experimental polytetrafluorethylene endograft. 
Patient Remote Occlusion Occlusion MJS 
endarterec- during 1st during 2nd investigation Clinical status 
tomyused follow-up follow-up at 25 months at25 months 
at baseline period period follow-up follow-up 
1 + Enduring patent 
2 + Enduring patent 
3 + + Enduring patent 
4 + + Enduring patent 
5 + + Enduring patent 
6 + Enduring patent 
7 ++ + Enduring patent 
8 ++ +** Enduring occluded 
9 ++ +* Bypass surgery 
10 +** Bypass surgery 
11 +* Bypass surgery 
12 Lost to follow-up 
IVUS - intravascular ultrasound; - "" no; + ... yes; + + = twice; * .. fibrinolysis not successful, 
** "' fibrinolysis not performed. 
After 
placement 
follow-up 
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follow-up 
25 months 
Figure 2. Corresponding intravascular ultrasound cross-sections obtained after endograft placement, and 
at 8 and 25 months follow-up from d1e distal endograft edge (upper panel) and anastomotic segment 
(lower paneD of a patient treated with an ePTFE endograft. The inner contour displays d1e lumen area 
(endograft) and the outer contour the vessel area. The endograft did not change at follow-up. At d1e 
anastomotic segment an increase i.n both lumen and vessel area was seen at 8 months follow-up, which 
tended to stabilize at 25 months follow-up. Plaque area increase encountered in bod1. follow-up periods 
was similar.(+"" catheter; calibrati.on = 1 mm). 
There were 8 anastomotic segments (3 proximal and 5 distal) available for 
analysis. During the first follow-up period there was a significant increase in 
LA (37%) and VA (26%) at the anastomotic segments; the increase in PLA 
(13%) was not significant (Table 2, Figures 2-4). Similarly, during the second 
follow-up period there was a significant increase in LA (8%) and VA (6%) at 
the anastomotic segments; the increase in PLA (3%) was not significant. In 1 
patient a distinct stenosis observed at the distal anastoosis was treated with 
percutaneous transluminal angioplasty. 
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DISCUSSION 
In the present study we compared changes in vessel dimensions encountered 
6 and 24 months following endograft placement of the femoropopliteal artery. 
It was found that inside the endograft and at the endograft edges the change 
in LA encountered during both follow-up periods was minimal and not 
significant. More important, there was no evidence of endograft recoil or 
intimal hyperplasia; these latter observations concur with the results of van 
Sambeek et al. 1 At the anastomoses, however, there was a significant increase 
in LA and VA associated with no significant change in PLA during both 
follow-up periods. The extent of LA and VA increase declined from 37% and 
26%, respectively during the first follow-up period to 8% and 6%, respectively 
during the second follow-up period (Table 2). The following issues 
encountered in the present study deserve specific comment. 
Table 2 Data on lumen, vessel and plaque area derived from the endograft (n=5) and d1e 
anastomoses proximal and distal of the endograft (n""8), after placement and at 8 and 
25 months follow-up seen with intravascular ultrasound. 
After 8 months 25 mond1s 
placement follow-up follow-up 
"'' "'' Area (mm2) (mm2) (mm2) (mm2) (m~') 
Endograft Lumen 22.1 ± 5.2 20.3 ± 5.0 20.6 ± 4.0 J 1.8 ± 2.9 1 0.2 ± 2.0 
(-8%) (1%) 
Anastomoses Lumen 15.4 ± 4.8 21.2±5.5 23.0 ± 5.7 i 5.7 ±4.9 1 1.8 ± 1.8 
(37%)* (8%)* 
Vessel 30.5 ± 4.7 38.4 ± 5.0 40.7 ± 4.6 1 7.9 ± 5.1 1 2.3 ± 2.5 
(26%)* (6%)* 
Plaque 15.2 ± 2.0 17.3 ± 4.8 17.8 ±43 1 2.0±4.5 10.5±1.6 
(13%) (3%) 
Values are mean± SD; L:. 1 ... difference at first follow-up; t..2 ... difference at second follow-up; 
l = decrease; T = increase; * = p < 0.05 . 
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Endograft 
In the present study there was no evidence for endograft recoil or intimal 
hyperplasia inside the endograft and at the endograft edges. This is a 
remarkable finding since previous rvus studies in femoropopliteal arteries 
demonstrated that both intimal hyperplasia and stent area reduction (especially 
at stent edges and stent junctions) resulted in lumen area reduction.5'6 
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Figure 3. Longirudinal changes seen with intravascular ultrasound in the lumen, vessel and plaque area 
encountered after endograft placement and at 8 and 25 months follow-up in the proximal (left, n=3) and 
distal (right, n=5) anastomotic segment adjacent to the endograft. Values are mean± SD. 
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Although the use of this new ePTFE endograft seems to overcome the problem 
of in -stent restenosis, acute occlusion of the endograft was observed in 4 
patients during the first follow-up period and in 5 patients during the second 
follow-up period (Table 1). Except for 1 patient presenting with a small LA 
proximal to the endograft, no IVUS characteristics (i.e. lumen area of the graft 
and the proximal and distal anastomosis) predictive for the occurrence of the 
occlusions were found. It is worth mentioning that in 3 patients in whom the 
mm' Lumen area 
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Figure 4. Mean changes seen with 
intravascular ultrasound in lumen, vessel 
and plaque area encountered after 
endograft placement and at 8 and 25 
months follow-up in the proximal and 
distal anastomotic segment (n-8). Values 
are mean ± SD. 
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remote endarterectomy was used before 
placement of the endograft, no acute occlusion 
was observed. In 2 other patients in whom the 
endograft was placed across the knee the 
endograft occluded during both follow-up 
periods (Table 1; patient nos. 7 and 8). 
Although reasons for the acute occlusions 
remain speculative, endograft placement in 
vascular segments proximal to the knee in 
combination with remote endarterectomy 
before implantation of the endograft might 
limit the problem of acute occlusion of the 
endograft. 
Anastomotic segment 
Results from the present study suggest that the 
local vasodilatory response at the anastomotic 
segment seen during the first follow-up period 
tends to stabilize during the second follow-up 
period. Previously, van Sambeek et al. 1 
hypothesized that the vasodilatory process 
could be explained by: (I) hypercompliance 
due to local high shear stress, (2) increased 
arterial pressure at follow-up due to the use 
of a 7 French sheath compared to a 14 
French sheath used during endograft 
placement, and (3) local tissue hypoxia 
resulting in neovascularization. Given the 
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present study results, the hypotheses presented by van Sambeek et al. 1 might 
be reconsidered: 
First: Hypercompliance due to local high shear stress. Hasson et al. 1 postulated 
that a "para-anastomotic hypercompliant" zone distal to end-to-end 
anastomosis could be associated with local high stress induced by compliance 
mismatch in a direct graft to artery anastomosis. This might explain the 
increase of LA and VA seen at the anastomotic segment. However, dilatation 
was encountered at both the proximal and distal anastomotic segments which 
is a counter-argument for this hypothesis. 
Second: Increased arterial pressure at follow-up. Difference in arterial pressure 
at implantation of the endograft (using a 14 French delivery sheath) and at 
follow-up study (using a 7 French sheath) could be responsible for the 
dilatation at the anastomotic segment. However, the observation that the 
vasodilatory response was a local process and that the increase in LA and VA 
was significant at both follow-up periods suggests that the higher arterial 
pressure is not responsible for the vasodilatory response. 
Third: Local tissue hypoxia resulting in neovascularization. Covering the 
arterial wall with an endograft may lead to local tissue hypoxia by 
discontinuation of the interaction between blood and vessel wall. Hypoxia may 
induce vasodilatation mediated by a local interplay of growth factors, adhesive 
proteins and other mediators. 8- 10 In brief, local hypoxia may stimulate vascular 
endothelial growth factor (VEGF) dependent signaling by upregulation of the 
expression ofVEGF, 10 a VEGF ligand and a specific signaling receptor. 8 VEGF, 
in tum, has been shown to stimulate dilatation of coronary microvessels; a 
mechanism which is mediated by nitric oxide (N0).9 Since the local 
vasodilatory response is encountered both at the proximal and distal 
anastomosis and tends to stabilize at 25 months follow-up, we believe an 
NO-dependent mechanism of dilatation might be at the basis of the local 
vasodilatory process. 
In addition to the 3 hypotheses presented by van Sambeek et al. 1, we opine that 
a multicellular inflammatory reaction triggered directly by PTFE could be 
responsible for the local vasodilatory response. There is evidence that PTFE 
activates alterations in expression of several surface adhesion molecules on 
granulocytes, monocytes and platelets such as b2-integrins and intercellular 
adhesion molecule (ICAM-1). 11- 13 
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However, the extent to which this inflammatory response can cause a dilatation 
is not yet fully understood. 
Limitation 
The main limitation of the present study is the small number of patients 
available for analysis. However, our study population has provided some 
additional insight into the progression of the vasodilatory process encountered 
at the anastomotic segment after endograft placement. 
CONCLUSIONS 
This longitudinallVUS study suggests that the ePTFE endograft inhibits 
plaque growth and constrictive remodeling. The vascular dilatory response 
at the anastomotic segment seen at 8 months follow-up tends to stabilize at 
25 months follow-up. This endovascular anastomosis acts as an "ideal" 
end-to-end anastomosis, jeopardized by the unexplained acute occlusions. 
Momentarily, these acute occlusions are subject to further investigation. 
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ABSTRACT 
Purpose: To evaluate the longterrn clinical outcome of patients treated with 
an polytetrafluoroethylene (ePTFE) endograft for long-segment obstructive 
and occlusive disease of the femoropopliteal artery. 
Methods: 89 patients (median age 69 years, range 43 to 81) were treated with 
an ePTFE (mean length 29 em) endograft for obstructive disease of the 
femoropopliteal artery. The follow-up protocol included Doppler scanning, 
duplex scanning or angiography of the endograft. Primary and secondary 
patency rates of the ePTFE endograft after 6, 12, 24 and 36 months follow-up, 
respectively, were analyzed. 
Results: At baseline, patients presented with disabling claudication (n=73) or 
critical ischemia (n=16). A high-grade stenosis (mean length 9 em) was 
involved in 7 patients and an occlusion (mean length 19 em) in 82 patients. At 
the end of the study, the endograft was patent in 52 patients (median 17 
months [range 7 to 50]), occluded in 35 patients (median 7 months [range 0 
to 40]) and 2 patients had deceased of no vascular cause (6.5 and 7 months, 
both with a patent endograft). At follow-up, the primary and secondary 
patency rates of the ePTFE endograft were 71% and 83% at 6 months, 57% 
and 69% at 1 year, 45% and 49% at 2 years and 30% and 44% at 3 years, 
respectively. 
Conclusions: The success of this new ePTFE endograft is limited. Therefore, 
refinements of the endograft are necessary if this new, minimal invasive, 
technique wants to compete with conventional bypass surgery. 
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INTRODUCTION 
One of the major complications of percutaneous transluminal angioplasty 
(PTA) for obstructive arterial disease is the occurrence of restenosis, which is 
the net result of both intimal hyperplasia and vascular remodeling. 1- 4 To 
prevent the development of intimal hyperplasia and vascular remodeling after 
vascular interventions, stents have been introduced. However, the benefits of 
stents in femoropopliteal arteries are still controversial. s-s Both intimal 
hyperplasia and stent area reduction have been observed to result in lumen 
area reduction, especially at stent edges and stent junctionsY0 In order to 
prevent these important factors from contributing restenosis, a 
polytetrafluorethylene (ePTFE) endograft was developed to cover the damaged 
arterial wall immediately after vascular intervention. In previous studies using 
intravascular ultrasound we established that the ePTFE endograft applied in 
femoropopliteal arteries inhibits intimal hyperplasia and constrictive vascular 
d I. 11,12 F th th . d. h remo e mg. ur ermore, at e anastomotic segments a Jacent to t e 
endografta local dilatory response was observed at 6-months follow-up, which 
tended to stabilize at 2-years follow-up. However, these positive findings were 
jeopardized by the occurrence of acute occlusions of the endograft. The aim of 
the present descriptive international multicenter study was to evaluate the 
longrerm clinical outcome of patients that received an ePTFE endograft. 
MATERIALS AND METHODS 
Patients 
From October 1996 to August 2000, 89 patients ( 68 men; median age 69 years 
(range 43-81 years) with long-segment obstructive disease of the 
femoropopliteal artery were treated with an ePTFE endograft. The study was 
conducted at the following institutions (with the number of patients enrolled 
in parentheses): St. Antonius Hospital, Nieuwegein (41); Erasmus University 
Medical Center Rotterdam (32); Catharina Hospital, Eindhoven (11); 
University Hospital Leuven (4). The investigation was approved by the local 
committee on Human Research in each hospital. Patients were included in the 
study after giving informed consent. 
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Endograft 
The endograft used was a balloon-expandable thin-walled ePTFE graft 
(Enduring™ vascular graft, W.L Gore & Associates, Flagstaff, AZ, USA) with 
a 4-mm outer diameter. The graft wall contains ring-shaped ePTFE 
reinforcements that are integrated in the material (no metal parts). The rings 
are compression resistant comparable to self-expandable stents (Figure 1). 
Gold markers are incorporated in the graft to allow visualization under 
fluoroscopy. The graft can be cut in any desired length and, depending on the 
balloon-size used, the graft can be expanded to a maximum inner diameter of 
7 mm, with a recoil of (10%). This maneuver fixes the graft to the arterial wall 
providing proper seal over its entire length. 
Figure 1. Sample of a partially dilated polytetrafluoroethylene (ePTFE) endograft. 
Operative technique 
All procedures were performed in the operating theater under fluoroscopic and 
angiographic guidance. Arterial access was gained through a surgical cutdown 
of the common or superficial femoral artery. Initially, in the first 10 patients 
a hydrophilic guidewire was placed beyond the lesion and predilatation with 
a 5 to 7 mm balloon was performed to facilitate passage of a 14-F sheath. 
Subsequendy, it was decided to modify the procedure. In the remaining 79 
patients, remote endarterectomy with a MollRing Cutter™ (Vascular 
Architects, Inc., Portola Valley, CA, USA) was performed before placement of 
a guidewire (Figure 2). Thereafter, the endograft was mounted on a balloon 
catheter with a pressure of2 atmospheres and positioned in the femoropopliteal 
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Figure 2. Angiographic images of a patient during polytetrafluoroethylene (ePTFE) endograft 
placement. Frames A and B show the Mollring Cutter at the proximal popliteal artery performing 
the remote endarterectomy. (A) closed position of the Mollring Cutter and (B) open position of the 
Mollring Cutter. Frame C shows the femoropopliteal artery after the remote endarterectomy. Note 
the distal occlusion due to the presence of a plaque dissection after remote endarterectomy. Frame 
D shows an e>..""Panded dilatation balloon, fixing the ePTFE endograft to the arterial wall. Frame E 
shows a control angiogram immediately after endograft placement, showing a good appositioned and 
widely patent endograft. 
47 
Longterm data on ePTFE endografts 
segment under fluoroscopic guidance. To cover the entire treated segment of 
the femoropopliteal artery, care was taken to position the endograft with 1 em 
overlap distally over the untreated (normal) arterial wall. After retraction of the 
sheath the endograft was expanded using the balloon catheter with a pressure 
of 12 atmospheres (Figure 2). The proximal end of the endograftwas cut to the 
desired length and subsequently sutured to the femoral artery using an 
end-to-end anastomosis or an end-to-side anastomosis. 
After endograft placement patients were given oral anti-coagulants, 
platelet-aggregation-inhibitors or both. 
Data collection 
Baseline data collected on each patient included age, gender, diabetes mellitus, 
hypertension, hypercholesterolemia, history of smoking, angina pectoris, 
myocardial infarction, cerebrovascular accident or transient ischemic attack, 
pulmonary disorders and vascular intervention prior to endograft placement. 
Data collected during the operating procedure included operating time, length 
of pre-dilatation PTA or remote endarterectomy, length of lesion/ endograft, 
balloon-size (diameter) and type of anastomosis used to suture the proximal 
part of the endograft to the arterial wall. 
Depending on the institution the follow-up protocol included regular duplex 
scanning, Doppler scanning or angiography of the endograft. Early failure of 
the endograft was defined as an acute occlusion of the endograft within 30 
days after the operating procedure. Patients presenting with an acute occlusion 
of the endograft were treated with fibrinolysis. In case fibrinolysis was not 
performed or was unsuccessful, conservative treatment was given or bypass 
surgery or lower-limb amputation was performed depending on the clinical 
condition of the leg. Primary and secondary patency rates of the ePTFE 
endograft at 1, 6, 12, 18, 24 and 36 months follow-up were analyzed with 
SPSS (version 9.0). The primary assisted patency rate was not calculated 
because intervention before graft occlusion rarely was performed. 
RESULTS 
Baseline patient characteristics and presenting symptoms are shown in Table 
1. Patients presented with disabling claudication (n=73) or critical ischemia 
(n=16). 
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A high-grade stenosis (mean length 9 em) was involved in 7 patients and an 
occlusion (mean length 19 em) in 82 patients. Characteristics of the operating 
procedure and follow-up data are shown in Table 2. 
Table 1 Patient characteristics and presenting symptoms 
of 89 patients treated wid1 an eP1FE endog:raft. 
Patient characteristics 
Age (years) (mean± SD) 
Sex (maldemale) 
Diabetes Mellitus 
Hypercholesterolemia 
Hypertension 
Pulmonary disease 
History of smoking 
History of angina pectoris 
M.I. 
T.!A/C.VA 
Prior vascular intervention 
Presenting symptoms 
Stenosis:occlusion 
Length of stenosis (em) 
Length of occlusion (em) 
Run-offvessels (1,2,3) (n•73) 
Rud1erford classification (2,3A) 
M.I. "" myocardial infarction; 
T.IA. = transient ischemic attack; 
C.V.A ... cerebrovascular accident. 
67.2 ± 8.8 
68,21 
23 (26%) 
34 (38%) 
43 (48%) 
10 (11%) 
52 (58%) 
16 (18%) 
17 (19%) 
12 (13%) 
55 (62%) 
7,82 
9.3 ± 6.1 
18.9 ± 7.3 
9,19,45 
73'7'9 
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Table 2 Characteristics of the operating procedure and follow-up data of 89 patients 
treated with an ePTFE endograft. 
Operating procedure 
Operating time (minutes) (median [range]) 
Endarterectomy used 
Length of endograft (em) 
Balloonsize proximal (5 ' 6 ' 7) 
distal (5 ' 6 ' 7) 
Follow-up 
Antithrombotics 
Oral anticoagulants ( Coumadin) 
Platelet-agregation -inhibitors (Aspirin) 
Both 
No data 
Additional treaonent 
PT AI stent proximal anastomosis 
PTA endograft 
PTA/stent distal anastomosis 
Current status (February 200 1) 
Patent (months) (median [range]) 
Occluded (months) (median [range]) 
Deceased (months) 
PTA ... percutaneous transluminal angioplasty 
180 [75 - 290] 
79 (89%) 
29 ± 6 
2' 53' 24 
6 '55' 18 
29 
44 
12 
4 
9 
3 
19 
52 
35 
2 
( 10 missing) 
( 10 missing) 
(17 [7- 50]) 
(7 [0 - 40]) 
6.5 and 7 
The median duration of the operating procedure was 180 minutes. The ePTFE 
endograft (29 ± 6 em) was sutured to the proximal femoral artery using an 
end-to-end anastomosis or an end-to-side anastomosis. Antithrombotic 
therapy was started immediately after endograftplacement; 29 patients received 
Coumadin, 44 patients Aspirin and 12 patients received both. 
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Graft patency 
Figure 3 presents the fate of the 89 patients treated with an ePTFE endograft. 
n·89 
Endograft placement 
I n•? 
,!, Early failure 
n•82 
Successful endograft placement 
I 
w w 
n•42 n•40 
Patent Acute occlusion 
I 
w w 
n·26 n•l4 
Fibrinolysis No fibrinolysis 
I 
w ,!, 
n•8 n•l8 
Patent Re-occlusion 
I 
,!, 
n•4 
Patent 
n•54 n•35 
Patent Occluded 
Figure 3. TI1e fate of 89 patients that received a polytetrafluoroed1.ylene 
(ePTFE) endograft. 
Early failure of the endograft was encountered in 7 of the 89 patients. In 4 2 
patients the endograft remained patent during the entire follow-up period. 
The other 40 patients presented with an acute occlusion later at follow-up. 
These patients were either treated conservatively (n=5), with femoropopliteal 
bypass surgery (n=9) or fibrinolysis was performed successfully (n=26). 
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Table 3 Primary patency rates of 89 patients treated with an ePTFE endograft. 
Time Withdrawn Cumulative 
interval Patients Events Permanent Interval primary 
(months) at risk (occlusion) occlusion Time Death patency patency(%) 
1 89 7 0 0 0 0.923 923 
6 82 19 7 0 0 0.768 70.9 
12 57 11 8 15 2 0.807 57.2 
18 33 6 10 14 0 0.818 46.8 
24 24 1 6 3 0 0.958 44.9 
36 9 3 3 12 0 0.667 29.9 
>36 8 1 
Totals 89 47 35 44 2 
Subsequently, re-occlusion of the endograft was encountered in 18 of the 26 
patients treated successfully with fibrinolysis. In 4 of these patients a repeat 
fibrinolysis was performed successfully. The remaining 14 patients were treated 
conservatively (n=4), with femoropopliteal bypass surgery (n=8) or with 
lower-limb amputation (n=2). 
Table 4 Secondary patency rates of 89 patients treated with an ePTFE endograft. 
Time Withdrawn Cumulative 
interval Patients Permanent Interval secondary 
(months) at risk occlusion Time Death patency patency(%) 
1 89 7 0 0 0.923 923 
6 82 8 0 0 0.902 83.3 
12 57 10 15 2 0.825 68.7 
18 33 6 14 0 0.818 56.2 
24 24 3 3 0 0.875 49.2 
36 9 1 12 0 0.889 43.7 
Totals 89 35 44 2 
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At the end of the study the endograft was patent in 52 patients (median 17 
months [range 7 to 50]), occluded in 35 patients (median 7 months [range 0 
to 40]) and 2 patients had deceased of no vascular cause (6.5 and 7 months, 
both with a patent endograft) (Table 2). In the present study no independent 
risk factors for the acute occlusions were encountered. 
Tables 3, 4 and 5 present the primary and secondary patency rates of the 
ePTFE endograft. Figure 4 shows the Kaplan-Meier plot of the primary and 
secondary patency data of the 89 patients treated with an ePTFE endograft. 
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Figure 4. Kaplan-Meier plot of the primary and secondary patency of 89 patients that 
received a polyretrafluoroethylene (ePTFE) endograft. n =number of patients at risk. 
The primarypatencyratewas 92% at 1-month, 71% at6-months, 57% at 12 
months, 47% at 18-months, 45% at 24-months and 30% at 36-months 
follow-up, respectively (Table 3). The secondary patency rate was 92% at 
1-month, 83% at 6-months, 69% at 12 months, 56% at 18-months, 49% at 
24-months and 44% at 36-months follow-up, respectively (Table 4). 
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DISCUSSION 
For patients with long-segment obstructive disease of the femoropopliteal 
artery, femoropopliteal bypass surgery is the most common treatment modality. 
However, conventional surgical femoropopliteal bypass surgery is associated 
with various problems and/ or complications such as the need for multiple 
incisions and the associated risk of wound infection, haematoma or 
haemorrhage, neuralgia around the knee joint and graft infection.13- 15 
Recently, the endobypass technique has emerged as a promising technique to 
provide a less invasive alternative to supragenicular bypass surgery in the 
treatment oflong-segment femoropopliteal obstuctive disease. 16- 21 Encouraged 
by this endobypass technique, a new ePTFE endograftwith ring-shaped ePTFE 
reinforcements that are integrated in the material was developed. Previous 
intravascular ultrasound studies using this completely supported ePTFE 
endograft have shown that endograft recoil and plaque growth were not 
encountered at 6-months11 and 2-years follow-up. 12 Furthermore, at the 
anastomotic segments adjacent to the endograft, an unexplained local 
vasodilatory response was observed at 6-months follow-up, which tended to 
stabilize at 2-years follow-up. However, these positive findings seen after 
placement of the ePTFE endograft were jeopardized by the occurrence of acute 
early and late occlusions of the endograft. In the present study, the longterm 
clinical follow-up data of 89 patients treated with an ePTFE endograft were 
reported. 
Experience with endografts 
In the present study early failure of the endograft was observed in 7 of the 89 
patients (8%). At the end of the study the endograft was patent in 54 of the 89 
patients (61 %) and occluded in 35 patients (39%). In addition, in 10 of the 54 
patients (19%) with a patent endograft at the end of the study, an acute 
occlusion of the endograft during follow-up was successfully treated with 
fibrinolysis. 
Early failure of the endograft used for treatment of long-segment 
femoropopliteal obstructive disease in 4 other studies (9% to 14%) was similar 
as observed in the present study. 18- 21 In these studies an endograft was used 
that required a stent at the distal anastomosis to provide proper seal of the 
endograft to the arterial wall and a surgical procedure to attach the proximal 
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anastomosis of the endograft. In contrast, in our study an endograft with 
ring-shaped reinforcements was used, making stent-placement at the distal 
anastomosis unnecessary in order to achieve proper seal of the endograft. 
Table 5 Primary and secondary patency rates and d1e number of acute occlusions in 
patients treated with endografts or conventional bypass surgery. 
Endograft Bypass 
Present Died1rich 18 Spoelstra 19 Stockx20 Hozt Abbott15 
study 
Primary patency 
6 months 71% 76% 80% <50% 85% 88% 
1 year 57% 72% 73% 70% 75% 
2 years 45% 61% 63% 
3 years 30% 59% 
Secondary patency 
6 months 83% 86% 90% 93% 
1 year 69% 84% 86% 78% 88% 
2 years 49% 70% 80% 
3 years 44% 78% 
Acute occlusions 
40/89 15/50 11/55 5/14 55/231 
(45%) (30%) (20%) (>50%) (36%) (24%) 
Primary and secondary patency rates and the percentage of patients that 
presented with an acute occlusion of the endograft during follow-up in the 
present study and the studies reported by others are shown in Table 5. 18- 21 The 
primary and secondary patency rates at 6-months follow-up in our study were 
similar to those reported by Diethrich et al. 18 and Spoelstra et al. 19 However, 
the patency rates at 1-year follow-up in those 2 studies were better than the 
patency rates in our study. The study reported by Stockx et al. 20 using the same 
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technique as described by Spoelstra et al19 could not duplicate Spoelstra's 
favourable results. Despite a similar initial technical success rate of98%, more 
than 50% of the endografts occluded within 6-months. Recently, Ho et al. 21 
reported on a study of 14 patients treated with an endograft after remote 
endarterectomy of the femoropopliteal artery (Table 5). Overall, the reported 
primary and secondary patency rates were similar to those reported without 
additional endarterectomy by Diethrich et al. 18 and Spoelstra et al. 19: 85% and 
93%, respectively, at 6-months follow-up, 70% and 78%, respectively, at 
1-year follow-up and 61% and 70%, respectively, at 2-years follow-up. The 
authors believed that deploying an endograft after remote endarterectomy 
should decrease the risk of an acute occlusion at follow-up. However, in 5 of 
the 14 patients an endograft occlusion was encountered. It was suggested that 
completely supported endografts might increase patency rates. However, the 
use of an ePTFE endograft with ring-shaped reinforcements integrated in the 
ePTFE endograft as tested in the present study did not improve primary and 
secondary patency rates. Furthermore, in the present study no differences were 
encountered between patients in whom remote endarterectomy before 
endograft placement was performed and patients in whom remote 
endarterectomy was not performed. Thus, remote endarterectomy may not be 
considered as obligatory strategy before endograft placement. 
Despite the enthusiastic reports of some authors, the use of endografts for 
treatment of long-segment femoropopliteal obstructive disease is still 
premature. The number of acute occlusions encountered in the present study 
and studies by others18- 21 are high, compared to approximately 24% acute 
occlusions encountered after conventional prosthetic above-knee 
femoropopliteal bypass graftingat3-years follow-up (Table 5).15 Furthermore, 
patency rates for conventional prosthetic above-knee femoropopliteal bypass 
grafting are still superior (Table 5); primary and secondary patency rates are 
75% and 88% at 1-year, 63% and 80% at 2-years, and 59% and 75% at 3-years 
follow-up, respectively.15 
Reasons why acute occlusions are more common after endograft placement 
than after conventional bypass surgery remain unknown. In the present study 
there was no difference in primary and secondary patency rates between 
patients treated with Aspirin and patients treated with Coumadin. We opine 
that the use of heparin -coated endografts or a different antithrombotic 
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strategy after endograft placement, for example, the use of Plavix, may decrease 
the number of acute occlusions. It is beyond dispute that the acute occlusions 
deserve further investigation. 
CONCLUSIONS 
Endovascular endograft placement could be an attractive, minimal invasive, 
alternative for conventional bypass surgery in treatment of patients with 
long-segment obstructive or occlusive disease of the femoropopliteal artery. 
However, as long as the problem of the high number of acute occlusions has 
not been solved, this new endograft used in the present study can not be 
considered as an improved treatment modality. 
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Effect of gamma radiation 
ABSTRACT 
Background: Endovascular brachytherapy (EBT) has shown to prevent 
restenosis after percutaneous transluminal coronary angioplasty (PTCA) in 
both animal and clinical studies. However, as yet, the effect of EBT on plaque 
growth and vascular remodeling in peripheral arteries is unknown. 
Objective: This intravascular ultrasound (IVUS) study evaluates the effect of 
EBT on the =ent of plaque growth and vascular remodeling after PTA of the 
femoropopliteal artery. 
Methods: Twenty-four patients with obstructive disease of the femoropopliteal 
artery underwent standard PTA. Patients were randomized to receive 
additional gamma-radiation after PTA. IVUS investigation was performed 
immediately after PTA and at 6-months follow-up. A comparison was made 
between patients without EBT (n=l6) and with EBT (n=8) in the change in 
both quantitative data (lumen, vessel and plaque area) and qualitative data 
(calcified lesion and dissection) seen with IVUS at 6-months follow-up. 
Results: At follow-up, IVUS revealed a significant difference in lumen area 
change between patients without EBT and patients with EBT (-9% and+ 23%, 
respectively): this difference was due to a significant difference in vessel area 
change (+ 2% and + 19%, respectively). In both groups of patients a similar 
increase in plaque area (+12% and +16%, respectively) was encountered. 
Qualitative IVUS data showed no change in the =ent and number of calcified 
lesions in both groups of patients. However, dissections encountered 
immediately after PTA were absent at follow-up in patients without EBT, 
whereas in 4 of the 8 patients with EBT a persistent dissection was 
encountered. 
Conclusion: This randomized IVUS study showed that gamma-radiation after 
PTA has a positive effect on lumen dimensions at 6-months follow-up by 
inducing positive vascular remodeling; gamma-radiation seemed not to affect 
plaque growth. In addition, gamma radiation has effect on the healing process 
of dissections after PTA. 
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INTRODUCTION 
Percutaneous transluminal angioplasty (PTA) is in common use for 
revascularisation of obstructive disease of femoropopliteal arteries. However, 
restenosis continues to be the main problem of this intervention with reported 
restenosis rates in up to 80% of patients at 1-year follow- up. 1-4 Intravascular 
ultrasound (IVUS) studies have shown that the restenosis process following 
PTA was the result of both plaque growth (i.e. intimal proliferation) and 
1 . . 5-9 vascu ar constr1ct10n. 
To diminish the vascular response to intervention, endovascular brachytherapy 
(EBT) has been proposed. The effective use of EBT to prevent intimal 
proliferation in animal models after balloon arterial injury has been 
demonstrated in preclinical studies using histology as gold standard.10-13 
Similarly, there is angiographic and clinical evidence that EBT reduces 
restenosis following both PTA14-19 and stent placement of coronary 
. 18,20-25 H h n: f EBT 1 d 1. . artenes. owever, as yet, t e enect o on vascu ar remo e 1ng IS 
unknown. The aim of the present randomized study was to determine the 
effect of EBT on the extent of plaque growth and vascular remodeling 6 
months after PTA of the femoropopliteal artery using IVUS. 
METHODS 
Study group 
In this multicenter trial, named V ARA (VAscular RAdiotherapy), 4 hospitals 
participated. Between September 1998 and August 2000, 38 patients (24 men; 
median age 65 (range 44-85) years) with disabling claudication were recruited. 
Entry criteria included angiographically proven femoropopliteal arterial 
stenosis (>50% diameter stenosis) or occlusion, lesion length <10 em, patients 
aged 40 to 85 years and no inflow obstruction or significant stenosis in the iliac 
artery. Exclusion criteria included impaired renal function (serum creatinine 
> 160 ,umol/l), acute ischemia, pregnancy and life expectancy less than 12 
months (Table 1). The study was approved by the local Committee on Human 
Research. Patients were included in the study after having given informed 
consent. 
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Table 1 Inclusion and exclusion criteria of d1e V ARA (VAscular 
RAdiotherapy) trial. 
Inclusions 
II Patients aged 40 to 85 years 
II Symptomatic femoropopliteal artetial disease eligible for PTA 
II Single lesion < 10 em 
8 Reference lumen diameter of 4 to 8 mm 
0 Written informed consent 
Exclusions 
8 Life expectancy< 12 months 
II Renal insufficiency (serum creatinine > 160 (umol/l) 
8 History of radiation therapy 
8 Obstructive disease of the iliac artery 
e Single vessel run-off 
II PTA>llcm 
PTA= percutaneous transluminal angioplasty. 
Procedure 
All patients underwent a standard PTA procedure. Heparin (5000 IU 
intravenously) was given at the onset of the procedure and additional Heparin 
(5000 IU intravenously) was given in case ofEBTbecause of the delay between 
the two interventions. Following intervention patients received standard oral 
anticoagulation (Ascal 100 mg daily) for 6 months. Patients were randomized 
to PTA only or to PTA with additional EBT using a minimization method 
(permuted blocks stratified by center, stenosis/ occlusion and lesion length). 
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Intravascular ultrasound 
Intravascular ultrasound was performed following angiographic successful PTA 
(diameter stenosis <50%). A guidewire-tipped 4.3F catheter Oomed, 
Ulestraten, The Netherlands; 0.035") containing a single rotating ultrasound 
element (30 MHz) was used. Antegradely through a 7F sheath in the ipsilateral 
femoral artery the IVUS catheter was advanced over a guidewire beyond the 
lesion. The guidewire was then removed and a manual pull-back of the IVUS 
catheter was performed. The location of the IVUS cathetertip was documented 
using fluoroscopy, a radiopaque ruler and a displacement sensing device. 26 The 
latter device documents the location of the cathetertip in relation to the patella 
in steps of 0.01 em during the pull-back maneuver. 26 The cathetertip position 
was documented together with the IVUS images on the monitor and the 
resulting images were stored on an S-VHS videotape for off-line analysis. 
Radiation therapy 
Immediately after the IVUS study was performed, radiation was given in those 
patients randomized for EBT using a 5F over-the-wire delivery catheter. 
Radiation was performed in the department of radiotherapy under supervision 
of a radiotherapist. A specially designed EBT centering catheter (Nucletron, 
Veenendaal, the Netherlands) was used which ensures optimal dose 
distribution over the vessel wall. The catheter was connected with a 
computerized afterloader, microSelectron HDR with an iridium-192 
radioactive source. Dose distribution was calculated on the basis of the 
post-PTA angiographic lumen diameter at the level of the target lesion and the 
length of the dilated segment with an additional 1 em at both the proximal 
and distal ends. The actual length of irradiation equalled the length of the 
dilated segment (maximal 11 em) plus 1.5 em proximal and distal, so that the 
100% isodose reaches 1 em beyond the proximal and distal ends: this was 
performed using a standard procedure. The prescribed dosage must be applied 
to the adventitia. Distance from the source axis to the adventitia was defined 
as the radius of the dilated vessel lumen plus 2 rom. In practice this means that 
this distance corresponded with the diameter of the EBT catheter balloon 
divided by 2 and plus 2 rom. 
A dose of 14 Gy was delivered at the prescribed points along the length of the 
dilated segment at a previously defined distance from the source axis. 
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Actual irradiation was applied by the 192-iridium source which was 
computer-guided to traverse the entire dilated segment in 5 mm steps moving 
from distal to proximal. After treatment, the catheter was removed afrer 
emptying the EBT centring balloon. 
Follow-up 
The follow-up protocol included single plane angiography and NUS imaging 
6 months after intervention. The angiograms obtained at follow-up were 
scored for lumen diameter stenosis by an independent radiologist blinded to 
EBT data. Angiographic restenosis of the vascular segment subjected to PTA 
was defined as >50% diameter stenosis. If a >50% diameter stenosis was 
involved at the reference segment (i.e. the segment proximal or distal to the 
dilated vascular segment) it was considered as a de novo stenosis. 
The IVUS procedure was performed in the same manner as described before. 
With the information of the displacement sensing device, the radiopaque ruler 
and anatomic markers such as side-branches and typical shaped calcifications, 
the IVUS cross-sections obtained immediately after PTA and at follow-up 
were matched. To ensure that the NUS cross-sections obtained after 
intervention corresponded with those that were obtained at follow-up 
examination, the cross-sections were studied side-by-side and 
frame-to-frame. Matched IVUS cross-sections obtained from the treated site 
and from the non-dilated reference site were selected with 1 em interval for 
analysis. In addition, from patients who received EBT, one IVUS cross-section 
located at the proximal and one at the distal junction between the treated and 
reference site (i.e. junction site) were selected for analysis. These junction sites 
included a 1 em non-dilated segment which received EBT. 
Quantitative analysis 
For the assessment of lumen, vessel and plaque area seen on IVUS a digital 
video analyzer system (IBM Corp. Boca Raton, USA) was used.27 The lumen 
area was defined as the area that was encompassed by the inner boundary of 
the intimal surface (characterized also by the presence of blood). The vessel 
area was defined as the area encompassed by the media-adventitia border. The 
plaque area was calculated by subtracting the lumen area from the vessel area. 
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Figure 1. Corresponding intravascular ultrasound cross-sections obtained after percutaneous trans-
luminal angioplasty (PTA) of the femoropopliteal artery (left) and at 6-months follow-up (right) from a 
patient without endovascular brachytherapy (EBT) (A) and a patient with EBT (B). At follow-up, the 
patient without EBT (A) showed a decrease in both lumen and vessel area, whereas the patient with EBT 
(B) showed an increase in both lumen and vessel area. Plaque area increase encountered in both patients 
(A and B) was similar. 
Calibration "' 1 mm; + "" catheter; 1f "' increase; .IJ. "' decrease 
When image quality was inadequate or extensive dropout due to calcification 
(> 120 degrees of the circumference) was encountered, the analysis of vessel area 
could not be performed and these IVUS cross-sections were excluded. 
Qualitative analysis 
IVUS cross-sections obtained after intervention and at follow-up were evaluated for 
hard lesion (i.e. calcified) and dissection. Calcified lesions were recognized by the 
presence of a bright echo structure casting peripheral shadowing. For the present study 
a calcified lesion was present if its arc was > 30 degrees of the circumference. Dissection 
was defined as the presence of a tear in the intimalsurfaceseparatingthe lesion ftom the 
underlying arterial wall. 28 
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Analysis of data 
First, lumen, vessel and plaque area measurements from each individual 
patient were averaged over the number of IVUS cross-sections acquired. 
Second, the averaged area measurements seen immediately after intervention 
and at 6-months follow-up were compared and the changes were calculated. 
First, a comparison was made between patients without EBT and with 
additional EBT after PTA in lumen, vessel and plaque area change seen at the 
treated site and at the reference site. Second, a comparison was made between 
the change in lumen, vessel and plaque area seen at the treated site, the 
reference site and the junction site in patients with EBT. Finally, the relation 
between morphologic features (i.e. calcified lesion and dissection) and the use 
of additional EBT was assessed. Observers were not aware of any patient 
characteristics or of the use/non-use of EBT. 
Statistical analysis 
Results are given as mean ± SD. To analyze differences between both groups 
of patients, the Student's t-testwas used. Differences between both groups of 
patients for non -parametric data were analyzed using the Mann-Whitney test. 
The statistical significance level was set at p<0.05. The reproducibility oflVUS 
parameters used in this study has been reported previously. 29 
RESULTS 
A complete IVUS follow-up (7.4 ±1.6 months) was obtained in 24 (17 men, 
7 women) of the 38 patients. The remaining 14 patients were excluded from 
the study for the following reasons: in 1 patient (randomized for EBT) 
additional PTA was necessary after IVUS investigation resulting in a treated 
segment too long for EBT; 2 patients presented with restenosis within 
5-months follow-up (1 with and 1 without EBT); 5 patients were lost to 
follow-up (2 without and 3 with EBT); 3 patients died (no vascular cause; 1 
without and 2 with EBT); and in 3 patients IVUS investigation was not 
performed at follow-up due to failure of the IVUS equipment (n=1; with 
EBT), the presence of an iatrogene dissection due to the arterial puncture (n= 1; 
with EBT) and occlusion of the artery (n= 1; with EBT). 
Of the 24 patients with a complete follow-up 8 patients received additional 
EBT. Table 2 presents demographic features, presenting symptoms, data on the 
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Table 2 Baseline patient characteristics, procedural data and follow-up data obtained in 
patients widlOut endovascular brachytherapy (EB1) and with EBT. 
Wid1outEBT With EBT 
(n=16) (n=8) p-value 
Patient characteristics 
Men/women 11/5 6/2 0.76 
Age (mean ± SD) (years) 65.9 ± 9.9 60.0 ± 9.8 0.18 
Diabetes mellirus 3 (19%) 2 (25%) 0.74 
Systemic hypertension 7 (44%) 5 (63%) 0.41 
Hypercholesterolemia 4 (25%) 5 (63%) 0.08 
Cigarette smoking 10 (63%) 7 (88%) 0.17 
Fontaine classification (2B/3/4) 6/6/4 6/1/1 0.13 
Stenosis/ occlusion 10/6 5/3 1.00 
Lesion 1engdl (em) 3.4 ± 2.9 5.2 ± 3.3 0.18 
Procedure 
Balloon diameter used (4/5/6) 1/6/9 0/4/4 0.89 
PTA lengd1 (em) 7.1 ± 3.6 8.6 ± 2.7 0.33 
Follow-up 
Clinical restenosis 3 (19%) 1 (13%) 0.71 
Angiographic stenosis 5 (31%) 3 (38%) 0.76 
- restenosis 5 0 0.08 
- de novo stenosis 0 3 0.01 
SD - Standard Deviation; PTA .. percutaneous transluminal angioplasty 
procedure and follow-up clara. With regard to patient characteristics and the 
procedural clara, no significant difference between patients without EBT and 
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with EBTwas seen. Angiographic, duplex and Doppler values at baseline were 
similar. In 38% of both groups of patients a total occlusion was involved. The 
remaining patients presented with a stenosis. At follow-up, restenosis was 
observed only in patients without EBT (n=5). This difference between patients 
without and with EBT in the occurrence of restenosis was not significant 
(p=O.OS). 
Change in quantitative IVUS data 
In total, 441 IVUS cross-sections (withoutEBTn=275;with EBTn= 166)were 
analyzed for the change in lumen, vessel and plaque area at 6-months 
follow-up; 180 (8 ± 3 per patient) from the treated site, 245 (10 ±3 per patient) 
from the reference site and 16 from the junction site (2 per patient). 
Table 3 summarizes the quantitative IVUS data derived from the treated and 
reference site in patients without EBT and with EBT. Immediately after PTA 
no significant difference in lumen, vessel and plaque area was encountered 
between both groups of patients at the treated site and the reference site. At 
follow-up, at the treated site a significant difference between both groups of 
patients was observed in the change in lumen and vessel area (Figure 1); in 
patients without EBT a decrease in lumen area of 9% and an increase in vessel 
area of2% was encountered, while in patients with EBT an increase in lumen 
and vessel area of 23% and 19%, respectively, was seen. Plaque area increase 
in both groups of patients was similar (12% and 16%, respectively). At the 
reference segment no significant differences between both groups of patients 
in lumen, vessel and plaque area were encountered (Table 3). 
Table 4 summarizes the quantitative IVUS data derived from the treated, 
junction and reference site acquired in patients with EBT. The changes in 
lumen, vessel and plaque area at the junction site were smaller (12 %, 10% and 
7%, respectively) than the changes observed at the treated site (23%, 19% and 
16%, respectively). The dimensions of the reference site remained unchanged 
(-2%, 0% and 1%, respectively) (Table 4). 
IVUS data confirmed that the restenotic lesion seen with angiography in 
patients without EBTwas located at the treated site. In patients with EBT, the 
de novo stenosis was seen proximal to the junction site at 1 em, 1.5 em and 3.5 
em distance, respectively. 
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Table 3 Quantitative intravascular ultrasound data from the treated and reference site obtained 
immediately after percutaneous transluminal angioplasty (PTA) and at follow-up in 
patients without endovascular brachytherapy (EB1) and wid1 EBT. 
EBT After PTA (mm2) Follow-up (mm2) Change (mm 2) 
Treated site 
Lumen area 18.3 ± 6.9 16.6 ± 7.4 -1.6 ± 5.1 (-9%) 
+ 18.8 ± 6.1 23.1 ± 7.7 4.3 ± 6.8 (23%) 
(p. 0.86) (p. 0.06) (p = 0.03) 
Vessel area 36.4 ± 12.9 37.3 ± 12.9 0.8 ± 5.5 (2%) 
+ 36.8 ± 8.6 43.7 ± 12.2 6.9 ± 8.7 (19%) 
(p. 0.94) (p = 0.26) (p = 0.05) 
Plaque area 18.3 ± 8.8 20.6 ± 8.6 2.2 ± 4.0 (12%) 
+ 17.9±6.4 20.7 ± 7.3 2.8 ± 6.0 (16%) 
(p = 0.91) (p = 0.98) (p = 0.80) 
Reference site 
Lumen area 16.8 ± 6.4 18.1 ± 6.6 13 ± 3.3 (8%) 
+ 16.6 ± 5.0 16.3 ± 5.0 -0.3 ± 3.2 (-2%) 
(p- 0.95) (p = 0.50) (p = 0.26) 
Vessel area 30.5 ± 9.8 32.5 ± 9.8 2.0 ± 3.5 (7%) 
+ 31.6 ± 5.6 31.5 ± 5.6 -0.1 ± 3.7 (0%) 
(p- 0.78) (p. 0.80) (p- 0.20) 
Plaque area 13.7 ± 6.0 14.4 ± 5.7 0. 7 ± 2.3 (5%) 
+ 14.8 ± 3.8 15.0 ± 3.6 0.2 ± 2.9 (I%) 
(p. 0.64) (p. 0.78) (p. 0.66) 
Values are mean ±standard deviation; - "" wid'lOut EBT; + "' with EBT. 
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Table 4 Quantitative intravascular ultrasound data from the treated site, the junction site and 
d1e reference site obtained immediately after percutaneous transluminal angioplasty 
(PTA) and at follow-up in patients with endovascular brachytherapy (n•8). 
Segment After PTA (mm2) Follow-up (mm2) Change 
(mm2) 
Lumen area Treated 18.8 ± 6.1 23.1 ± 7.7 4.3 ± 6.8 (23%) 
Junction 17.2 ± 4.8 19.2 ±55 2.0 ±5.7 (12%) 
Reference 16.6 ± 5.0 16.3 ± 5.0 -0.3 ± 3.2 (-2%) 
Vessel area Treated 36.8 ± 8.6 43.7 ± 12.2 6.9 ± 8.7 (19% 
Junction 32.4 ±8.2 35.6 ± 8.7 3.1 ± 7.0 (10%) 
Reference 31.6 ± 5.6 31.5 ± 5.6 -0.1 ± 3.7 (0%) 
Plaque area Treated 17.9 ± 6.4 20.7 ± 7.3 2.8 ± 6.0 (16%) 
Junction 15.3 ± 6.5 16.4 ± 5.4 1.1 ± 4.2 (7%) 
Reference 14.8 ± 3.8 15.0 ± 3.6 0.2 ± 2.9 (1 %) 
Values are mean ± standard deviation. 
Change in qualitative IVUS data 
The number of IVUS cross-sections showing a calcified lesion was 93 (34%) 
immediately after PTA and 101 (37%) at follow-up in patients without EBT 
and 45 (27%) and 44 (27%), respectively, in patients with EBT. 
All patients without EBT and 7 of the 8 patients with EBT presented a 
dissection immediately after PTA. In patients without EBT dissections 
observed after PTA (n=43) were absent at follow-up. Four of the patients with 
EBT presented with a persistent dissection at follow-up (Figure 2). The mean 
arc of the dissections (n=6) in these patients decreased ftom 65° ± 29° 
immediately after PTA to 35° ±12° at follow-up (p=0.04). 
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Figure 2. Corresponding intravascular ultrasound cross-sections obtained after 
percutaneous rransluminal angioplasty (PTA) of the femoropopliteal artery (left) 
and at 6-month.s follow-up (right} from a patient without endovascular 
brachytherapy (EBT) (A) and a patient with EBT (B). Immediatdy after PTA a 
small dissection (arrows) was present in both patients. At follow-up, no 
dissection was encountered in the patient without EBT, whereas in the patient 
with EBT a persistent dissection (arrow) was seen. 
Calibration "' 1 mm; + "' cad1eter. 
DISCUSSION 
Endovascular brachytherapy has recently emerged as a promising technique to 
reduce the incidence of restenosis after vascular intervention. Clinical studies 
have shown that radiation therapy in addition to PTCA or stent placement in 
coronary arteries is successful, with restenosis rates of 8% to 22% 15'18- 21 at 
6-months follow-up (39%-54% in patients without EBT) and 33% at 3-years 
follow-up (64% in patients without EBT).21 Furthermore, coronary studies 
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using radiation therapy in addition to PTCA for treatment of in-stent 
restenosis showed restenosis rates of 19% to 28% in patients with EBT, 
compared to 44% to 58% in patients without EBT at 6-months 
follow-up. z3-zs Until now, two studies have reported on the use of 
gamma-radiation in femoropopliteal arteries. The first group, represented by 
Minaret al.30 documented a restenosis rate of 40% at 1-year follow-up; in this 
study 10 patients with long-segment lesions (mean 16 em) were included. The 
second group, represented by Liermann et al.31 studied 40 patients with 
in-stent restenosis. These patients treated with PTA and additional EBT 
showed a clinical restenosis rate of 16% at follow-up (4 months to 7.5 years). 
The present study represents the first randomized study in which the effects of 
gamma radiation on both plaque growth and vascular remodeling after PTA 
of the femoropopliteal artery has been studied using IVUS. This study revealed 
a significant difference between patients without EBT and with EBT in lumen 
area change at 6-months follow-up at the treated site; in patients without EBT 
lumen area decreased with 9%, whereas in patients with EBT an increase in 
lumen area of 23% was observed (Table 3). This difference in lumen area 
change at follow-up was the result of a difference in vessel area change; in 
patients without EBT vessel area remained unchanged (+2%), whereas in 
patients with EBT a vessel area increase of 19% was observed. Overall, both 
groups of patients showed a similar increase in plaque area (12% and 16%, 
respectively). Changes observed at the junction site were similar to the changes 
at the treated site in patients with EBT (Table 4). In other words, EBT 
appeared to have a beneficial effect on lumen size due to its effect on the mode 
of vascular remodeling rather than on the degree of plaque growth. 
Some issues encountered in the present study deserve further discussion. 
Lumen gain at 6-months follow-up 
The observation that lumen gain following gamma-radiation of the 
femoropopliteal artery seen at 6-months follow-up was the result of positive 
vascular remodeling confirms the effects of EBT evidenced with IVUS in 
coronary arteries. 16'3z'33 In two of these studies 16'32 beta-radiation was used as 
adjunct to PTCA and in one study33 gamma-radiation was used in untreated 
coronary segments. These studies showed an increase in vessel dimension in 
the presence of an increase in plaque dimension resulting in no change to a 
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small increase in lumen dimension. Furthermore, in the study described by 
Ahmed et aL33 both patients without and with EBT were studied and results 
of their study were similar to the results seen in our study; patients without 
EBT showed a decrease in vessel dimension, whereas in patients with EBT an 
increase in vessel dimension was encountered. Both groups of patients showed 
a similar increase in plaque dimension. The reason why these observations 
were not documented in animal studies and in clinical studies using 
angiography, is that the latter technique only displays a silhouette of the 
lumen, without any information on plaque dimensions. The importance of 
IVUS in this respect is that IVUS is the only available imaging technique to 
document both plaque growth and vascular remodeling. 
The "edge effect" of radiation 
Although the mean lumen area at the junction site in patients with EBT 
increased by 12% at 6-months follow-up (Table 4), late lumen loss at 1 em 
and 1.5 em proximal to the junction site was observed in 2 of the 3 patients 
with an angiographic de novo stenosis. IVUS data showed that the decrease in 
lumen area at the stenotic lesion resulted from a decrease in vessel area (i.e. 
vascular shrinkage). Whether this late lumen loss was due to the "edge effect" 
of radiation therapy or a coincidental finding remains speculative. However, 
in a study performed by Kozuma et aL 32 in coronary arteries using 
beta-radiation after PTCA, similar results were encountered; vessel volume at 
the non-dilated edges in patients with EBT decreased, whereas vessel volume 
at the non -dilated edges in patients without EBT remained unchanged. Plaque 
volume increase in both groups of patients was similar. In contrast, in two 
other IVUS studies in stented coronary arteries using gamma-33 or 
beta-radiation34 the "edge effect" was not encountered. Reasons why these 
results differ from the results of the present study and the study performed by 
Kozuma et aL 32 remain speculative, bur may be due to the use of stents. Further 
investigation of the "edge effect" of EBT may be warranted. 
Persistent dissections after radiation 
Although qualitative IVUS data showed no change in the extent and number 
of calcified lesions in both groups of patients, dissections encountered 
immediately after PTA were absent at follow-up in patients without EBT, 
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whereas in 4 of the 8 (50%) patients with EBT a persistent dissection was 
encountered. Similar results were seen in an NUS study performed by Kay et 
aL35 in coronary arteries using beta-radiation. In their study a persistent 
dissection was encountered in 8 of the 16 patients (50%) with EBT at 
6-months follow-up. 
Results of their study raised the question whether persistent dissections in 
patients with EBT represent permanent dissections to the vessel wall or merely 
retardation in the healing process. Since the arc of the persistent dissections in 
the present study decreased from 65° to 35°, one may conclude that EBT 
seems to slow the normal healing process of the artery. However, whether this 
retardation in the healing process influences lumen dimensions in the 
longterm needs further investigation. 
Limitations 
The major limitation of the present study is the small number of patients with 
a completed IVUS follow-up (24 of the 38 patients). Consequently, a potential 
selection bias in the patient population may have occurred. 
CONCLUSION 
This randomized IVUS study in femoropopliteal arteries showed that 
gamma-radiation after PTA 1) has a positive effect on lumen dimensions at 
6-months follow-up by inducing positive vascular remodeling, 2) seems not 
to reduce plaque growth, and 3) appears to delay the healing process of 
dissections after PTA. 
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Automated Analysis of IVUS Images 
ABSTRACT 
The reproducibility of volume measurements in intravascular ultrasound 
(IVUS) images derived from separate pull-back manoeuvres remains to be 
elucidated. Patients (n=23) were imaged with IVUS prior to (first series) and 
following percutaneous transluminal angioplasty (PTA) (second series). In 15 
patients, one matched vascular segment (3-4 em in length), not subjected to 
PTA, was used for analysis of lumen, vessel and plaque volume using an 
automated contour analysis system. Volume measurements assessed by two 
independent observers and in the two separate series were compared. 
Interobserver differences in volume measurements were small (,;0.4%), with 
low coefficients ofvariation (,; 1. 7%) and high correlation coefficients (r= 1.00). 
Differences in volume measurements obtained in the two separate series were 
small(,; 2.6%), with low coefficients of variation(,; 8.6%) and high correlation 
coefficients (r=0.97 -0.99). In conclusion, volume measurements derived from 
IVUS images are highly reproducible. Therefore, IVUS may be used to 
monitor the progression/regression of atherosclerotic plaque volume in a 
longitudinal study. 
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INTRODUCTION 
The beneficial effect of statins on the secondary prevention of cardiovascular 
disease has been shown in studies with clinical endpoints l-Z and in studies with 
surrogate endpoints using angiography and external ultrasound.3-4 However, 
angiography displays a planar view giving information on vessel lumen 
diameter only, whereas external ultrasound gives information on arterial wall 
thickness only. In contrast, intravascular ultrasound (NUS) provides a 
cross-sectional view of the vessel with information on lumen, vessel and 
plaque area. 5-7 Recently, the reduction of plaque area by statins in segments 
with angiographically silent atherosclerotic plaques in patients with elevated 
serum cholesterol has been demonstrated by NUS.8 Nowadays, the use of an 
automated contour analysis system, which creates a three-dimensional (3-D) 
reconstruction of cross-sectional NUS images, allows assessment of 
atherosclerotic plaque volume.9- 12 
To use the automated contour analysis system in a clinical serting to establish 
the effect of lipid-lowering drugs on plaque volume, the reproducibility of 
volume measurements by two observers and from two separate pull-back 
manoeuvres obtained from femoropopliteal arterial segments was determined. 
METHODS 
Study group 
The study group comprised 23 patients: 14 men, 9 women; age range 48-88 
(median 71) y. Patients were selected from an existing study group with 
symptomatic femoropopliteal artery disease eligible for percutaneous 
transluminal angioplasty (PTA), who were studied with IVUS during 
intervention. The investigation was approved by the local committee on 
human research. Patients were included in the study after giving written 
informed consent. The patient selection was based on: (1) the availability of 
NUS images prior to and following intervention; (2) the use of a displacement 
sensing device to document the location of the NUS catheter; and (3) the 
presence of a side-branch together with a moderately diseased vascular 
segment 3-4 em in length not subjected to PTA. 
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Intravascular ultrasound 
The lVUS studies were performed using a mechanical system based on a single 
ultrasound element (30 MHz); the tomographic image is produced by a 
rotating element mounted on a guidewire-tipped 4.3F catheter (Du-MED, 
Rotterdam, The Netherlands, 0.035"=0.89 mm). 
IVUS images were obtained prior to (first series) and following PTA (second 
series) using the following procedure. The ultrasound catheter was introduced 
antegradely through a sheath into the femoropopliteal artery. Following 
catheter tip advancement distally across the symptomatic lesion, the catheter 
position was documented using fluoroscopy and a radiopaque ruler as 
reference. Then the catheter was pulled back manually. If possible, the 
guidewirewas removed first to avoid drop-out. A displacement-sensing device 
was used to document the location (i.e., position) of the catheter tip in steps 
of 0.1 mm. This device consists of a small, sterile, disposable sensing unit. The 
movement of the catheter activates a rotating wheel that converts the linear 
movement into an electronic pulse train signal so that the advancement or 
withdrawal of the catheter is digitized and wirelessly registered by a sterilizable 
unit to which the sensing unit is mounted. 13 The information on the position 
of the catheter tip was combined with the lVUS information on the monitor. 
To avoid the time-consuming process of manual selection of IVUS images 
required for automated analysis, a computerized position registry device with 
audio feedback enabling automatic selection of IVUS images was used. Based 
on the position information from the displacement-sensing device, the 
position of the IVUS catheter tip was translated into a digital audio signal, 
which was stored on the audio channel of the videotape using a time-code 
generator and a special video recorder. 
Automated analysis system 
The automatic contour detection is based on the minimum-cost algorithm, as 
described previously.9 The analysis program uses the Microsoft Windows 
operating system on a Pentium (100 MHz) personal computer with 32 Mbytes 
of internal RAM. In short, a maximum of 200 IVUS cross-sections was stored 
per vessel segment using a framegrabber (DT -3852; resolution 800 x 600 x 8 
bits). The analysis procedure can be divided into three steps (Figure 1). First, 
a sequence of lVUS images was digitized, and two perpendicular planes, 
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parallel to the longitudinal axis of the vessel, were selected to reconstruct 
longitudinal views. The user was able to optimize the angle and location of the 
perpendicular planes within the arterial lumen. Second, the program defined 
the contours of lumen boundary and vessel boundary (media-adventitia 
border) on these longitudinal planes by applying a minimum cost algorithm. 
In brief, a matrix was yielded from the digitized images, producing low values 
(costs) for large changes in echo intensity. Through this matrix, the algorithm 
determined a path with the smallest accumulated cost, which represents the 
boundaries (contours) of the arterial structures. Third, the longitudinal 
contour information was transformed to the cross-sections defining four 
guiding points on the two perpendicular planes. These points were used to 
facilitate automated contour detection oflumen and vessel boundary on each 
individual cross-section. During all steps, the user could interactively modify 
the contours of lumen and vessel boundary that were detected by the 
automated analysis system. The results were presented in a graph containing 
the measurements of each individual cross-section (Figure 1).9 
Lumen, vessel and plaque volumes were calculated as: 
n 
Volume= L,AxH 
i= I 
where A is the area, H is the interval between two cross-sections (slice 
thickness) and n is the number of IVUS images acquired. 
To select IVUS images for analysis, two methods were applied: ( 1) using the 
information on the audio channel, IVUS images were automatically selected 
and digitized at 0.2-mm intervals. The automated selection of IVUS images 
is limited to eight images per second. In case of missing images at 0.2-mm 
interval (caused by a too fast pull-back manoeuvre), the next image at a 
0.2-mm interval was selected. At the end of the analysis, the volume was 
determined by adjusting the slice thickness for the number of missing 
cross-sections; (2) using the displacement-sensing device information on the 
video screen, IVUS images were manually selected at 0.2-mm intervals and 
subsequently digitized. If cross-sections were missing, the gap was filled with 
neighbouring images. Selection of these neighbouring images was performed 
during the selection procedure. 
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Step 1 
--"+ 
Step3 
--"+ 
Figure 1. Automatic contour detection of intravascular ultrasound {IVUS) images. Upper panel: two 
perpendicular planes are used to reconstruct two longitudinal sections (A and B) from the digitized MJS 
images (step 1). Automatic contour detection of the intimal leading edge and the external boundary of the 
vessel is performed on these longitudinal sections (step 2). TI1.e longirudinal contours are represented as 
individual edge points in the cross-sectional images. TI1ese points define center and range of the final 
contour detection process on the cross-sectional images (step 3). Lower left panel presents a standard 
display of lumen, vessel and plaque area measurements derived from a femoropopliteal artery. Lower right 
panel: the wo reconstructed longitudinal sections (A and B) correspond to the perpendicular planes seen 
in the cross-section. 
Analysis 
Vascular segments obtained from the two separate pull-back manoeuvres were 
matched using side-branches (Figure 2). Subsequently, for each patient, one 
vascular segment (3-4 em in length) not subjected to PTA was selected for the 
following analyses: (1) assessment of lumen, vessel and plaque volume in the 
first and second series following automatic and manual selection of IVUS 
cross-sections; (2) assessment of lumen, vessel and plaque volume in the first 
and second series by a second independent observer using the automatically 
acquired series ofiVUS cross-sections. Volume measurements in IVUS images 
assessed by the two observers, in the automatically and manually selected 
images and in the first and second series, were subsequently compared. 
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First series Second series 
Figure 2. Schematic drawing showing how corresponding vascular segmenrs 
obtained from two separate pull-back manoeuvres are marched using 
side-branches and d1e information derived from the displacement sensing 
device. TI1.e two intravascular ultrasound (IVUS) images represent matched 
cross-sections showing the side-branch. 
Statistical analysis 
Results are given as mean± standard deviation (SD), or as a median and range. 
To compare the volume measurements, mean and SD of the paired differences 
were calculated. Systematic differences were analyzed with the Student's t-test 
for paired observations. The degree of variation was presented as a coefficient 
of variation, defined as the SD of the paired difference divided by the mean of 
the absolute value. Differences in volumes were plotted against the mean of the 
volume measurements. Linear regression analysis was performed to assess the 
sttength of the relation between the volume measurements. A p-value < 0.05 
was considered statistically significant. 
RESULTS 
For the present study, one corresponding vascular segment was used for 
analysis in 15 of the 23 patients; in the eight remaining patients, the 
analysis could not be performed due to extensive calcification(> 30° of 
the lumen circumference) (n=4) and the presence of a guide-wire and/ or 
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Table 1 lnterobserver reproducibility on lumen, vessel and plaque volume 
assessed in the two separate pull-back manoeuvres (n=30). 
First Second Coefficient 
observer observer a±SD of Variation 
(mm~ (mm~ (mm~ a(%) p-value (%) 
' 
Lumen volume 804.31 800.95 -3.36 ± 3.38 -0.4 0.00 0.4 1.00 
Vessel volume 1287.50 1285.20 -2.30 ± 8.16 -0.2 0.13 0.6 1.00 
Plaque volume 483.19 484.25 1.06 ± 8.45 0.2 0.50 1.7 1.00 
~;:, = mean difference; SD = standard deviation 
a too fast pull-back manoeuvre of the IVUS catheter, resulting in low image 
quality (n=4). The median length of the vascular segment selected for 
automated contour analysis of each patient was 3.7 (range 3.0-4.0) em. The 
selected vascular segments had a maximum area stenosis of 45% (median) 
(range 36-7 5%). 
The number of IVUS cross-sections selected manually per segment was 
determined by the length of the segment, and ranged from 151 to 200 (median 
194) in the two separate pull-back manoeuvres. 
Table 2 Data on lumen, vessel and plaque volume assessed in automatically 
and manually selected intravascular ultrasound images (n=30). 
Auto- Coefficient 
mated Manual •±SD • of variation (mm3) (mm3) (mm3) (%) p-value (%) 
' 
Lumen volume 804.31 803.75 -0.56±11.26 0.0 0.79 1.4 1.00 
Vessel volume 1287.50 1284.98 - 2.52±13.95 -0.2 0.33 1.1 1.00 
Plaque volume 483.19 481.23 -1.96±9.29 -0.4 0.26 1.9 1.00 
1:. "" mean difference; SD - standard deviation 
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Figure 3. lnterobserver difference in lumen, vessel 
and plaque volume assessed in the two separate 
pull-back manoeuvres (n·30). 
Figure 4. Difference in lumen, vessel and plaque 
volume assessed in automatically and manually 
selected intravascular ultrasound images (n=30). 
The number of cross-sections selected automatically per segment ranged from 
40 to 197 (median 157) in the first series, and from 47 to 195 (median 151) 
in the second series. The number of missing images using automated selection 
was 0 to 130 (median 16) in the first series, and 0 to 153 (median 12) in the 
second series. The interobserver differences in volume measurements were 
minimal (0.2-0.4%) and not significant (Table 1, Figure 3); the coefficient of 
variation was small (:d.7%) and correlation coefficients were high (r=l.O for 
all). 
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Table3 Inter-exam reproducibility on lumen, vessel and plaque volume 
assessed by the first observer. 
First Second Coefficient 
series series /:,. ±SD • of Variation (mm~ (mm3) (mm3) (%) p-value (%) r 
Automatic selection (n-15) 
Lumen volume 79391 81472 20.81 ± 68.58 26 26 85 99 
Vessel volume 127572 129928 23.55 ± 79.59 19 27 62 98 
Plaque volume 48182 48455 2.73 ± 26.90 6 70 56 98 
Manual selection (n•15) 
Lumen volume 79647 81103 14.56 ± 68.81 -1.8 43 86 98 
Vessel volume 127419 129577 21.58 ± 86.15 -1.7 35 67 98 
Plaque volume 47772 48473 7.01 ± 30.77 -1.5 39 64 97 
1:,. .. mean difference; SD .. standard deviation 
Table 2 and Figure 4 summarize the differences in lumen, vessel and plaque 
volumes assessed in the automatically and manually selected IVUS 
cross-sections. Differences in volume measurements were minimal (0.0-0.4%) 
and not significant; the coefficient of variation was small (:s: 1.9%) and 
correlation coefficients were high (r= LO for all). 
Results of lumen, vessel and plaque volumes assessed in the two separate 
pull-back manoeuvres (i.e., intere:xam reproducibility) are summarized in Table 
3 and Figure 5. Results of the volume measurements in the automatically and 
manually selected IVUS images were given separately. Differences in the 
volume measurements were minimal (0.6-2.6%) and not significant; the 
coefficient of variation was small (:s: 8.6%) and correlation coefficients were 
high (r=0.97 -0.99). 
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DISCUSSION 
Serial IVUS studies have been used to study the mechanism of vascular 
. . 14-16 d . 17-19 I dd. . . . f mtervennon an restenos1s. n a 1t1on, 1t may perm1t assessment o 
the progression or regression of atherosclerosis and the effects of 
pharmacological agents on this process. 8 In these studies, single or multiple 
IVUS cross-sections with a given interval were manually analyzed. The main 
problem in these studies is to find the same location during the next catheter 
passage following a certain time interval. Initially, the IVUS cross-sections 
were matched using anatomic markers such as side-branches and calcium 
and/ or using the position of the ultrasound catheter documented under 
fluoroscopic control. To facilitate matching of IVUS images, a motorized 
pull-back device for coronary application 20 and a displacement-sensing device 
£ . h 1 1" . 13'21 d 1 d 10r penp era app rcatlon were eve ope . 
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Figure 5. lnterexamination difference in lumen, vessel and plaque volume assessed by the first observer. 
The left panels represent data following automatic selection of intravascular ultrasound (IVUS) images. The 
right panels represent data following manual selection of NUS images. 
91 
Automated Analysis of IVUS Images 
These systems allow accurate documentation of NUS cross-sections in 
relation to any given side-branch. To enable volume measurements, which 
might be more reproducible in serial IVUS studies than area measurements, 
an automated contour analysis system was developed. 
The present study was aimed at the reproducibiliry of volume measurements 
obtained using the automated analysis system, as well as the agreement of 
volume measurements, in IVUS images acquired from two separate pull-back 
manoeuvres. This study demonstrated that: (1) the automated contour 
detection system results in volume measurements with a high degree of 
interobserver agreement, (2) automatic selection oflVUS images is feasible and 
(3) there is good agreement in volume measurements in NUS images acquired 
from two separate pull-back manoeuvres. 
lnterobserver reproducibility 
Previous studies performed in coronary10'22 and peripheral arteries 12'23 have 
shown that automated contour analysis has two main advantages over manual 
contour tracing: (1) the reduction in analysis time, and (2) the improvement 
in interobserver reproducibiliry of area measurements [the coefficient of 
variation improved from 17.2% to 11.3% for lumen area and from 10.5% to 
5. 7% for vessel area]. 12'23 The present study showed that measurement of 
volumes rather than areas further improved the interobserver reproducibiliry; 
the coefficient of variation was 0.4% and 0.6% for lumen and vessel volume, 
respectively. This reflects an averaging of the differences of the area 
Th h b d ' ' 11,24 measurements. e same p enomenon was o serve m coronary artenes. 
The interobserver difference oflumen and vessel area was 0.8% ± 7.3% and 
0.2% ± 4.4%, respectively, whereas the interobserver difference oflumen and 
vessel volume was 0.7% ± 2.7% and 0.2% ± 0.7%, respectively.24 
It should be acknowledged that the accuracy of volume measurements obtained 
in coronary arteries may be hampered by curvature of the vessel, the vessel 
distensibiliry and by cardiac movement. 25 In the absence of vessel curvature in 
femoropopliteal arteries, the problem of nonuniform rotational distortion of 
the catheter is not encountered in femoropopliteal arteries. To overcome the 
problem of vessel distensibiliry and cardiac movement, von Birgelen et al. 11 
introduced ECG-gated NUS image acquisition for volume measurements. 
However, we did not observe the characteristic sawtooth artifacts seen in 3-D 
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reconstructions of nongated images from coronary arteries in femoropopliteal 
arteries (Figure 1). In addition, given the high reproducibility of the volume 
measurements in femoropopliteal arteries, it is unlikely that ECG-gated image 
acquisition is required. 
The reproducibtlity of the plaque volume in the present study was lower than 
for lumen and vessel volume (coefficient of variation 1. 7% vs. 0.4% and 0.6%, 
respectively). This reflects the combined variabilityoflumen and vessel volume, 
a common observation reported in other studies.u'26 
Automatic and manual selection of IVUS cross-sections 
To avoid the time-consuming process of manual selection ofiVUS images, in 
the present study, a computerized position registry device with audio feedback 
was used. Depending on the speed of the pull-back of the IVUS catheter, both 
automatic and manual selection resulted in a certain number of missing 
images. The following solution was applied to overcome this problem: for 
automatic selection of IVUS cross-sections, the slice thickness was adjusted, 
and for manual selection of IVUS cross-sections, the neighbouring image was 
used. Although the latter solution is better than the first, no significant 
differences in volume measurements were found between the automatically 
and manually selected images, whereas the coefficients of variation were low. 
This suggests that (1) automatic selection is reliable, and (2) the interval 
between IVUS cross-sections selected for analysis might be increased. 
lnterexamination reproducibility 
This study showed for the first time that volume measurements are 
reproducible in IVUS images that were acquired from two separate pull-back 
manoeuvres. This high reproducibility is the summation of very low observer 
variability, the absence of significant vessel distensibility and the absence of 
significant catheter movement. Although no difference was found between 
automatically and manually selected images (Table 3, Figure 5), a slow 
pull-back, without missing images at the interval of 0.2 mm, might increase 
the agreement between the assessed volumes. 
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Clinical implication 
The results of this srudy suggest that IVUS has the potential to image the same 
vascular segment during follow-up and to assess changes in lumen, vessel and 
plaque volume in a longirudinal srudy. This permits assessment of progtession 
and regtession of atherosclerosis and the influence of pharmacological agents 
on the atherosclerotic plaque. 26 Furthermore, measurement of lumen, vessel 
and plaque volume may be used as a basis for dosimetry for subsequent 
radiation treatment approaches. 
Limitations 
It should be acknowledged that patients were selected from an existing srudy. 
In eight patients, no suitable vascular segment was available for analysis. 
Therefore, the ultimate quality of furure IVUS srudies may benefit from a slow 
pull-back manoeuvre and removal of the guide-wire. 
Secondly, at present, the automated system is limited in the length of the vessel 
segment (4.0 em) that can be analyzed at once. Increasing the interval between 
IVUS images to be gtabbed may extend the vessel length to be srudied. 
Finally, the automated contour analysis system is not a true 3-D acquisition 
system, but one that gives a "stacked coins" geometry of the vessel segment. 
However, in the straight femoropopliteal artety, the distortion will be smalL To 
obtain a real 3-D reconstruction in a curved coronary artery the ANGUS 
method, a combination of X-ray angiogtaphic and IVUS data may be used.27 
SUMMARY 
This study indicates that lumen, vessel and plaque volume in peripheral 
arteries can be assessed with low differences between observers and separate 
acquisitions of IVUS images. Therefore, in the future, IVUS may be used to 
monitor the progression/ regression of atherosclerotic plaque volume in a 
longitudinal study. 
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ABSTRACT 
In view of a prospective intravascular ultrasound (NUS) study, the 
reproducibility of the extent of the calcified lesion in NUS images derived 
from separate pull-back maneuvers was assessed. Patients (n=34) were imaged 
with NUS before and afrer percutaneous transluminal angioplasty (PTA) and 
at 1-y follow-up. In the presence of a calcified lesion, the largest arc and the 
length of the matched calcified lesions was assessed. lnterobserver differences in arc 
measurements were low(,;O. 7%), with low coefficients ofvariation (,; 5.8%). Similarly, 
interexamination differences in arc and length measurements were small 
(,;1.1%), with low coefficients of variation (,;3.2%). At follow-up, a 
nonsignificant increase in both the arc (1.9%) and length (1.7%) of the 
calcified lesion was observed. This study showed that measurements of the 
calcified lesion are highly reproducible; changes seen at 1-y follow-up were not 
significant. We conclude that NUS may be used to monitor the effect of 
medical intervention on the extent of the calcified lesion in a longitudinal 
study. 
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INTRODUCTION 
Previous studies have suggested good correlation between IVUS and histologic 
findings regarding the identification of calcified and noncalcified lesions. 1- 3 
Clinical IVUS studies were aimed at identifying whether or not calcified 
lesions were associated with restenosis 4-7 and with intimal hyperplasia and 
vascular remodeling. 8 In view of a prospective IVUS study on the effect of 
medical intervention on the progression and composition of the 
atherosclerotic lesion, the present study was designed to determine: (1) the 
reproducibility of the extent of the calcified lesion derived from separate 
pull-back maneuvers, and (2) to assess the progression of the extent of the 
calcified lesion seen at 1-y follow- up. 
METHODS 
Study group 
The study group consisted of 34 patients (23 men, 11 women; ages 43 to 88, 
median 68, y). Patients were selected from an existing study group with 
symptomatic femoropopliteal artery disease eligible for percutaneous 
trans luminal angioplasty (PTA). In patients with suspected restenosis on the 
basis of recurrent clinical symptoms (intermittent claudication, rest pain or 
night pain), the angiographic and IVUS investigation was repeated. The 
patients with no evidence of restenosis were studied by protocol with 
angiography and IVUS at 1-y follow-up. 8 The investigation was approved by 
the local committee on Human Research. Patients were included in the study 
after giving written informed consent. The patient selection was based on: (1) 
the availability of data from a displacement sensing device to document the 
location of the IVUS catheter, (2) the availability of corresponding IVUS 
images before and after intervention (group I), and (3) the availability of 
corresponding IVUS images after intervention and at 1-y follow-up (group II). 
Intravascular ultrasound 
The IVUS studies were performed using a mechanical system based on a single 
US element (30 MHz); the tomographic image is produced by a rotating 
element mounted on a guidewire-tipped 4.3 F catheter (Endosonics, Rijswijk, 
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Before PTA After PTA Follow-up 
Figure 1. Corresponding calcified lesion seen with intravascular US before (left) and after (middle) 
percutaneous transluminal angioplasty oftl1e femoropopliteal artery and at 1-y follow-up (right). Calcified 
lesions are characterized by the presence of a bright echo together with acoustic shadowing of the 
underlying strucrures (arrows). + "' catheter; calibration = 1 mm. 
The Netherlands, 0.035" = 0.89 mm). NUS images were obtained before and 
immediately after PTA using the following procedure; through a 7-F sheath 
in the femoropopliteal artery, the IVUS catheter was introduced antegradely 
over a guidewire, distal to the symptomatic lesion. The information on the 
location (i.e., position) of the cathetertip was documented using a radiopaque 
ruler and a displacement sensing device. The catheter was pulled back 
manually. If possible, the guidewire was removed first to avoid dropout. The 
displacement sensing device was used to document the location of the catheter 
tip in relation to the patella in steps of 0.1 mm during the pull-back 
maneuver.
9 This displacement-sensing device consists of a small, sterile 
disposable sensing unit. The movement of the catheter activates a rotating 
wheel that converts the linear movement into an electronic pulse train signal 
so that the advancement or withdrawal of the catheter is digitized and 
registered by a sterilizable unit to which the sensing unit is mounted. The 
information on the position of the catheter tip was combined with the IVUS 
information on the monitor and stored on an S-VHS videotape. After 1-y 
follow-up, the IVUS study was repeated. The procedure was performed in the 
same manner as described before. Using the radiopaque ruler as reference, care 
was taken to image both the vascular segment not subjected to PTA (i.e., 
nondilated vascular segment) and the vascular segment subjected to PTA (i.e., 
dilated vascular segment). 
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With the information of the radiopaque ruler, the displacement-sensing 
device and anatomic markers such as side-branches, the IVUS series of the 
non dilated and the dilated segment obtained before and after PTA and at 1-y 
follow-up were matched. These matched IVUS series were subsequently 
analyzed for the absence or presence of calcified lesions (Figure 1). 
Measurement of the calcified lesion 
Calcified lesions were easily identified by US imaging and were characterized 
by the presence of a bright echo together with acoustic shadowing of the 
underlying structures (Figure 1). In the presence of a calcified lesion(~ 30°), 
both the arc of calcium and the length of the lesion involved were assessed. 
The arc of the calcified lesion was measured from the IVUS cross-section 
showing the largest arc of calcium within the selected lesion using a protractor. 
The protractor was centered in the vessel circumference defined by the 
hyperechoic adventitia (Figure 2). 
Figure 2. An intravascular US image showing how 
the largest arc of the calcified lesion was measured 
using a protractor (two lines) centered in the vessel 
circumference. + = catheter; calibration '"' 1 rom. 
In the presence of acoustic shadowing of the vessel circumference caused by 
lesion calcification, extrapolation of the circumference of the vessel area was 
applied. If necessary, neighboring IVUS cross-sections were used to define the 
vessel area in the IVUS cross-section showing the largest arc of calcium. 
The length of the calcified lesion was measured using the information derived 
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from the displacement-sensing device. Lesion length was measured as the 
distance between the first and last NUS image showing the calcified lesion. 
Analysis 
1 Assessment of the arc of the calcified lesions obtained before PTA, after 
PTA and at 1-y follow-up by two independent observers (T. Hagenaars and 
E. J. Gussenhoven). 
2 Assessment of the length of the calcified lesions obtained before PTA, after 
PTA and at 1-y follow-up by the first observer. 
A comparison was made between: (1) the arc of the calcified lesions assessed 
by the two observers (i.e., interobserver difference), (2) the arc and length of 
the calcified lesions seen before and after PTA (i.e., interexamination 
difference) both in the nondilated and dilated vascular segment, and (3) the arc 
and length of the calcified lesions seen after PTA and at 1-y follow-up. 
Statistical analysis 
Results are given as mean ±standard deviation (SD), or as median and range. 
To compare the measurements of the arc and length of the calcified lesions, 
mean and SD of the paired differences were calculated. Systematic differences 
were analyzed with the Student's t-test for paired observations. The degree of 
variation was presented as a coefficient of variation, defined as the SD of the 
paired difference divided by the mean of the absolute value. A p value <0.05 
was considered statistically significant. 
RESULTS 
All 34 IVUS studies were completed successfully and complications as result 
of the NUS procedure were not encountered. Reviewing the IVUS records, 
11 patients were excluded from the study for the following reasons: absence of 
a calcified lesion (n=4), diffuse mediasclerosis of the vessel limiting length 
measurements of the calcified lesion (n=4), and the presence of a guidewire 
that hampered analysis of the calcified lesion (n= 3). In the remaining 23 
patients, a multitude of calcified lesions was selected for analysis. In group I 
(n=19), there were 54 calcified lesions (median 2; range 1 to 5 per patient) 
matched from the IVUS records obtained before and after PTA. From the 
remaining 4 of the 23 patients, NUS records before PTA were not available 
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(n=2), the displacement-sensing device was not used (n= 1), or the presence of 
a guidewire hampered analysis (n= 1). In group II (n= 12) there were 33 calcified 
lesions (median 2; range 1 to 5 per patient) matched from the IVUS records 
obtained after PTA and at 1-y follow-up. From the remaining 11 of the 23 
patients, IVUS records at follow-up were not available (n=10) or the 
displacement-sensing device was not used (n=1). 
Table 1 Interobserver reproducibility of d1e arc of d1e calcified lesion assessed with 
intravascular US before and after percutaneous transluminal angioplasty (PTA) and at 
1-y follow-up in 23 patients. 
ObseNer 
first second ~ ±SD ~ Coefficient 
CO) n (") (%) p-value of variation (%) r 
Before PTA (n-54) 118 119 0.9 ± 5.1 0.7 0.23 4.3 0.997 
After PTA (n-67) 110 110 0.1 ± 4.5 0.1 0.81 4.1 0.997 
Follow-up (n-33) 102 103 0.2 ± 5.9 0.2 0.82 5.8 0.992 
Total (n •154) 111 112 0.4 ± 5.0 0.4 0.31 4.5 0.997 
n "" number of calcified lesions, .D. - mean difference, SD .. standard deviation. 
The total number of IVUS cross-sections presenting with a calcified lesion 
analyzed after PTA was 67; of these, 20 were matched with both the IVUS 
cross-sections obtained before PTA (n=54) (group I) and the IVUS 
cross-sections obtained at follow-up (n= 33) (group II). The calcified lesions 
analyzed presented a median arc of98° (range 41 to 360°) and a median length 
of 88 (range 26 to 9 31) mm. 
The interobserver differences in measurement of the arc of the calcified lesions 
were minimal (,;0.7%) and not significant; the coefficients of variation were 
small (,;5.8%) and the correlation coefficients were high (r<:0.992) (Table 1). 
Table 2 summarizes the interexamination differences in the arc and length of 
the matched calcified lesions obtained before and after PTA. 
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Table2 lnterexamination reproducibility on the arc and length of the calcified lesion assessed 
with intravascular US before and after percutaneous rransluminal angioplasty in 19 
patients. 
Series A Coefficient 
first second A±SD (%) p-value of variation (%) r 
Non-dilated segment (n•29) 
Arc (0 ) 111 110 -1.2 ± 3.6 1.1 0.07 3.2 0.998 
Length (mm) 115 116 0.7 ± 3.3 0.6 0.27 2.8 0.999 
Dilated segment (n•25) 
Arc CO) 126 120 -6.2 ± 11 -4.9 0.01 8.8 0.989 
Lengd1 (mm) 133 135 1.4 ± 5.3 1.1 0.19 3.9 0.999 
n ... number of calcified lesions, 1::.- mean difference, SD "' standard deviation. 
The numbers of individual matched calcified lesions obtained from the 
nondilated and the dilated vascular segments were 29 and 25, respectively. The 
differences in both the arc and length of the calcified lesions acquired from the 
nondilated vascular segments were minimal (;; 1.1 %) and not significant; the 
coefficients of variation were small (:>3.2%) and the correlation coefficients 
were high (r<:0.998). Similarly, the difference in the length of the calcified 
lesions acquired from the dilated vascular segments was minimal (1.1 %) and 
not significant. However, a significant difference (-4.9%) in the arc of the 
calcified lesions was encountered at the dilated vascular segments. 
Table 3 presents measurements of the arc and length of the calcified lesions 
obtained afrer PTA and at 1-y follow-up. A nonsignificant increase in both 
the arc (1.9%) and length (1. 7%) of the calcified lesions was observed. 
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Table 3 Difference in the arc and length of calcified lesions (n=33) assessed with 
intravascular US after percutaneous transluminal angioplasty (PTA) and 
at 1-y follow-up in 12 patients. 
After PTA At Follow-up 
Arc eJ 101 ± 20 
Length (mm) 100 ± 48 
103 ± 20 
102 ± 47 
~ .. mean difference, SD = standard deviation. 
DISCUSSION 
A±SD 
1.9 ± 10.4 
1.7 ± 5.8 
A (%) p-value 
1.9 
1.7 
0.54 
0.34 
Previous studies have suggested good correlation between IVUS and histologic 
findings regarding the identification of calcified and noncalcified lesions.1-3 
From a previous study, we learned that the sensitivity of angiography as 
compared to IVUS was poor for calcified lesions (30%) 10; therefore, 
angiography should not be used to assess progression of calcium in a 
longitudinal follow-up study. Because thickness oflesion calcification cannot 
be measured, the arc and length should be regarded as the "best" possible 
measurement. 11 The present IVUS study aimed to document the 
reproducibility of the extent of the calcified lesion, as well as the progression 
of the extent of the calcified lesion seen at 1-y follow-up. The following issues 
should be addressed. 
Reproducibility 
The results of the current study indicated that the reproducibility of both arc 
and lengrh measurements assessed by independent observers and from separate 
pull-back maneuvers was high, showing small differences (<1.1%), low 
coefficients of variation (<5.8%) and high correlation coefficients (>0.992). In 
vascular segments that were subjected to PTA, however, the interexamination 
difference encountered in the arc of the calcified lesion was significant ( -4 .9%; 
p=0.01). This may be explained by the fact that, as a result of balloon 
angioplasty, the vessel circumference after intervention is larger than the 
preintervention vessel circumference. 
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As a consequence, the arc of the calcified lesion measured after intervention 
was significantly smaller (-6.2°) than the arc measured before intervention. 
Our study results on the interobserver variability of arc measurements of the 
calcified lesion concur with others. Fitzgerald et aL4 and van der Lugt et aL 12 
reported close agreement for the interobservervariability of arc measurements 
of the calcified lesion. 
In the present study, we used the vessel circumference to center the protractor 
to quantitate the arc of the calcified lesion. Other approaches have been 
advocated as well: either the protractor was centered on the imaging catheter 4' 13 
or centered on the lumen. 14 These latter studies aimed to relate the extent of 
the calcified lesion obtained from one single pull-back maneuver to predict 
future cardiac events or to define risk factors leading to lesion calcification. 
However, the position of the imaging catheter may be different at each 
pull-back maneuver and the center of the lumen may be more liable to change 
at follow-up compared to the center of the vessel circumference. In view of 
future longitudinal IVUS studies, we believe that the center of the vessel 
circumference should be used for analysis of the arc of the calcified lesion. 
To measure the length of the calcified lesion, we used a validated 
displacement-sensing device.9 Results from the present study indicate that this 
system reproducibly measures the length of the calcified lesion 
(interexamination differences ~ 1.1 %). For coronary application, Mintz et aL 13 
used a motorized pull-back device, using the number of seconds or the 
number of frames of the videotape in which the calcification appeared to 
determine the lesion length; however, they did not report on the 
reproducibility of this procedure. It is worth mentioning that the errors in 
calcium length measurements using pull-back techniques in coronary arteries 
may include: (1) angulation of the catheter tip in relation to the imaged 
calcification, (2) catheter-induced deformation or straightening of the natural 
coronary artery tortuosity, and (3) beam thickness. 11 The results of the present 
study indicate that these problems are not encountered in straight peripheral 
arteries. 
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Change at follow-up 
This study showed a nonsignificant increase in both the arc and length of the 
calcified lesion at 1-y follow-up. Recently, van Lankeren et al.8 reported that 
the extent of the calcified lesion significantly increased from 51 o to 66° at 16 
months follow-op. The reason why the results from the latter study differ from 
the present study may be due to the difference in follow-up duration and to 
the difference in arc measurements; van Lankeren et al. 8 graded the extent of 
the calcified lesion in steps of 30° by visual estimation. 
Clinical implication 
One may argue whether or not a future study using a larger study population 
and/ or a longer follow-up might achieve a statistically significant increase in 
the extent of the calcified lesion. Moreover, because IVUS is a costly and 
invasive procedure, future IVUS studies aimed at monitoring the effect of 
medical intervention on the progression of atherosclerosis should be executed 
in conjunction with regular interventional procedures. 
CONCLUSION 
This IVUS study showed that measurements of the extent of the calcified 
lesion are highly reproducible; the changes seen at 1-y follow-up were not 
significant. We conclude that IVUS may be used in a longitudinal study to 
monitor the effect of medical intervention on the composition of the 
atherosclerotic lesion. 
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ABSTRACT 
Volume measurements derived from intravascular ultrasound (IVUS) images 
assessed with an automated contour analysis system are accurate and 
reproducible. However, it is unknown to what extent plaque volume may 
change at follow-up. Therefore, the purpose of this longitudinal study is to 
examine whether IVUS is a sensitive means to identify progression of 
atherosclerosis and its derived primary end point plaque volume at 1-year 
follow-up. Patients (n= 11) undergoing percutaneous trans luminal angioplasty 
(PTA) of the femoropopliteal artery were studied with IVUS immediately after 
PTA in the same session and at 1-year follow-up. Matched well-identified 
vascular segments (3 to 4 em in length), not subjected to PTA, imaged at 
baseline and after 1-year follow-up, were used for calculation of the 
longitudinal change in lumen, vessel and plaque volume, and mean plaque 
thickness. The median length of the selected vascular segments was 4 em. At 
follow-up (12 ± 2 months) a nonsignificant increase in lumen volume (2.3 ± 
11 %), vessel volume (2.0 ± 7 .0%), and plaque volume (3.0 ± 5.1 %) was seen; 
the mean plaque thickness increase was 2.2 ± 5.6%. In conclusion, progression 
of atherosclerosis implies changes in plaque and vessel volume, resulting in 
lumen volume change. This observation has imporrant implications for future 
clinical trials aimed at monitoring the effect of pharmacologic agents on the 
progression and/ or regression of atherosclerosis. 
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INTRODUCTION 
Intravascular ultrasound (IVUS) is an acknowledged technique to assess the 
different components of the diseased vessel wall and to measure the change in 
lumen, vessel, and plaque area as result of vascular intervention.1·7 Serial IVUS 
studies have shown that following successful vascular intervention, plaque 
growth and the mode of vessel area change (compensatory enlargement or 
vascular shrinkage) determined the change in lumen area at follow- up. 8• 12 To 
document progression and/ or regression of atherosclerotic plaque volume in 
a longitudinal study, an automated contour analysis system was developed; this 
system creates a 3 -dimensional reconstruction from a multitude of IVUS 
cross-sectional images. 13 Validation studies have shown that volume 
measurements obtained with this analysis system were accurate with low 
. b . b'l' 14. 17 d h' hl d 'bl 18 Th d mtero servervana 1 1ty an were 1g y repro uc1 e. e present stu y 
examines whether IVUS is the means to sensitively identify progression of 
atherosclerosis at !-year follow-up. 
METHODS 
The study group consisted of 16 patients (12 men, 4 women; aged 43 to 80 
years [median 71]). Patients were selected from an existing study group with 
symptomatic femoropopliteal artery disease. At baseline, these patients were 
studied with IVUS before and after percutaneous transluminal angioplasty 
(PTA). A per-protocol follow-up IVUS investigation was performed after 1 
year. 12 The investigation was approved by the local committee on Human 
Research. Patients were included in the study after they gave informed consent. 
Patient selection was based on an angiographically successful intervention 
(diameter stenosis <50%) and on the availability of a vascular segment not 
subjected to PTA (<:3 em length together with a side-branch) imaged with 
IVUS immediately after intervention in the same session. 
Intravascular ultrasound 
The IVUS studies were performed using a single rotating ultrasound element 
(30 MHz) on a guidewire-tipped 4.3Fr catheter (Endosonics, Rijswijk, The 
Netherlands, 0.035 in). The following procedure was applied: the IVUS 
catheter was introduced antegradely over a guidewire through a 7Fr sheath in 
the femoropopliteal artery, distal to the lesion. The information on the 
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location (i.e., position) of the catheter tip was documented using a radiopaque 
ruler and a displacement sensing device. 19 The latter device was used to 
document the location of the catheter tip in relation to the patella in steps of 
0.1 mm during the pull-back maneuver. The information on the catheter tip 
position was mixed with the IVUS images on the monitor and ttanslated into 
a digital audiosignal, which was stored on the audiochannel of the videotape 
using a timecode generator and a special videorecorder. This enabled 
automated selection of IVUS images required for the longitudinal 
reconstruction. For the purpose of this study care was taken that vascular 
segments not subjected to PTA, proximal to the tteated site, were recorded for 
analysis. To avoid dropout due to the guidewire, the IVUS images were 
recorded after the guidewire was removed. After 1-year follow-up, the IVUS 
study was repeated. The procedure was performed in the same manner as 
described previously. Vascular segments imaged after PTA and at follow-up 
were matched with the use of side-branches and the information of the 
displacement sensing device 
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After PTA Follow-up 
Side-branch 
Figure 1. Schematic drawing showing how corresponding vascular segments obtained 
immediately after intervention and at follow-up are matched using side-branches and 
d1e information from the displacement sensing device. 
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(Figure 1). From each patient the most proximal located vascular segment 
(3 to 4 em in length) that had not been subjected to PTA was selected for 
automated analysis. 
Automated analysis system 
An automated contour analysis system, which created a longitudinal 
reconstruction of a multitude of cross-sectional IVUS images, was used to 
assess volume measurements of lumen, vessel, and plaque. The automated 
contour detection was based on the minimum-cost algorithm, as described 
previously. 13 In brief, a matrix was yielded from the digitized images, 
producing low values (costs) for large changes in echo intensity. Through this 
matrix, the algorithm determined a path with the smallest accumulated cost 
that represents the boundaries (contours) of the arterial structures. The analysis 
program uses the Microsoft Windows operating system on a Pentium (100 
MHz) personal computer with 32 Mbytes of internal RAM. Using a 
framegrabber (DT -3852; resolution 800 x 600 x 8 bits) a maximum of 200 
IVUS cross sections was stored per vascular segment. The analysis procedure 
could be divided in 3 steps (Figure 2). First, a sequence of IVUS images was 
selected and digitized at 0.2-mm intervals. Two perpendicular planes, parallel 
to the longitudinal axis of the vessel, were selected to reconstruct longitudinal 
views. Second, the program defined the contours of lumen and vessel 
boundaries on these longitudinal planes by applying the algorithm. Third, the 
longitudinal contour information was transformed to the cross sections by 
defining 4 guiding points. By applying the algorithm and the information of 
the 4 guiding points, lumen and vessel boundaries on each cross section were 
detected. During all steps, the user could interactively refine the analysis. The 
results were presented in a graph containing the measurements of each cross 
section. 13 Lumen, vessel, and plaque volumes were calculated as: 
n 
Volume=L,AixH 
i=l 
where A is the area, H is the interval between the 2 cross sections, and n is the 
number of acquired IVUS images. In addition, the mean plaque thickness (i.e., 
intima-media thickness) of each vascular segment was determined. 
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Reproducibility of volume measurements 
The reproducibility of volume measurements using the automated contour 
analysis system was determined in a previous study.18 Briefly, 15 patients were 
imaged with IVUS before and after PTA of the femoropopliteal artery. From 
each patient, 1 vascular segment of 3 to 4 em (median 3. 7), which was not 
subjected to PTA, was selected for measurements oflumen, vessel, and plaque 
volume. The analysis was performed by 2 independent observers. 
Figure 2. Automatic contour detection of 
IVUS images. Upper . panel: 2 
perpendicular planes are used to 
reconstruct 2 longitudinal sections (A 
and B) from the digiti:ed IVUS images 
(Step 1). Automatic contour detection of 
the intimal leading edge and the o..-cernal 
boundary of the vessel is performed on 
these longirudinal sections (Step 2). 'TI1e 
longitudinal contours are represented as 
individual edge points in the 
cross-sectional images. These points 
define center and range of the final 
contour detection process on the 
cross-sectional IVUS images (Step 3). 
Lower panel: the 2 reconstructed 
longitudinal sections {A and B) 
correspond to the perpendicular planes 
seen in the cross section. 
The results showed that the interobserver differences in volume measurements 
oflumen, vessel, and plaque were small (0.2% to 0.4%), with low coefficients 
of variation (0.4% to 1. 7%) and high correlation coefficients (r = 1.00 for all). 
Similarly, volume measurements obtained in the 2 separate pull-back 
maneuvers were small (0.6% to 2.6%), with low coefficients of variation (5.6% 
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to 8.6%) and high correlation coefficients (r = 0.97 to 0.99). 
Data analysis 
First, a comparison was made between lumen, vessel and plaque volume, and 
mean plaque thickness assessed at baseline and after 1-year follow- up. Because 
the length of the vascular segments used for analysis was not uniform, the 
change in volume was given in cubed millimeters per centimeter and as a 
percentage of the volume measurements after intervention. Second, a 
comparison was made between the change in plaque volume and mean plaque 
thickness. 
Results are given as mean ± SD or as median and range. The volumes seen 
immediately after intervention and at follow-up were compared with Student's 
t test for paired observations. A p value of <0.05 was considered statistically 
significant. 
RESULTS 
The mean follow-up period was 12 ± 2 months. Vascular segments initially 
selected after intervention could in all instances be matched with the vascular 
segments obtained at follow-up using side-branches and the information of 
the displacement sensing device. The IVUS quality of the vascular segment 
selected was adequate to document lumen, vessel, and plaque volume in 11 of 
the 16 patients; in the 5 remaining patients the analysis of lumen volume 
(n=1), vessel volume (n=3), or both (n=1) could not be performed due to low 
image quality at follow-up (n=1), progression of calcified lesions (n=3), and 
subintimal introduction of the guidewire (n= 1). The side-branch of the 
selected vascular segments was situated proximally (n=6) or distally (n=3); in 2 
patients the vascular segment was interposed between 2 side-branches. The 
median distance between the segment subjected to PTA and the selected 
vascular segment used for analysis was 8 em (range 1 to 17). The median length 
of the vascular segments selected for analysis was 4 em (range 3.2 to 4). The 
selected vascular segments had a maximum area stenosis of 44% (median) 
(range 31% to 63%). 
Table 1 summarizes the measurements of lumen, vessel and plaque volume, 
and mean plaque thickness of each patient after intervention and at 1-year 
follow-up. Changes in lumen, vessel and plaque volume, and mean plaque 
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thickness seen with IVUS in the individual matched vascular segments after 
intervention and at follow-up are summarized in Table 2. The mean increase 
in plaque volume of 3.7 ± 7.1 mm3/cm (3.0 ± 5.1%; p=0.12) was associated 
with an increase in vessel volume of 3.9 ± 27 mm3/cm (2.0 ± 7.0%; p=0.64), 
resulting in an increase in lumen volume of 0.2 ± 23 mm3 /em (2.3 ± 11 %; 
p=0.98). At follow-up the mean plaque thickness increased to 0.02 ± 0.08 mm 
(2.2 ± 5.6%; p=0.34). 
Table 1 Lumen, Vessel and Plaque Volume and Mean Plaque Thickness Seen in Matched Vascular 
Segments* 
Lumen volume Vessel volume Plaque volume Plaque thickness 
.. After PTA Follow-up After PTA Follow-up After PTA Follow-up After Follow-
" 0 
- " 
" " (mm3/cm) (mm3/cm) (mm3/cm) (mm3/cm) (mm3/cm) (mm3/cm) PTA v 0 up 
" ~ >~ (mm) (mm) 
1 262 263 358 370 96 108 0.98 1.09 
2 230 261 323 359 93 99 1.00 1.00 
3 106 137 226 258 120 121 1.69 1.55 
4 171 177 301 305 430 129 1.54 1.50 
5 322 348 478 519 156 171 1.40 1.47 
6 187 177 289 285 102 108 1.18 1.28 
7 249 245 392 386 143 141 1.44 1.44 
8 241 246 408 411 166 165 1.69 1.65 
9 404 363 528 487 125 124 1.04 1.08 
10 313 282 502 465 189 183 1.68 1.70 
11 263 252 476 479 213 227 2.01 2.16 
Mean 250 250 389 393 139 143 1.42 1.45 
±SD ± 80 ± 69 ± 99 ± 88 ± 39 ±39 ± 0.34 ± 0.33 
*From 11 patients studied with IVUS after intervention and at 1-year follow-up. 
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The comparison between the change in plaque volume and mean plaque thickness 
in the individual vascular segments is shown in Figure 3 and Table 2. 
It was discovered that the location of the vascular segments selected for analysis 
(distance to the segment subjected to PTA) and the position of the side-branch 
Table 2 Changes in Lumen, Vessel and Plaque Volume and Mean Plaque 1l1id.'ness Seen in 
Matched Vascular Segments* 
ALumen volume t::. Vessel volume .Ll..Plaque volume L!..Plaque d1id."lless 
" ~ 
" c 
- v a a 
" " >eX (mm
3/cm) % (mm3/cm) % (mm3/cml % (mm) % 
1 0.7 0.3 12 3.4 11 12 0.11 11 
2 31 13 37 11 6.0 6.4 0.01 0.5 
3 31 29 32 14 0.7 0.5 -0.14 -8.2 
4 5.9 3.5 4.1 1.4 -1.8 -1.4 -0.05 -2.9 
5 26 8.2 41 8.6 15 9.4 0.07 5.1 
6 -10 -5.4 -4.0 -1.4 6.2 6.1 0.10 8.1 
7 -4.7 -1.9 -6.9 -1.8 -2.2 -1.5 -0.004 -0.3 
8 4.9 2.0 3.3 0.8 -1.6 -0.9 -0.03 -2.0 
9 -41 -10 -41 -7.7 -0.3 -0.3 0.04 4.3 
10 -30 -9.7 -37 -7.3 -6.1 -3.2 0.02 1.1 
11 -11 -4.3 2.6 0.6 14 6.6 0.15 7.4 
Mean 0.2 2.3 3.9 2.0 3.7 3.0 0.02 2.2 
±SD ± 23 ±11 ± 27 ± 7.0 ± 7.1 ± 5.1 ±0.08 ± 5.6 
(p=0.98) (p•0.64) (p-0.12) (p-0.34) 
*From 11 patients srudied with IVUS after inteNention and at 1-year follow-up. 
A .. Change; - "" Decrease 
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in relation to the selected vascular segment had no influence on the changes 
in lumen, vessel and plaque volume, and mean plaque thickness seen at 
follow-up. 
DISCUSSION 
The present IVUS study is the first in which vascular segments obtained at 
baseline were matched with the vascular segments at 1-year follow-up using 
side-branches, to document the change in lumen, vessel and plaque volume, 
and mean plaque thickness. 
By combining the IVUS procedure with angiography at baseline and at 
follow-up, the additional burden to the patient was smalL The advantage of 
using the automated contour analysis system to determine volume 
measurements from a multitude of IVUS cross sections, rather than using 
manual analysis to assess area measurements from single IVUS cross sections, 
was improved interobserverreproducibility. 18 From coronary artery studies, we 
learned that the accuracy of volume measurements may be hampered by the 
vessel distensibility, cardiac movement, and curvature of the vesseL 16 However, 
in the relatively straight femoropopliteal artery used in the present study the 
problem of vessel distensibility and cardiac movement was not observed in the 
longitudinal reconstructions of the IVUS cross-sectional images (Figure 2). 
Based on these findings, we postulate that the femoropopliteal artery will be 
suitable for progression and/ or regression studies using IVUS together with 
the automated contour analysis system. The following issues encountered in 
the present study deserve specific comment. 
Volume change at 1-year follow-up 
The present longitudinal IVUS study revealed that at follow-up the plaque 
volume increase (3.0 ± 5.1 %) was associated with an increase in vessel volume 
(2.0 ± 7 .0%), resulting in an increase in lumen volume (2.3 ± 11 %) (see Tables 
1 and 2). Although these changes were not statistically significant, the increase 
in plaque volume should be regarded as progression of atherosclerosis, whereas 
the increase in vessel volume might be explained by the Glagov effect.20 
Recently, van Lankeren et al12 reported an increase in both the plaque (15%) 
and vessel (6%) areas offemoropopliteal arteries afrer 16 months of follow-up, 
resulting in a decrease in lumen area (- 3%). Similarly, Takagi et af' reported 
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that at 3-year follow-up, plaque area (41 %) and vessel area (9%) increased in 
the coronary arteries, resulting in a decrease in lumen area ( -9%). The 
difference between plaque volume change encountered in the present study 
and plaque area change reported by others may be attributed to the difference 
in patient selection, selection of individual cross sections, and the difference 
in follow-up duration. 
Plaque volume versus mean plaque thickness 
Although the mean change in plaque volume (3.0 ± 5.1 %) was of the same 
order as the mean change in mean plaque thickness (2.2 ± 5.6%), individually, 
the 2 parameters were different (see Table 2; Figure 3). The difference can be 
explained by the change in mean plaque thickness, which is intimately related 
to changes in both plaque and vessel volume. In other words, in the presence 
(%) 15 
10 
5 
-5 
Plaque 
Volume 
Plaque 
thickness 
Figure 3. TI1e relation between the change in plaque volume (left) and mean plaque 
thickness (right) seen at follow-up in d1e patients. T11e 2 measurements from each 
patient are connected by a line, showing the discrepancy between the change in 
plaque volume and mean plaque thickness. 
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of no change in plaque volume and an increase or decrease in vessel volume, 
plaque thickness measurements may either underestimate or overestimate the 
change in plaque seen at follow-up. With these findings in mind, one should 
reconsider the value of intima-media thickness measurements derived from 
external ultrasound, used to document the progression of atherosclerosis. 22- 26 
De Groot et af6 established that the intima-media thickness did not change 
afrer 2-year follow-up in the control group. In contrast, in the present study 
an increase in plaque volume (3%) and vessel volume (2%) were evidenced at 
1-yearfollow-up; in addition, the mean plaque thickness increased by 2.2 %. 
The difference between plaque thickness change seen in the control group 
reported by de Groot et al26 and that in the present study may be because 
external ultrasound provided data on the far wall of an arterial segment only, 
whereas IVUS has the potential to image the total arterial segment. The strong 
advantage of IVUS compared with intima-media thickness measurements is 
embedded in that IVUS has the potential to sensitively observe the impact of 
arterial remodeling on the lumen and plaque change. 
Clinical implications 
The results of this study support the idea, dating from 1989, that IVUS can be 
used to grade the effect of pharmacologic interventions on the progression 
and/ or regresssion of atherosclerosis. 27'28 Because the potential of IVUS to 
sensitively observe arterial remodeling has been established,8- 12 we believe that 
the results of progression and/or regression studies using intima-media 
thickness measurements from external ultrasound should be reconsidered. 
Indeed, in the presence of an increase in plaque and vessel volume seen at 
follow-up, intima-media thickness measurements may reveal no change. With 
these findings in mind, we believe that volumetric IVUS studies are excellendy 
suited to establish the basic mechanism associated with progression and/ or 
regression of atherosclerotic plaque and the influence of pharmacologic agents 
on these processes. 
Study limitations 
In 5 of the 16 patients in whom a vascular segment was selected after 
intervention, the quality of the vascular segment at follow-up hampered 
analysis. Second, currendy, the automated contour analysis system is restricted 
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in the length of the vascular segment (4 em) that can be analyzed. Increasing 
the capacity of storing IVUS images may overcome this problem. Another 
solution might be to increase the interval (0.2 mm) between the stored IVUS 
images. Third, determination of the factors that may affect an increase or 
decrease in vessel and plaque volume at follow-up needs further investigation. 
It should be stressed that the automated contour analysis system cannot be 
used in vascular segments containing a dissection as a result of intervention. 29 
Fourth, we must bear in mind that thus far no correlation has yet been 
established between change in volumetric IVUS parameters and future vascular 
events. Finally, contrary to intima-media thickness measurements obtained 
with external ultrasound, IVUS is an expensive and invasive procedure, and 
is, for ethical reasons, less fit for investigation of control groups without disease 
and largescale epidemiologic-oriented population studies. 
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ABSTRACT 
The purpose of this study was to compare the vascular response seen with 
intravascular ultrasound (IVUS) at 1-year follow-up between statin-treated 
and non-statin-treated patients. Patients (n=10) undergoing percutaneous 
transluminal angioplasty (PTA) of the femoropopliteal artery were studied with 
IVUS immediately after PTA and at 1-year follow-up. In non dilated matched 
vascular segments the change in lumen, vessel and plaquevolumewas assessed. 
In balloon -dilated matched vascular segments, the change in lumen, vessel and 
plaque area was assessed. A comparison was made between statin-treated (n=5) 
and non-statin-treated patients (n=5) in lumen, vessel and plaque changes. At 
follow-up, both statin-treated and non-statin-treated patients showed a 
similar increase in plaque volume at the nondilated segment (+4% and+ 2%, 
respectively). In statin-treated patients the plaque volume increase was 
compensated by an increase in vessel volume (+2%), resulting in an increase 
in lumen volume(+ 1 %). In non-statin-treated patients, on the other hand, 
the increase in plaque volume was associated with a decrease in vessel volume 
(-2%), resulting in a decrease in lumen volume (-4%). At the balloon-dilated 
segment a similar trend in changes of lumen, vessel and plaque was 
encountered. Differences between both groups of patients were not statistically 
significant. Despite the nonsignificant nature of the observation, this small 
retrospective IVUS study may generate the hypothesis that statin therapy may 
contribute to superior long-term lumen dimensions by inducing positive 
vascular remodeling both in nondilated and balloon-dilated vascular segments. 
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INTRODUCTION 
Over the past decade, intravascular ultrasound (IVUS) has become an 
acknowledged technique to document immediate and long-term changes in 
lumen, vessel and plaque area following a vascular intervention.1- 4 Encouraged 
by these results, an automated contour analysis system was developed to assess 
lumen, vessel and plaque volume derived from IVUS images. 5-8 In a previous 
study we established that this analysis system is a sensitive means to identify 
progression of atherosclerosis at 1-year follow-up.9 The scope of the present 
retrospective observational IVUS study was to determine the difference 
between statin-treated and non-statin-treated patients in progression of 
atherosclerosis seen at 1-year follow-up. 
METHODS 
The study group comprised 16 patients (12 men, 4 women), with an age range 
of 43 to 80 (median 71) years. Patients were selected from an existing study 
group with symptomatic femoropopliteal artery disease. At baseline session 
these patients were studied with IVUS immediately after percutaneous 
transluminal angioplasty (PTA). A per protocol follow-up investigation was 
performed after 1 year. The local Committee on Human Research approved 
the investigation. Patients were included in the study after they gave informed 
consent. The patient selection was based on: (1) an angiographically successful 
PTA (angiographic diameter stenosis <50%), (2) the availability of IVUS 
images immediately after PTA and at 1-year follow-up, and (3) the use of a 
displacement sensing device. Data collected on each patient included age, 
gender, systemic hypertension, diabetes, cigarette smoking, indication for 
intervention (Fontaine classification 2B [claudication], 3 [rest pain] and 4 
[ulceration]) and total cholesterol levels during the follow-up period. 
Intravascular ultrasound 
The IVUS studies were performed using a single rotating ultrasound element 
(30 MHz) on a guidewire-tipped 4.3F catheter (Endosonics, Rijswijk, The 
Netherlands, 0.035"). Briefly, the following procedure was applied: Through 
a 7F sheath in the femoropopliteal artery the IVUS catheter was introduced 
antegradely over a guidewire, distal to the lesion. After the guidewire was 
removed to avoid dropout, the ultrasound catheter was pulled back manually. 
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A displacement sensing device was used to document the location (i.e. 
position) of the cathetertip in steps of0.1 mm during the pullback maneuver. 10 
The information on the cathetertip location was (1) combined with the NUS 
images on the monitor and (2) translated into a digital audiosignal that was 
stored on the audiochannel of the videotape using a timecode generator and 
a special videorecorder. This digital audiosignal enabled automatic selection 
of the NUS images required for volume measurements. Using the information 
on the cathetertip and anatomic markers such as side branches and typical 
shaped calcifications, the NUS cross sections obtained after PTA and at 
follow-up were matched. 
From each patient 1 or 2 vascular segments (3- to 4-cm length) not subjected 
to PTA (i.e. nondilated segments) were selected for volume measurements of 
lumen, vessel and plaque using an automated contour analysis system. Vascular 
segments subjected to PTA (i.e. ba!!oon-di!ated segments) could not be analyzed 
using the automated contour analysis system due to an irregular-shaped lumen 
circumference caused by a dissection as result of the vascular intervention. 7 
For this reason, the change in vascular dimensions in the balloon-dilated 
segments was assessed in individual matched NUS cross sections selected with 
1 em interval. These cross sections were subsequently manually analyzed for 
lumen, vessel and plaque area. 
Automated contour analysis 
The automated contour analysis program uses the Microsoft Windows 
operating system on a Pentium ( 100 MHz) personal computer with 3 2 Mbytes 
of internal RAM. Using a framegrabber (DT -3852; resolution 800 x 600 x 8 
bits), a maximum of200 1VUS cross sections was stored per vascular segment. 
The analysis procedure could be divided in 3 steps (Figure 1). First, a sequence 
of IVUS images was selected at 0.2 mm interval using the information 
provided by the displacement sensing device and was subsequently digitized. 
Two perpendicular planes, parallel to the longitudinal axis of the vessel, were 
selected to reconstruct longitudinal views. Second, the program defined the 
contours ofboth lumen and vessel boundaries on these longitudinal planes by 
applying a minimum cost algorithm, as described previously.5 Third, the 
longitudinal contour information was transformed to the cross sections by 
defining 4 guiding points. By applying the algorithm and the information of 
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Figure 1. Automatic contour detection of 
intravascular ultrasound (IVUS) images. 
Upper panel: Two perpendicular planes 
are used to reconstruct 2 longitudinal 
sections (A and B) from the digitized 
IVUS images (Step 1). Automatic contour 
detection of the intimal leading edge and 
tb.e e:..'ternal boundary of the vessel is 
performed on these longitudinal sections 
(Step 2). TI1e longirudinal contours are 
represented as individual edge points in 
the cross-sectional images. These points 
define center and range of the final 
contour detection process on d1e 
cross-sectional IVUS images (Step 3). 
Lower panel: the 2 reconstructed 
longitudinal sections (A and B) 
correspond to the perpendicular planes 
seen in the cross-section. 
the 4 guiding points, lumen and vessel boundary on each individual 
cross-section was detected. During all steps, the user could interactively modify 
the contours of lumen and vessel boundary that were detected by the 
automated contour analysis system. Lumen, vessel and plaque volume were 
calculated as: 
n 
VoLume= :I,AxH 
i= 1 
where A is the area, H is the interval between 2 cross sections (slice thickness) 
and n is the number of IVUS images acquired. 
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Manual analysis 
For the assessment of lumen, vessel and plaque area, a digital video analyzer 
system (IBM, Boca Raton, FL, USA) was used. 11 When image quality was 
inadequate or extensive dropout due to calcification was encountered, the 
analysis of vessel area could not be performed and these NUS cross sections 
. were excluded from the study. 
Reproducibility 
The reproducibility of volume and area measurements was established in 
previous studies 8'12 The interobserver difference for lumen, vessel and plaque 
volume measurements using the displacement sensing device was ,; 0.4%, with 
low coefficients of variation(,; 1. 7%) and high correlation coefficients (r= 1.00 
for all).8 The interobserver difference for lumen, vessel and plaque area was 
,; 0.9%, with coefficients of variation ,; 14% and correlation coefficients 
1' ;,0.93. -
Statical analysis 
Volume measurements of the nondilated segment from each individual patient 
were summed when 2 vascular segments were analyzed. Because the length of 
the nondilated segments was not uniform, the change in volume was given in 
mm
3/cm and as a percentage of the volume measurements afrer PTA. 
Similarly, area measurements from the balloon-dilated segment were averaged 
over the number ofiVUS cross sections acquired from each individual patient. 
Results are given as mean and standard deviation. For comparison of changes 
in volume and area measurements seen in statin-treated and non-statin-
treated patients the Student's t-test was used. A p value <0.05 was considered 
statistically significant. 
RESULTS 
The IVUS quality of the vascular segment selected was adequate to document 
lumen, vessel and plaque volume in 11 of the 16 patients; in the 5 remaining 
patients the analysis oflumen volume (n= 1), vessel volume (n= 3), or both (n= 1) 
could not be performed due to low image quality at follow-up (n= 1), 
progression of calcified lesion (n= 3), and subintimal introduction of the 
guidewire (n=1), respectively. 
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Table 1 Characteristics of the srudy population 
Gender, male 
Age, mean (±SD), years 
Diabetes Mellirus 
Systemic hypertension 
Cigarette smoking 
Cessation of cigarette smoking 
Fontaine classification, 2B/3/ 4 
Follow-up, mean (±SD), mondlS 
Cholesterol, mean (±SD), mmol/L 
Statin~treated 
patients 
(n-5) 
4 
70.8 ± 8.4 
2 
3 
3 
0 
4/1/0 
13.0 ± 0.9 
5.5 ± 1.4 
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Non-statin-treated p value 
patients 
(n•5) 
5 0.37 
64.8 ± 12.9 0.41 
3 0.58 
1 0.24 
5 0.14 
0 n.a. 
4/0/1 0.88 
11.1± 2.9 0.21 
5.6 ± 1.4 0.91 
SD = Standard Deviation; n = number of patients; n.a .... not applicable 
Because one patient received Gemfibrozil (lipid-lowering medication) 
periodically during the follow-up period, this patient was excluded from the 
study. Of the remaining 10 patients, 5 patients were treated with statin (Group 
1) during the entire follow-up period: 4 with Simvastatin 10 mg (n=3) or 20 
mg (n= 1), and 1 patient with Pravastatin 20 mg. Five other patients were not 
treated with statin (Group 2). No significant differences were encountered 
between both groups of patients with regard to demographic features, 
presenting symptoms and mean follow-up duration (Table 1). Total 
cholesterol levels obtained 3 ± 2 months after the initial PTA and IVUS study, 
in all statin-treated patients and in 3 of the 5 non-statin-treated patients, 
showed no difference; 4.0-7.5 mmol/l and 4.3-7.0 mmoVl, respectively. 
In total16 matched non dilated segments (14 proximal, 2 distal) were analyzed: 
2 segments in 6 patients and 1 segment in 4 patients. 
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Table 2 Quantitative data on lumen, vessel and plaque volume and area seen with 
intravascular ultrasound immediately after percutaneous transluminal angioplasty 
(PTA) and at 1-year follow-up in statin-trcated patients(+) and in non-statin-
trcated patients(-). 
Starin After PTA Follow-up 
Nondilated segment (mm3/cm) 
+ 267 ± 82 269 ± 64 
Lumen volume 
247 ± 46 237 ± 44 
+ 389 ± 92 395 ± 78 
Vessel volume 
402 ± 91 395 ± 85 
+ 123 ± 23 127 ± 28 
Plaque volume 
!55± 51 !58± 52 
Volume stenosis + 32% 32% 
39% 40% 
Balloon-dilated segment (mm2) 
+ 25 ± 5.6 23 ± 6.5* 
Lumen area 
17 ± 5.2 13 ± 1.6* 
+ 43 ± 5.9 45 ± 6.4 
Vessel area 
42 ± 14 40 ± 12 
+ 19 ± 1.9 22 ± 3.4 
Plaque area 
25 ± 9.3 28 ± 11 
+ 44% 49% 
Area stenosis 
60% 70% 
Differences were not statistically significant except* (p<0.05) 
Change 
+1.9 ± 26 (+!%) 
-9.8 ± 18 (-4%) 
+6.2± 30(+2%) 
-6.8 ± 18 (-2%) 
+4.3 ± 6.1 (+4%) 
+3.1 ± 9.4 (+2%) 
+0% 
+1% 
-1.8 ± 2.6 (-7%) 
-3.9 ± 3.7 (-23%) 
+ 1.5 ± 2.0 ( +4%) 
-1.2 ± 2.2 (-3%) 
+3.3 ± 1.8 (+18%) 
+2.7 ± 1.8 (+!!%) 
+5% 
+10% 
The median length of the nondilated segments analyzed in each individual 
patient was 6.9 (range 3.6-8.0) em. The median distance between the 
nondilated and balloon-dilated segment was 7 (range 3-19) em. 
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In total 63 (median 6, range 3-14) of the 97 matched IVUS cross sections 
from the balloon-dilated segment were manually analyzed for lumen, vessel 
and plaque area. In the remaining 34 cross sections, the vessel area could not 
be analyzed due to extensive calcification, causing drop-out. 
Table 2 summarizes the quantitative data on lumen, vessel and plaque volume 
and area seen immediately afrer PTA and at 1-year follow-up. At baseline no 
significant difference was encountered between both groups of patients. At 
follow-up there was a significant difference between both groups of patients 
in lumen area at the balloon-dilated segment. At follow-up, both 
statin-treated and non-statin-treated patients showed a similar increase in 
plaque volume at the nondilated segment (+4% and +2%, respectively). In 
statin-treated patients the plaque volume increase was compensated for by an 
increase in vessel volume ( + 2%), resulting in an increase in lumen volume 
(-1%). In non-statin-treated patients, on the other hand, the increase in 
plaque volume was associated with a decrease in vessel volume (-2%), resulting 
in a decrease in lumen volume (-4%). At the balloon-dilated segment a similar 
difference between both groups of patients was encountered. In statin-treated 
patients the extent of plaque area increase was similar to that seen in 
non-treated patients ( + 18% and+ 11%, respectively). In statin-treated patients 
the plaque area increase was partially compensated for by an increase in vessel 
area (+4%), whereas in non-statin-treated patients a decrease in vessel area 
(-3%) was encountered. The resulting decrease in lumen area was 7% in 
statin-treated patients and 23% in non-statin-treated patients. All differences 
in volume and area changes between Group 1 and 2 were not significant. 
DISCUSSION 
The conventional concept of progression/regression of atherosclerotic plaque 
is that statin therapy reduces the progression of atherosclerosis or even induces 
regression. 13- 16 Current findings, although obtained from a small set of data, 
suggest an alternative pathway for the beneficial effect of statin therapy on 
lumen size. Surprisingly, in statin treated patients the extent of plaque volume 
and area increase was similar to that seen in non-statin-treated patients. 
Positive vascular remodeling seen in statin-treated patients and negative 
vascular remodeling in non-statin-treated patients determined the lumen 
change at 1-year follow-up (Figure 2, Table 2). 
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Figure 2. Standard display of the information on lumen, vessel and plaque area 
immediately after PTA (fine lines) and at 1-year follow-up (thick lines) derived from a 
nondilated segment using an automated contour analysis system. The upper panel 
represents a vascular segment derived from a statin-treated patient (Group 1): plaque 
area remained unchanged while the vessel area increased resulting in an increase in 
lumen area. The lower panel represents a vascular segment derived from a 
non-statin-treated patient (Group 2): plaque area remained unchanged while tb.evessel 
area decreased, resulting in a decrease in lumen area. 
Thus one may hypothesize that statin therapy might have a beneficial effect on 
lumen size due to its effect on the mode of vascular remodeling rather than on 
the degree of plaque growth. With these findings in mind one should 
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reconsider the value of angiography 13' 14 and external ultrasound 15'16 studies 
used to document the beneficial effect of statin therapy on the progression of 
atherosclerosis. Although these latter studies could not provide insight into the 
change in atherosclerotic plaque volume or area, the general consensus was 
that the effect of statin was related to the degree of plaque growth. 
To date, two IVUS studies have reported on the effect of statin therapy in 
nondilated vascular segments using area measurements. 17' 18 In a 3-year 
follow-up study in 18 coronary arteries not subjected to vascular intervention, 
Takagi et aL 17 revealed an increase in lumen area (10%) due to a decrease in 
plaque area (-7%) and no change in vessel area (0%) in statin-treated patients. 
Reasons why the latter results differ from ours remain speculative, but may be 
related to the difference in follow-up duration and/ or to the use of a different 
vascular region. Recently, Hamasaki et aL 18 established that the effect of statin 
therapy on lumen size was the result of an increase in vessel area rather than 
a decrease in plaque area, supporting the possible mechanism of action of 
statin hypothesized in the present study. 
Limitations 
The main limitations of this study are the small number of patients examined, 
the retrospective and observational protocol, the short period of exposure to 
statin therapy ( 1 year), and the fact that the patients were treated with different 
statins. Second, it should be acknowledged that in 5 of the 16 patients in 
whom a nondilated segment was selected afrer intervention, the quality of the 
vascular segment at follow-up hampered the analysis. Finally, because IVUS 
is a costly and invasive procedure, prospective IVUS studies should be carried 
out in patients undergoing vascular intervention. 
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Future implications 
This small retrospective IVUS study may generate the hypothesis that statin 
therapy contributes to superior long-term lumen dimensions by inducing 
positive vascular remodeling. A prospective IVUS study should include 
measurements of both the nondilated and balloon-dilated vascular 
segments. Analysis of the nondilated segment will elucidate the effect of 
statin therapy on the progression of atherosclerosis, without the side-effects 
of an intervention. Analysis of the balloon-dilated segment will reveal the 
beneficial effect of statin on the prevention of restenosis. 
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INTRODUCTION 
Clinical studies using angiography have shown that HMG-CoA reductase 
inhibitors (statins) may reduce restenosis after coronary angioplasty.1-3 
However, the precise effect of statin therapy on the mechanism of restenosis 
after vascular intervention remains to be elucidated. The purpose of the 
present retrospective observational intravascular ultrasound (IVUS) study was 
to evaluate whether simvastatin therapy limits lumen area reduction 1 year 
after percutaneous transluminal angioplasty (PTA) by reducing reactive plaque 
growth, reducing reactive vasoconstriction, or both. 
METHODS 
The study group comprised 24 patients (16 men, 8 women); age range 44 to 89 
years (median 72) with obstructive femoropopliteal artery disease treated 
successfully with PTA (angiographic diameter stenosis <50%). The study group 
consisted of a subset of patients retrospectively selected from the Peripheral 
Arterial Restenosis assessed with Intravascular Sonography (PARIS) study4 
based on the availability of IVUS images immediately after PTA and at 1-year 
follow-up. The study was approved by the Medical Ethics Committee. Patients 
were included in the study after they gave informed consent. Data collected on 
each patient included gender, age, diabetes, hypertension, history of smoking, 
and indication for intervention (intermittent claudication, pain at rest or night 
pain, and ulceration). Data on clinical and angiographic restenosis were 
collected at follow-up. Clinical restenosis was based on recurrent symptoms; 
angiographic restenosis was defined as a diameter stenosis of ;,50%. 
The IVUS studies were performed immediately after PTA and at 1-year 
follow-up using the following procedure: the IVUS catheter was advanced 
distally through a 7Fr sheath in the femoropopliteal arrery over a guidewire 
beyond the lesion. The IVUS catheter consisted of a single rotating ultrasound 
element(30 MHz) on aguidewire-tipped 4.3Fr catheter (Endosonics, Rijswijk, 
The Netherlands, 0.035 in). After the guidewire was removed to avoid 
drop-out, the ultrasound catheter was pulled back manually. The information 
on the location of the catheter tip was documented using a radiopaque ruler 
and a displacement sensing device. The latter device documents the location 
of the catheter tip in relation to the patella in steps of 0.01 em during the 
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pull-back maneuver.5 The information on the catheter tip pos1t10n was 
correlated with the IVUS images on the monitor and the resulting images were 
stored on S-VHS videotape. With the information of the displacement sensing 
device, the radiopaque ruler, and anatomic markers such as side branches and 
typical-shaped calcifications, the IVUS cross sections obtained after PTA and 
at follow-up were matched. To ensure that the IVUS cross sections that were 
obtained after intervention corresponded with those that were obtained at 
follow-up examination, the cross sections were studied side-by-side and 
frame-to-frame. Matched IVUS cross sections obtained from the treated sites, 
including the most stenotic site (i.e., the cross section showing the smallest 
lumen area) after PTA, were selected with 1-cm intervals for analysis. 
A digital video analyzer system (IBM Corp., Boca Raton, Florida) was used to 
assess the lumen, vessel, and plaque area. 6 Observers were blinded to patient 
characteristics and their use of simvastatin. The lumen area was defined as the 
area that was encompassed by the inner boundary of the intimal surface (also 
characterized by the presence of blood). The vessel area was defined as the area 
bounded by the media-adventitia border. The plaque area was calculated by 
subtracting the lumen area from the vessel area. When image quality was 
inadequate or there was extensive dropout due to calcification (> 120° of the 
circumference), the analysis of vessel area could not be performed and these 
IVUS cross sections were excluded. 
Lumen, vessel, and plaque area measurements from each patient were averaged 
over the number of IVUS cross sections acquired. Subsequently, the 
differences of the averaged area measurements at baseline and at 1-year 
follow-up were calculated. A comparison was made between patients who 
received and did not receive simvastatin in the absolute change of lumen, 
vessel, and plaque area seen at the treated site and at the most stenotic site by 
means of Student's t test. A p value of <0.05 was considered statistically 
significant. Results are given as mean and SD. The reproducibility of IVUS 
parameters used in.this study has been reported previously.4 
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RESULTS 
There were no complications as result of the IVUS procedure. Seven of the 24 
patients were excluded from the study: 3 patients (who did not receive 
simvastatin) had angiographic restenosis within 6 months after PTA; in 2 
patients the image quality was too low for analysis; and 2 patient were excluded 
because gemfibrozil or pravastatin was used during the follow-up period. IVUS 
images obtained after intervention and at 1-year follow-up were adequate for 
analysis in the remaining 17 patients. Patients given simvastatin (n=6) were 
treated during the entire follow-up period with 10 mg (n=4) or 20 mg (n=2) 
simvastatin; the remaining 11 patients were not treated with simvastatin. 
At baseline no significant difference between patients who received and did 
not receive simvastatin, with regard to demographic features or presenting 
symptoms, was seen (Table 1). At follow-up, no clinical or angiographic 
restenosis was evident in patients who received simvastatin; in patients who did 
not receive simvastatin there was evidence for both clinical restenosis (n =4) and 
angiographic restenosis (n=S) (Table 1). 
The length of the lesion treated with PTA (median 9.5 em, range 4 to 21) did 
not differ among the 2 groups of patients ( 11 ± 6 and 9 ± 4 em, respectively, 
p=0.53). In total183 IVUS cross sections from the treated site were matched: 
in 14 7 of these IVUS cross sections (median 8, range 3 to 15) lumen, vessel, 
and plaque area could be analyzed. Fourteen of these 14 7 cross sections were 
derived from the most stenotic site ( 4 patients on simvastatin and 10 patients 
not on simvastatin). The remaining 36 cross sections (20%) were excluded 
from the study because of extensive dropout due to calcification. 
Table 2 summarizes the quantitative data on lumen, vessel, and plaque area 
acquired in patients who received and did not receive simvastatin. Immediately 
after PTA no significant difference in lumen, vessel, and plaque area was 
encountered between both groups of patients. At the treated site, a significant 
difference between both groups of patients in lumen area and a borderline 
significant difference in vessel area change was seen at follow-up; in patients 
given simvastatin a lumen area decrease ( -4%) and a vessel area increase (4%) 
was seen, whereas in patients not given simvastatin, lumen and vessel area 
decreased (-25% and -2%, respectively) (Figure 1). 
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Table 1 Patient Characteristics and Clinical and Follow-Up Data Obtained in Patients \Xlho 
Received and Did Not Receive Simvastatin 
Men/women 
Age (mean±SD) (yrs) 
Diabetes Mellitus (n [%]) 
Systemic hypertension 
Cigarette smoking 
Fontaine classification, l/2B/3/ 4 
Follow-up 
Follow-up (mean ± SD) (mo) 
Clinical restenosis 
Angiographic restenosis 
Total-cholesterol (mean ± SD) 
(mmol/1) 
Patients who 
receiced 
simvastatin 
(n=6) 
3/3 
71.1±7.5 
2 (33 %) 
2 (33 %) 
3 (50%) 
0/5/1/0 
13.5 ± 1.3 
0 (0 %) 
0 (0 %) 
5.7 ± 1.2 (n•6) 
Patients who 
did not receive 
simvastatin 
(n=ll) 
6/5 
70.6 ± 9.3 
5 (45 %) 
3 (27 %) 
7 (64 %) 
1/6/1/3 
12.6 ± 2.3 
4 (36 %) 
8 (73 %) 
6.4 ± 0.8 (n=5) 
p-value 
0.87 
0.85 
0.46 
0.81 
0.61 
0.41 
0.36 
0.10 
0.002 
0.31 
There was no difference in plaque area change in both groups of patients at 
follow-up. 
Similarly, at the most stenotic site, a significant difference between both groups 
of patients in lumen and vessel area change was seen at follow-up; in patients 
given simvastatin, the lumen and vessel area increased, whereas in patients not 
given simvastatin, the lumen and vessel area decreased. There was no 
difference in plaque area change in both groups of patients at follow-up. 
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Table 2 Mean change in lumen, vessel and plaque area seen with intravascular ultrasound 
at one-year follow-up in patients treated with ( +) and without (-) simvastatin 
Starin After PTA (mm2) Follow-up Change (mm2) 
(mm2) 
Treated sites (n=17) 
Lumen area + 22.7 ± 6.3 21.8 ± 6.3 -0.9 ± 3.6 (-4%) 
18.3 ± 7.4 13.7 ± 6.6 -4.6 ± 2.5 (-25%) 
(p=0.24) (p=0.03)* (p=0.03)* 
Vessel area + 41.2 ± 6.5 42.9 ± 6.7 1.7 ± 3.2 (4%) 
41.7 ± 12.9 40.7 ± 13.2 -1.0 ± 2.3 (-2%) 
(p=0.94) (p•O. 70) (p•0.06) 
Plaque area + 18.5±1.7 21.2 ± 3.3 2.6 ±1.8 (14%) 
23.4 ± 7.3 27.0 ± 8.1 3.6 ± 2.4 (15%) 
(p=0.13) (p-0.12) (p•0.39) 
Most stenotic sites (n=14) 
Lumenarea + 17.3±3.2 19.3 ± 3.4 2.0 ± 1.8 (12%) 
12.3 ± 5.8 10.9 ± 5.9 -1.4 ± 2.2 (-11%) 
(p•0.14) (p=0.02)* (p•0.02)* 
Vessel area + 41.4 ± 10.8 46.2 ± 12.3 4.8 ± 1.5 (12%) 
37.9 ± 12.6 36.9 ± 12.7 -0.9 ± 2.1 (-2%) 
(p=0.63) (p=0.24) (p•0.001)* 
Plaque area + 24.2 ± 7.7 27.0±9.3 2.8 ± 2.5 (12%) 
25.6 ± 10.6 26.0 ± !0.5 0.4 ± 2.2 (2%) 
(p-0.81) (p-0.87) (p-0.10) 
*Significant difference betwreen patients treated wid1 and without simvastatin. 
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Lumen area: 
Vessel area: 
Plaque area, 
Lumen area: 
V esse! area' 
Plaque area' 
Change 
it 4.8 mm2 
it 8.1 mm2 
it 3.3 mm2 
1> 3.1 mm2 
it 0.7 mm2 
it 3.7 mm2 
Calibration = 1 mm; + = catheter 
it "" increase; .JJ. c: decrease 
Figure 1. Corresponding intravascular ultrasound cross sections obtained after PTA of the 
femoropopliteal artery (left) and at 1-year follow-up (right) from a patient who received 
simvastatin (A) and a patient who did not receive simvastatin (B). Note the calcified spot in the 
corresponding images from the patient who did not receive simvastatin (arrow). At follow-up, 
d1e patient who received simvastatin (A) had an increase in lumen and vessel area, whereas the 
patient who did not receive simvastatin (B) had a decrease in lumen area and a negligible 
increase in vessel area. The increase in plaque area in bod1 patients was similar. 
DISCUSSION 
The present retrospective observational IVUS study revealed a significant 
difference between patients who received and did not receive simvastatin in 
lumen area reduction at 1-year follow-up: -4% in patients who received 
simvastatin and -25% in patients who did not receive simvastatin (Table 2). 
Overall, both groups of patients showed an identical increase in plaque area. 
Surprisingly, the increase in plaque area was associated with an increase in 
vessel area in patients given simvastatin and a decrease in vessel area in patients 
not given simvastatin. In other words, the use of simvastatin appeared to have 
a beneficial effect on lumen size due to its effect on the mode of vascular 
remodeling rather than on the degree of plaque growth. Angiographic records 
confirmed the difference between both groups of patients in lumen area 
reduction; patients given simvastatin showed no angiographic restenosis, 
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whereas 8 patients who did not receive simvastatin had angiographic restenosis. 
The importance of IVUS in this respect is that vessel area measurement is 
unique to IVUS and has no angiographic equivalent. 
In summary, this retrospective observational IVUS study showed that plaque 
growth at 1-year follow-up is a general response after PTA regardless of the 
use of simvastatin; simvastatin has the potential to induce positive vascular 
remodeling, thereby reducing the occurrence of restenosis. 
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Rationale and design of the SARIS-study 
ABSTRACT 
The SARIS study (effect of Starin on Atherosclerosis and vascular Remodeling 
assessed with Intravascular Sonography) is a prospective randomized 
multicenter trial designed to assess the dose dependent effect of statin therapy 
on the vascular anatomy and endothelial function. Participating centers will 
include 50 patients with normal to mildly elevated cholesterol levels eligible for 
balloon angioplasty and/ or stent placement of the common iliac artery. 
Patients will be randomized to 1-year treatment with either low-dose (1 0 mg) 
or high-dose (80 mg) atorvastatin. The primary objective of this study is the 
use of intravascular ultrasound (IVUS) to document the dose dependent effect 
of atorvastatin on plaque volume and vascular remodeling seen at 1-year 
follow-up. The secondary objective is the use of dobutamine stress 
echocardiography (DSE) to assess the dose dependent effect of atorvastatin on 
myocardial coronary flow reserve (MCFR) at 6-months and 1-year follow-up. 
The design of the present study is noteworthy in respect that: (1) IVUS is the 
only available technique to sensitively measure the effect of statin therapy on 
both plaque growth and vascular remodeling, and (2) DSE is a non-invasive 
test to objectively quantify the effect of statin therapy on the functionality of 
the coronary artery. 
150 
--------------------- Chapter 11 
INTRODUCTION 
The beneficial effect of HMG-CoA reductase inhibitors (statins) on the 
primary and secondary prevention of cardiovascular disease has been shown in 
studies with both hard endpoints and with surrogate endpoints using external 
ultrasound and angiography. 1- 4 However, angiographic studies are not capable 
to reveal the precise mechanism how statin acts, as angiography merely shows 
a silhouette of the lumen. Studies using intravascular ultrasound (IVUS) have 
documented that the lumen dimension is not only influenced by plaque 
growth, but is also influenced by vascular remodeling ("shrinkage" vs. 
" l ") 5-10 en argement . 
In addition, recent studies have reported that besides the positive effects of 
statin therapy on the vascular anatomy, statin therapy may exert a direct 
positive effect on the endothelial function of diseased arteries. 11 '12 Myocardial 
coronary flow reserve (MCFR) is known to be a functional test of the coronary 
artery and is determined by local nitric oxide production of the endothelium. 
Nitric oxide induces vasodilatation, which is impaired in patients with 
coronary artery disease. !3-ls Dobutamine stress echocardiography (DSE) can 
assess MCFR during dobutamine infusion as an improved Doppler velocity 
value using pulsed-wave Doppler tissue sampling (PW-DTS). 16- 18 
This study addresses the dose-dependent effect of statin therapy on the 
vascular anatomy using IVUS and on the endothelial function using DSE. 
STUDY DESIGN 
The SARIS study (effect of Statin on Atherosclerosis and vascular Remodeling 
assessed :with Intravascular Sonography) is a prospective randomized 
multicenter trial designed to assess the dose dependent effect of atorvastatin 
on atherosclerosis and vascular remodeling. The primary objective of this study 
is the use of IVUS to document the dose dependent effect of statin on plaque 
volume and vascular remodeling and on the extent of in -stent intimal 
hyperplasia in the absence of vascular remodeling seen at 1-year follow-up. 
The secondary objective is the use of DSE to assess the dose dependent effect 
of atorvastatin on MCFR evaluated during dobutamine infusion, compared to 
baseline value. 
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Table 1 Inclusion and ex:clusion criteria of the SARIS trail (effect of Starin on Atherosclerosis 
and vascular Remodeling assessed with Intravascular Sonography). 
INCLUSIONS 
Ill Symptomatic iliac arterial disease eligible for PTA and/ or stent-placement in d1e 
common iliac artery 
1111 Serum total cholesterol5-8 mmol/1 
1111 Serum LDL >3 mmol/1 
Ill Written informed consent 
EXCLUSIONS 
II Endocrine disorders (Diabetes Mellitus) 
1111 Use of lipid-lowering drugs within the last year 
Ill Uncontrolled hypertension (DBP > 110 mmHg, SBP > 180 mmHg) 
Ill Use of drugs known to be associated with rhabdomyolysis when used in conjunction 
with statins (e.g. cyclosporin, erythromycin, azole anti-fungal drugs and niacin) 
II History of serious adverse drug reactions, hypersensitivity or allergy to statins 
Ill Significant active liver disease (> 3x upper limit of normal) 
Ill Renal insufficiency (serum creatinine> 160 mol/1) or micro-albumin in urine 
Ill Concurrent therapy with long-term immunosuppressants 
II History of alcoholism, drug abuse or other emotional or intellectual problems likely to 
invalidate informed consent, or limit the ability of the subject to comply with the 
protocol requirements 
PTA= percutaneous transluminal angioplasty; LDL • low-density lipoprotein; DBP ... 
diastolic blood pressure; SBP "" systolic blood pressure. 
Participants 
This is a multicenter study in association with the Erasmus Medical Center 
Rotterdam, Leiden University Medical Center, University Medical Center 
Utrecht, St. Elisabeth Hospital Tilburg, Twee Steden Hospital Tilburg and 
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St. Franciscus Hospital Rotterdam. The participating centers will recruit 50 
consecutive patients (male and female) with symptomatic obsttuctive vascular 
disease eligible for percutaneous transluminal angioplasty (PTA) and/ or stent 
placement in the common iliac artery. Patients with normal to mildly elevated 
cholesterol levels will be included; total cholesterol levels between 5 and 8 
mmol/l and low-density lipoprotein (LDL) levels ;;,3 mmol/l. In- and 
exclusion criteria are listed in Table 1. 
Medication and randomization 
Patients will be randomized to 1-year treatment with either low dose (10 mg) 
or high dose (80 mg) atorvastatin daily. The dosage remains fixed during the 
follow-up duration unless clinically important adverse reactions occur. 
Randomization will be performed in permuted blocks stratified by center. 
Observers responsible for analysis of IVUS and DSE data will be blinded for 
patient characteristics, induding treatment with either 10 mg or 80 mg 
atorvastatin. 
METHODS 
Intravascular ultrasound 
The IVUS studies will be performed using a single rotating ultrasound element 
(30 MHz) on a 0.035" guidewire-tipped 4.3F catheter (Endosonics, Rijswijk, 
The Netherlands). Briefly, the following procedure will be applied. After 
angiographic successful PTA and/ or stent placement, the IVUS catheter will 
be advanced retrogradely over the guidewire to the aortic bifurcation. After the 
guidewire is removed to avoid drop-out of a catheter segment, the ultrasound 
catheter will be pulled back manually. A displacement sensing device will be 
used to document the location (i.e. position) of the cathetertip in relation to 
the aortic bifurcation in steps of 0.1 mm during the pull-back maneuver. 19 
The information on the cathetertip position will be: ( 1) combined with the 
IVUS images on the monitor, and (2) translated into a digital audiosignal that 
will be stored on the audiochannel of the videotape using a timecode generator 
and a special videorecorder. This digital audiosignal enables automatic 
selection of the IVUS images required for volume measurements. 
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After 1-year follow-up, the angiographic and IVUS study will be repeated 
using the procedure as described above. Vascular segments seen with IVUS 
(including the stent, adjacent reference segments and external iliac artery) 
obtained at intervention and at 1-year follow-up, will be matched. These 
matched vascular segments will be used to assess the volume of lumen, 
vessel/stent and plaque using an automated contour analysis system. 
In our previous study the reproducibility of serial volume measurements using 
this system has been established. 19 This study showed that matching of vascular 
segments using side-branches and the information of the displacement sensing 
device is highly reliable and reproducible. The interobserver difference for 
lumen, vessel and plaque volume was ,; 0.4%, with low coefficients of variation 
(,; 1. 7%) and high correlation coefficients (r= 1.00 for all). 
Follow-up 
Recently, we completed a longitudinal study to examine whether IVUS is a 
sensitive means to identify progression of atherosclerosis and its derived 
primary endpoint plaque volume at 1-year follow-up. 10 This study showed that 
(1) vascular segments obtained at baseline could in all instances be reliably 
matched with the vascular segments obtained at follow-up, and (2) progression 
of atherosclerosis implies a change in both plaque and vessel volume, resulting 
in lumen volume change. 
Analysis of data 
Analysis will include assessment of the change in lumen, vessel/stent and 
plaque volume seen after 1-year oflipid -lowering treatment in both groups of 
patients. A comparison will be made between patients treated with 10 mg and 
80 mg atorvastatin using the Student's t-test. 
Dobutamine stress echocardiography 
All echocardiograms will be performed with the SystemFive imaging system 
(Vingmed, General electric) equipped with a 1.8 MHz transducer using second 
harmonic imaging to optimize endocardial border visualization. Standard 
parasternal long- and short-axis views will be obtained as well as apical 
long-axis 2- and 4-chamber views. The left ventricle will be divided into 6 
walls (septum anterior, septum posterior, posterior, inferior, anterior and 
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lateral wall) and 16 segments. Wall motion of each segment will be scored as 
normokinesia, mild-hypokinesia, severe-hypokinesia, akinesia or dyskinesia. 
After baseline echocardiography, dobutamine infusion will be starred with 5 
f.!g/kg/min for 5 minutes followed by 10 f.!g/kg/min for 5 minutes. 
Dobutamine will then be increased by 10 f.!g/kg/ min every 3 minutes until test 
end-point (target hearr rate or signs or symptoms of ischemia occur). In 
patients not achieving the target hearr rate atropin (up to 2 mg) will be injected 
intravenously. Images will be acquired continuously and recorded on tape at 
the end of every dose-step. 
Pulsed-wave Doppler tissue sampling 
PW-DTS will be performed using a 3.7 MHz probe, with a pulse repetition 
ftequency of4.5-6.0 KHz. The temporal resolution ofPW-DTS is 4±3 ms. A 
sample volume of 4 mm3 will be used. The continuous measurement of 
velocity of the 16 segments will be sampled in apical views during a minimum 
of 5 consecutive beats in order to minimize the variability induced by 
respiration. Measurements will be performed at rest, low-dose dobutamine 
and at peak stress. The depth of the sample volume of every wall will be kept 
constant during DSE. After stopping dobutamine infusion the measurements 
will be repeated at 3-min. interval. Measurements will be stopped if baseline 
velocities are recorded or after a 30-minutes period. 
Analysis of data 
All the measurements will be performed off-line using a software system of 
VingMed. The velocity values (cm/s) will be obtained on calibrated still ftames 
by automatically measuring the distance between the zero baselines and the 
peak Doppler profile of ejection phase, early and late diastole in reference to 
both the electrocardiogram and phonocardiogram. Analysis will include the 
change in velocity values, evidenced at 6 and 12 months follow-up. A 
comparison will be made between patients with 10 mg and 80 mg atorvastatin 
using the Student's t-test. 
155 
Rationale and design of the SARIS-study 
DISCUSSION 
This prospective randomized study has 2 objectives. First, to assess the 
dose-dependent effect of statin on the progression of atherosclerosis and 
vascular remodeling using IVUS. Second, to assess the dose-dependent effect 
of statin on MCFR using DSE. 
To date, 3 IVUS studies have reported on the effect of statin on the vascular 
walL 20- 22 These IVUS studies had in common to report a positive effect of 
statin on lumen area. In 1997 Takagi et aL 20 reported that the increase in 
lumen area in coronary arteries was due to a decrease in plaque area with no 
change in vessel area. Subsequently, Hamasaki et aL 21 showed that patients 
with coronary artery disease adequately treated with statin therapy had a larger 
vessel area than patients not adequately treated with statin therapy. This latter 
observation concurs with our study performed in peripheral arteries22 showing 
that the increase in lumen area as result of statin therapy was due to a positive 
effect on vascular remodeling. Moreover, we found that irrespective of the use 
of statin during 1-year following PTA of the femoropopliteal artery plaque 
growth is a universal response. 
The design of the present study is noteworthy in respect that IVUS is the only available 
technique to sensitively measure the impact of arterial remodeling on lumen dimensions. 
In addition, in this study DSE will be used to assess the dose-dependent effect 
of statin on MCFR. DSE can assess MCFR during dobutamine infusion as an 
improved velocity value using PW-DTS. Recently, studies showed that MCFR 
in patients with hypercholesterolemia improved after statin therapy. 23 '24 In 
these studies positron emission tomography and single photon computed 
tomography were used in combination with a perfusion marker 
[13N-ammonia] during dipyridamole and dobutamine stimulation. Stress 
echocardiography can be used as a more widely available and less expensive 
alternative for nuclear scanning. 25- 27 
It is noteworthy that PW -DTS is a non-invasive test to objectively quantify the effect 
of statin therapy on the functionality of the coronary artery. 
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APPENDIX 
Participating centers and principal investigators 
Erasmus Medical Center Rotterdam, E.J. Gussenhoven, MD, PhD, T. Hagenaars, MSc, P.M.T. Pattyruuna, 
MD, PhD, D. Poldennans, MD, PhD, H. van Urk, MD, PhD, Leiden University Medical Center, J.H. van 
Beckel, MD, PhD, E. van der Linden, MD, University Medical Center Utrecht, J.D. Blankensteijn, MD, 
PhD, W.P.T.M. Mali, MD, PhD, St. Elisabed1 Hospital, Tilbutg, D.P. van Berge Henegouwen, MD, PhD, 
J.F. Hamming, MD, PhD, L.E.H. Lampmann, MD, PhD, Twee Steden Hospital, Tilburg, G.P. Gerritsen, 
MD, S.E. Kranendonk, MD, PhD,J.L. Seelen, MD, PhD, and St. Franciscus Hospital, Rotterdam, C.H.A 
Wittens, MD, PhD, F.J.M. Kemper, MD. 
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In the last decade several new treatment modalities have emerged for the 
management of patients with obstructive disease of the femoropopliteal artery. 
This thesis addresses the effect of endografts, endovascular brachytherapy and 
statin therapy on plaque growth, and especially vascular remodeling, at 
follow-up using intravascular ultrasound (IVUS). 
In addition, the role of intravascular ultrasound as research tool is discussed. 
Endografts 
Chapter 2 presents an IVUS study in which 12 patients with long-segment 
obstructive femoropopliteal artery disease were treated with a newly developed 
polytetrafluoroethylene (ePTFE) endograft. Intravascular ultrasound 
investigation was performed immediately after endograft placement and at 
6-months follow-up. Corresponding IVUS images obtained ftom inside the 
endograft, the anastomotic segment and a reference segmentwere subsequently 
analyzed for the change in area measurements. At 6-months follow-up, the 
change in lumen area inside the en do graft ( + 3%) and in the reference segment 
(+6%) were minimal; however, a distinct increase in lumen area of 85% was 
observed at the anastomotic segment. This increase in lumen area was 
associated with an increase in vessel area of 42%, overcompensating the 
increase in plaque area of 15%. The study shows that vascular remodeling can 
compensate for plaque growth at the anastomotic segment of an ePTFE 
endograft. 
Chapter 3 presents the long-term results after implantation of an ePTFE 
endograft. In this study, repeat IVUS investigation was performed at 2-years 
follow-up in 5 of the 12 patients that were treated with the ePTFE endograft. 
The change in area measurements between 6-months and 2-years follow-up 
was analyzed and subsequently compared with the change in area 
measurements at 6-months follow-up. During the second follow-up period, 
the change in lumen area inside the endograftwas minimal(+ 1 %) and similar 
to the lumen area change at 6-months follow-up. At the anastomotic segment 
an increase in lumen area of 8% was observed during the second follow-up 
period, associated with an increase in vessel area of 6% and no change in 
plaque area. Although still significant, these changes were much smaller than 
the changes observed at 6-months follow-up. This study shows that 1) the 
ePTFE endograft appears to inhibit plaque growth and constrictive vascular 
163 
Summary------------------------
remodeling, and 2) the vasodilatory response at the anastomotic segment tends 
to stabilize in the long term. 
Chapter 4 presents a multicenter study to evaluate the long-term clinical 
outcome of 89 patients who were treated for long-segment obstructive and 
occlusive disease of the femoreopopliteal artery with an ePTFE endograft 
(mean length 29 em); a high-grade stenosis (mean length 9 em) was involved 
in 7 patients and an occlusion (mean length 19 em) was involved in 82 
patients. Early failure of the endograftwas encountered in 7 of the 89 patients: 
these patients presented with an acute occlusion of the endograft within 30 
days after the operating procedure and were subsequently treated with 
femoropopliteal bypass surgery.ln 42 patients the endograft remained patent 
during the entire follow-up period. The remaining 40 patients presented with 
a late acute occlusion of the endograft (median 7 months). These patients were 
either treated with femoropopliteal bypass surgery (n=9), conservatively (n=5) 
or fibrinolysis was performed successfully (n=26). Eighteen of the 26 patients 
treated successfully with fibrinolysis presented with a re-occlusion at a later 
stage. In 4 of these 18 patients repeat fibrinolysis was performed successfully. 
The remaining 14 patients were treated with femoropopliteal bypass surgery 
(n=8), lower-limb amputation (n= 2) or conservatively (n=4). The primary and 
secondary patency rates of the ePTFE endograft were 71% and 83% at 
6-months follow-up, 57% and 69% at 1-year follow-up, 45% and 49% at 
2-years follow-up and 30% and 44% at 3-years follow-up, respectively. This 
study shows that the success of the ePTFE endograft is limited by the 
occurrence of acute occlusions. Therefore, refinements of the endograft are 
necessary if this new, minimal invasive, technique wants to compete with 
conventional bypass surgery. 
Endovascular brachytherapy 
Chapter 5 describes a randomized IVUS study in which 24 patients with 
obstructive femoropopliteal artery disease were treated with percutaneous 
transluminal angioplasty (PTA) without or with additional endovascular 
brachytherapy (EBT). Intravascular ultrasound investigation was performed 
immediately after PTA and at 6-months follow-up. Corresponding IVUS 
images obtained from both the treated and the untreated (i.e. reference) site 
were analyzed for the change in lumen area, vessel area and plaque area at 
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6-months follow-up; a comparison was made between patients without 
additional EBT (n=16) and with additional EBT (n=8). At 6-months 
follow-up, IVUS measurements of the reference site revealed no significant 
difference in the change in lumen, vessel and plaque area between both groups 
of patients. In contrast, IVUS measurements of the treated site revealed a 
statistically significant difference (p=0.03) in lumen area change between 
patients without EBT and those with EBT (-9% and +23%, respectively): 
this was due to a significant difference (p=0.05) in vessel area change ( + 2% and 
+ 19%, respectively). In both groups of patients a similar increase in plaque area 
( + 12% and + 16%, respectively) was encountered. This study shows that EBT 
as adjunct therapy immediately after PTA in femoropopliteal arteries has a 
positive effect on lumen dimensions at 6-months follow-up by inducing 
positive vascular remodeling. 
Intravascular ultrasound as research tool 
Since the introduction of IVUS as a research tool in the late 1980s, it was 
suggested that IVUS could be used to grade the effect of pharmacologic 
interventions on the progression/regression of atherosclerosis. However, to 
investigate both local and diffuse effects of pharmacologic interventions on 
plaque growth and vascular remodeling, volumetric IVUS measurements were 
thought necessary. In order to acquire such measurements an automated 
contour analysis system, which creates three-dimensional (3-D) 
reconstructions of cross-sectional IVUS images, has been developed. 
In addition, to grade the effect of pharmacologic interventions on the 
composition of the atherosclerotic plaque, especially the calcified lesion, a 
sensitive method for calcified lesion quantification in IVUS images was 
developed. 
Chapter 6 presents an IVUS study aimed at determining the reproducibility 
of volume measurements in IVUS images acquired by two observers (i.e. 
interobserver reproducibility) and derived ftom two separate pull-back 
maneuvers (i.e. interexamination reproducibility). For this study, the 
automated contour analysis system was used to generate 3-D reconstructions 
of cross-sectional IVUS images. A total of 15 patients was included in the 
study and ftom each patient one matched vascular segment (3-4 em in length), 
not subjected to intervention, was used for analysis oflumen, vessel and plaque 
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volume. The results show that volume measurements derived from IVUS 
images are highly reproducible; the interobserver differences in volume 
measurements were ~0.4%, with low coefficients of variation(~ 1.7%) and 
high correlation coefficients (r= 1.00). Similarly, interexamination differences 
were ~2.6%, with low coefficients of variation (~8.6%) and high correlation 
coefficients (r=0.97 -0.99). Therefore, IVUS may be used to monitor the 
progression/regression of atherosclerotic plaque volume in a longitudinal 
study. 
Chapter 7 describes a longitudinal IVUS study aimed at determining the 
reproducibility of circumferential arc and length measurements of calcified 
lesions in IVUS images. In addition, the change in circumferential arc and 
length measurements at 1-year follow-up was determined. For the purpose of 
this study, 34 patients were imaged with IVUS before and after PTA and at 
1-year follow-up. The interobserver and interexamination differences in 
circumferential arc and length measurements were low (~ 1.1 %), with low 
coefficients of variation (~5.8%). At 1-year follow-up, a non-significant 
increase in both the circumferential arc (1.9%) and length (1.7%) of the 
calcified lesion was observed. This study shows that measurements of the 
circumferential arc and length of the calcified lesion are highly reproducible; 
changes seen at 1-year follow-up are not significant. It was concluded that 
IVUS may be used to monitor the effect of medical intervention on the extent 
of the calcified lesion in a longitudinal study. 
Chapter 8 presents an IVUS study in which the natural progression of 
atherosclerosis at 1-yearfollow-up was examined using volume measurements 
obtained with the automated contour analysis system. For the purpose of this 
study 11 patients were imaged with IVUS at baseline and at 1-year follow-up 
and subsequently analyzed for the change in lumen, vessel and plaque volume. 
At follow-up, a non-significant increase in lumen volume (2.3%), vessel 
volume (2%) and plaque volume (3%) was encountered. This study shows that 
progression of atherosclerosis implies changes in both vessel and plaque 
volume, resulting in lumen volume change. With these findings in mind, we 
believe thatvolumetric IVUS studies are excellently suited to establish the basic 
mechanism associated with progression/regression of atherosclerotic plaque 
and vascular remodeling and the influence of pharmacologic agents on these 
processes. 
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Starin therapy 
Chapter 9 describes a retrospective non-randomized study in 10 patients, in 
which 3-D IVUS was used to document the effect of 1-year treatment with 
statin therapy on vascular segments of the femoropopliteal artery not subjected 
to PTA Patients were imaged with IVUS at baseline and at 1-year follow-up 
and subsequendy analyzed for the change in lumen, vessel and plaque volume. 
A comparison was made between the change in volume measurements seen in 
patients with statin therapy (n=5) and patients withoutstatin therapy(n=5). At 
follow-up, both groups of patients showed a similar increase in plaque volume 
( +4% and + 2%, respectively). In patients with statin therapy the plaque volume 
increase was compensated by an increase in vessel volume (+2%), resulting in 
an increase in lumen volume ( + 1 %). In contrast, in patients without statin 
therapy, the increa.Se in plaque volume was associated with a decrease in vessel 
volume (-2%), resulting in a decrease in lumen volume (-4%). Despite the 
non -significant nature of this retrospective observation, this small IVUS study 
generates the hypothesis that statin therapy may contribute to superior 
long-term lumen dimensions by inducing positive vascular remodeling. 
Chapter 10 presents an IVUS study aimed at determining the effect of 1-year 
treatment with statin therapy in 17 patients with obstructive femoropopliteal 
artery disease. Intravascular ultrasound investigation was performed 
immediately after PTA and at 1-year follow-up. Corresponding IVUS images 
obtained ftom the treated site were analyzed for the change in lumen, vessel 
and plaque area at 1-yearfollow-up; a comparison was made between patients 
with statin therapy (n=6) and without statin therapy (n= 11). In this study area 
measurements, rather than volume measurements, were performed since the 
automated contour analysis system is unable to determine lumen dimensions 
after PTA, due to the presence of dissections. After PTA no difference in 
lumen, vessel and plaque area between both groups of patients was 
encountered. However, at follow-up a significant difference between both 
groups of patients in lumen area change and a borderline significant difference 
in vessel area change was seen; in patients with statin therapy a lumen area 
decrease (-4%) and a vessel area increase (+4%) was seen, whereas in patients 
without statin therapy, lumen and vessel area decreased (-25% and -2%, 
respectively). There was no difference in plaque area change at follow-up (14% 
and 15%, respectively). This IVUS study shows that plaque growth is a 
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universal response after PTA regardless of the use of statin therapy; statin 
therapy has the potential to induce positive vascular remodeling, thereby 
reducing the occurrence of restenosis. 
Chaper 11 describes a prospective randomized IVUS study designed to assess 
the dose-dependent effect of statin therapy on both plaque growth and 
vascular remodeling. Recendy, this study was canceled due to a patient intake 
that was too slow. The original study design was as follows: 50 patients with 
symptomatic obstructive vascular disease eligible for PTA and/ or stent 
placement in the common Uiac artery would be included. Patients would be 
randomized to 1-year treatment with either 10 mg atorvastatin or 80 mg 
atorvastatin daily. Intravascular ultrasound investigation would be performed 
immediately after successful PTA and/ or stent placement in the common iliac 
artery and at 1-year follow-up. Both the treated common iliac artery and the 
untreated external iliac artery would be documented using IVUS. Analysis of 
the common iliac artery would reveal the dose-dependent effect of statin 
therapy on the prevention of restenosis. Analysis of the external iliac artery 
would elucidate the dose-dependent effect of statin therapy on the progression 
of atherosclerosis and vascular remodeling, without the side-effects of an 
intervention. 
In conclusion, the IVUS studies in this thesis contributed to the knowledge 
and understanding of the mechanism of action of several new treatment 
modalities for patients with obstructive disease of the femoropopliteal artery. 
The studies showed that vascular remodeling, besides plaque growth, is an 
important factor that determines the change in lumen dimension at 
follow-up. 
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In het afgelopen decennium zijn verschillende nieuwe methodes ontwikkeld 
voor de behandeling van patienten met obsrructief vaatlijden van de arteria 
femoralis superficialis. Dit proefschrift beschrijft de effecten van endografts, 
endovasculaire bestraling en behandeling met een statine op de progressie van 
atherosclerose, en in het bijzonder op veranderingen van de vaarwand, zeals 
gedocumenteerd met intravasculaire echografie (IVUS). 
Bovendien is de rol van IVUS voor het uitvoeren van wetenschappelijk 
onderzoek van door atherosclerose aangetaste bloedvaten beschreven. 
Endografts 
Hoofdstuk 2 beschrijft een IVUS-studie waarin 12 patienten met obstructief 
vaatlijden van een lang segment van de arteria femoralis superficialis behandeld 
werden met een nieuw ontworpen polytetrafluoroethylene (ePTFE) endograft. 
Deze patienten werden onderzocht met IVUS direct na het plaatsen van de 
endograft en na 6 maanden follow-up. Corresponderende IVUS-beelden 
verkregen van de endograft, het overgangsgebied naar het oorspronkelijke 
bloedvat en een referentie vaatsegmentwerden geanalyseerd om te bepalen in 
hoeverre veranderingen hadden plaatsgevonden in lumen-, vaatwand- en 
plaque-oppervlak na 6 maanden. Het bleek dat de veranderingen in 
lumen-oppervlak zowel in de endograft (+3%) als in het referentie segment 
(+6%) minimaal waren. Daarentegen werd een duidelijke toename van het 
lumen-oppervlak ( +85%) gezien in het overgangsgebied. Deze toenamewas het 
netto resultaatvan een toename in hetvaatwand-oppervlak ( +42%), terwijl de 
toename in het oppervlak van de atherosclerotische plaque ( + 15%) gering was. 
Deze stu die toont aan dat ondanks toename van een atherosclerotische plaque 
in het overgangsgebied van een ePTFE endograft, het lumen toe kan nemen 
door het optreden van, watgenoemd wordt, "positiefvaatwand remodelleren". 
Hoofdstuk 3 beschrijft de lange termijn resultaten na plaatsing van een ePTFE 
endograft. In deze studie was het mogelijk de IVUS-procedure 2 jaar na 
plaatsing van de endograft in 5 van de 12 patienten te herhalen. De 
veranderingen in oppervlakte metingen tussen 6 maanden en 2 jaar follow-up 
werden geanalyseerd en vervolgens vergeleken met de veranderingen die waren 
opgetreden na de eerste 6 maanden follow-up. In de endograft zelf was de 
verandering van het lumen-oppervlak tijdens de tweede follow-up periode 
minimaal ( + 1 %), net zeals gezien werd na de eerste follow-up period e. 
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Daarentegen werd in het overgangsgebied naar het oorspronkelijke bloedvat 
een toename in het lumen-oppervlak gezien ( +8%), gepaard gaande met een 
toename in het vaatwand-oppervlak (+6%) terwijl het oppervlak van de 
atherosclerotische plaque niet was veranderd. Deze veranderingen in lumen-
en vaatwand -oppervlak waren vee! kleiner dan de veranderingen die waren 
opgetreden na de eerste 6 maanden follow-up. Deze stu die laat zien dat na het 
plaatsen van een ePTFE endograft 1) geen plaquegroei plaatsvindt binnen de 
endograft en de vaatkrimp, die traditioneel gezien wordt als mede oorzaak van 
een restenose, niet optreedt, en 2) plaquegroei en vaatwand remodelleren in 
het overgangsgebied van endograft naar oorspronkelijk bloedvat, gezien na de 
eerste 6 maanden follow-up, zich lijkt te stabiliseren op de lange termijn. 
Hoofdstuk 4 beschrijft een multicenter stu die naar de klinische lange termijn 
resultaten van ePTFE endograft-plaatsing. In totaal waren 89 patienten met 
obstructief vaatlijden van een lang segment van de arteria femoralis 
superficialis behandeld met een ePTFE endograft (gemiddelde lengte 29 em); 
7 patienten werden behandeld voor een hoog-gradige stenose van het bloedvat 
(gemiddelde lengre 9 em) en 82 patienten werden behandeld voor een occlusie 
van het bloedvat (gemiddelde lengre 19 em). Vroeg falen van de endograftwerd 
gezien in 7 van de 89 behandelde patienten: bij deze patienten was een acute 
occlusie van de endograft opgetreden binnen 30 dagen na plaatsing. Deze 7 
patienten werden vervolgens behandeld met bypass-chirurgie. Bij 4 2 patienten 
bleef de endograft open gedurende de gehele follow-up periode. Bij de 
resterende 40 patienten trad een late acute occlusie van de endograft op 
(mediaan 7 maanden). Deze patienten werden behandeld met bypass-chirurgie 
(n=9), werden conservatief vervolgd (n=S) of werden succesvol behandeld met 
fibrinolyse (n=26). In 18 van de 26 patienten die succesvol behandeld werden 
met fibrinolyse trad in een later stadium her-occlusie van de endograft op. 
Vier van deze 18 patienten werden opnieuw succesvol behandeld met 
fibrinolyse. De overige 14 patienten werden behandeld met bypass-chirurgie 
(n=8), onderbeens-amputatie (n=2) of erwerd een conservatiefbeleid gevolgd 
(n=4). De primaire en secundaire doorgankelijkheids-percentages na ePTFE 
endograft plaatsing waren respectievelijk 71% en 83% na 6 maanden 
follow-up, 57% en 69% na 1 jaar follow-up, 45% en 49% na 2 jaar follow-up 
en 30% en 44% na 3 jaar follow-up. Deze studie toont aan dat het succes van 
ePTFE endograft plaatsing beperkt is door het optreden van acute occlusies van 
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de endograft. Er kan gesteld worden dat verbeteringen van de endograft 
noodzakelijk zijn als deze nieuwe, minimaal-invasieve, techniek wil 
concurreren met conventionele bypass chirurgie. 
Endovasculaire bestraling 
Hoofdstuk 5 beschrijfteengerandomiseerde IVUS-studiewaarin 24 patienten 
met obstructief vaatlijden van de arteria femoralis superficialis behandeld 
werden middels een Dotterprocedure met of zonder endovasculaire besttaling 
(Endovasculaire Brachy Therapie, EBT). Deze patienten werden onderzocht met 
IVUS direct na de Dotterprocedure en na 6 maanden follow-up. 
Corresponderende IVUS-beelden verkregen van zowel het behandelde als een 
onbehandeld vaatsegment werden geanalyseerd met bettekking tot de 
veranderingen in het oppervlak van lumen, vaatwand en atherosclerotische 
plaque die na 6 maanden hadden plaatsgevonden. Vervolgens werd er een 
vergelijking gemaakt tussen patienten zonder EBT (n=16) en patienten met 
EBT (n=8).ln hetonbehandeldevaatsegmentwerden na 6 maanden follow-up 
met IVUS geen verschillen gezien tussen de 2 groepen patienten in de 
veranderingen die plaatsvonden in het lumen-, vaatwand- en 
plaque-oppervlak. Daarentegen werd in het behandelde vaatsegment een 
statistisch significant verschil gevonden tussen patienten zonder en met EBT 
in de verandering van het lumen-oppervlak (-9% en +23%, respectievelijk): 
Dit verschil was het resultaat van een significantverschil in de verandering van 
het vaatwand-oppervlak (+2% en+ 19%, respectievelijk). In beide groepen 
patienten was de toename van de atherosclerotische plaque even groot ( + 12% 
en + 16%, respectievelijk). Deze studie toont dat EBT direct na een 
Dotterprocedure in de arteria femoralis superficialis een positief effect heeft op 
lumen dimensies na 6 maanden door het induceren van positief vaatwand 
remodelleren. 
Intravasculaire echografie voor wetenschappelijk onderzoek 
Na de introductie van IVUS eind jaren '80, werd geopperd dat deze techniek 
gebruikt kon worden om het effect van een farmacologische behandeling op 
de progressie/regressie van atherosclerotische plaques te onderzoeken. Echter, 
om zowel lokale als diffuse effecten van een farmacologische behandeling te 
onderzoeken werd aangenomen datvolume-metingen noodzakelijkwaren. Om 
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volullle-Dletingen n1ogelijk te n1aken werd een automatisch contour-analyse 
systeem ontwikkeld, waarmee een drie-dimensionale (3-D) reconstructie van 
het bloedvat gen1aakt kon worden. Om bovendien het effect van een 
farmacologische behandeling op de compositie van de atherosclerotische 
plaque, met name de hoeveelheid kalk, te onderzoeken, werd een methode 
ontwikkeld om de hoeveelheid kalk in IVUS-beelden te kwantificeren en in 
de tijd te vervolgen. 
Hoofdstuk 6 beschrijft een IVUS-studie waarin de reproduceerbaarheid van 
lumen-, vaatwand- en plaque-volume, verkregen met het automatische 
contour-analyse systeen1, werd onderzocht. Voor deze studie werden de 
analyses uitgevoerd 1) door twee onderzoekers om de interobserver 
reproduceerbaarheid van volume-metingen te bepalen en 2) in twee series 
IVUS-beelden om de reproduceerbaarheid van de metingen binnen hetzelfde 
bloedvat te bepalen. Van 15 n1et IVUS onderzochte patienten werd een 
corresponderend onbehandeld vaatsegrnent (3 tot 4 em lang) gebruikt voor de 
analyse van lun1en-, vaatwand- en plaque-volume. De resultaten van deze 
IVUS-studie lieten zien dat volume-metingen reproduceerbaar zij. De 
verschillen in volume-metingen verkregen door de twee onderzoekers waren 
,;0,4%, met lage variatiecoefficienten (,; 1, 7%) en hoge correlatiecoefficienten 
(r=1,00). Deverschillen in volume-metingen verkregen in hetzelfde bloedvat 
waren ,;2,6%, met lage variatiecoefficienten (,;8,6%) en hoge 
correlatiecoefficienten (r=0,97-0,99). De resultaten geven aan dat volume 
metingen verkregen n1et het automatisch contour-analyse systeem 
reproduceerbaar zijn en daarom gebruikt zouden kunnen worden om de 
effecten van een farmacologische behandeling op de vaatwand te onderzoeken 
in een longitudinale studie. 
Hoofdstuk 7 beschrijft een IVUS-studie waarin de reproduceerbaarheid van 
metingen van de hoeveelheid kalk in IVUS-beelden werd onderzocht. 
Daarnaast werd onderzocht in hoeverre de uitgebreidheid van kalk veranderde 
na 1 jaar follow-up. IVUS-beelden van 34 patienten onderzocht voor en 
direct na Dotterbehandeling en na 1 jaar follow-up werden gebruikt voor 
analyse. Voor deze studie werden de analyses uitgevoerd 1) door twee 
onderzoekers Olll de interobserver reproduceerbaarheid van kalkmetingen te 
bepalen en 2) in twee series IVUS-beelden om de reproduceerbaarheid van 
kalkmetingen binnen hetzelfde bloedvatte bepalen. Deverschillen in metingen 
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van de cirkelboog en lengte van de kalk in de axiale vaatrichtingverkregen door 
twee onderzoekers en in twee IVUS-series van hetzelfde bloedvat waren klein 
(:,;1,1 %), met !age variatiecoefficienten (,;5,8%). Na 1 jaar werd een 
niet-significante toename gezien in zowel de cirkelboog (1,9%) en de lengte 
(1, 7%) van kalk. Deze studie toont dat metingen van de cirkelboog en lengte 
van kalk in IVUS-beelden reproduceerbaar zijn; veranderingen na 1 jaar zijn 
niet significant. Er werd geconcludeerd dat IVUS gebruikt kan worden om het 
effect van een medische interventie op de hoeveelheid kalk te onderzoeken in 
een longitudinale studie. 
Hoofdstuk 8 presenteert een IVUS-studie die de progressie van atherosclerose 
na 1 jaar beschrijft met behulp van volume-metingen verkregen met het 
automatisch contour-analyse systeem. In deze studie werden de IVUS-beelden 
van 11 patienten verkregen na een Dorterbehandeling en na 1 jaar follow-up 
geanalyseerd om de veranderingen in het volume van lumen, vaatwand en 
atherosclerotische plaque vast te stellen. Na 1 jaar werd een niet-significante 
toename in lumen-volume (2,3%), vaatwand-volume (2%) en plaque-volume 
(3%) gezien. Deze studie toont aan dat progressie van atherosclerose gepaard 
gaat met een toename van omvang van de vaatwand, wat resulteert in een 
verandering in lumen-volume. Met deze resultaten in het achterhoofd, kan 
gesteld worden datvolumetrische IVUS-studies bij uitstek geschikt zijn om het 
basale mechanisme van zowel de progressie en regressie van de 
atherosclerotische plaque als van vaatwand-remodelleren te documenteren en 
eveneens geschikt zijn om de invloed van farmacologische behandeling op deze 
processen te doorgronden. 
Statine behandeling 
Hoofdstuk 9 beschrijft een retrospectieve stu die waarin bij 10 patienten 
3-D-IVUS gebruiktwerd om het effect van 1 jaar behandeling met een statine 
op onbehandelde vaatsegmenten van de arteria femoralis superficialis te 
documenteren. De patienten waren onderzocht met IVUS direct na een 
Dorterbehandeling en na 1 jaar follow-up. De verkregen IVUS-beelden van 
de niet-geDotterde vaatsegmenten werden geanalyseerd om de veranderingen 
in volume van lumen, vaatwand en atherosclerotische plaque te meten. De 
veranderingen die optraden in patienten met statine behandeling (n=5) en in 
patienten zonder statine behandeling (n=5) werden met elkaar vergeleken. Na 
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1 jaar follow-up bleek dat de toename in plaque-volume in patienten met en 
zonder statine behandelingvergelijkbaarwas ( +4% en+ 2%, respectievelijk).ln 
patienten met statine behandeling werd deze toename in plaque-volume 
gecompenseerd door een toename in vaatwand-volume ( + 2%), waardoor het 
lumen-volume grater werd ( + 1 %). Daarentegen werd er in patienten zonder 
statine behandeling een afname in vaatwand-volume (-2%) gezien, waardoor 
het lumen-volume kleiner werd (-4%). Alhoewel de verschillen tussen beide 
groepen patienten statistisch niet significant waren, genereert deze kleine 
retrospectieve IVUS-studie de hypothese dat statine behandeling bijdraagt aan 
betere lange termijn lumen-dimensies door het induceren van positief 
vaatwand -remodelleren. 
Hoofdstuk 10 beschrijft een IVUS-studie naar het effect van 1 jaar statine 
behandeling in 17 patienten na een Dotterbehandeling voor obstructief 
vaatlijden van de arteria femoralis superficialis. In deze studie werden 
oppervlakte-metingen verricht in plaats van volume-metingen, omdat het 
automatische contour-analyse systeem niet in staat is lumen-dimensies te 
bepalen in de aanwezigheid van een dissectie die het gevolg is van de 
Dotterbehandeling. De IVUS-onderzoeken waren verricht direct na de 
Dotterbehandeling en na 1 jaar follow-up. Corresponderende IVUS-beelden 
van het geDotterde vaatsegment werden geanalyseerd voor de veranderingen 
in het oppervlak van lumen, vaatwand en atherosclerotische plaque na 1 jaar 
follow-up; de veranderingen gezien in patienten met statine behandeling (n=6) 
en patienten zonder statine behandeling (n= 11) werden met elkaarvergeleken. 
Na de Dotterbehandeling waren er geen verschillen in het oppervlak van 
lumen, vaatwand en plaque tussen beide groepen patienten. Echter, na 1 jaar 
werd er een significant verschil in de verandering van het lumen-oppervlak en 
een borderline significant verschil in de verandering van het 
vaatwand -oppervlak gezien; in patienten met statine behandeling werd een 
afname in het lumen-oppervlak (-4%) en een toename in het 
vaatwand-oppervlak ( +4%) gezien. Daarentegen werd in patienten zonder 
statine behandeling een afname in zowel het lumen-oppervlak als het 
vaatwand-oppervlak gezien (-25% en -2%, respectievelijk). Er werd geen 
verschil gezien tussen beide groepen patienten in de verandering van het 
plaque-oppervlak ( + 14% en + 15%, respectievelijk). Deze IVUS-studie toont 
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aan dat plaquegroei een universele response is na een Dotterbehandeling, 
ongeacht een behandeling met statines; statine behandeling heeft de potentie 
om positief vaatwand-remodelleren te stimuleren en heeft daardoor invloed 
op het voorkomen van restenose. 
Hoofdstuk 11 beschrijft een prospectief gerandomiseerde IVUS-studie die 
ontworpen was om het dosis-afhankelijke effect van statine behandeling op 
zowel plaquegroei als vaatwand-remodelleren te onderzoeken. Onlangs is deze 
studie gestopt, omdat de intake van patienten voor deze stu die te gering was. 
Ret originele antwerp van de studie was als volgr: 50 patienten met 
symptomatisch obstructief vaatlijden in aanmerking komend voor een 
Dotterbehandeling en/ of stentplaatsingvan de arteria iliaca communis zouden 
geincludeerd worden. Patienten zouden gerandomiseerd worden voor 1 jaar 
behandeling met ofwel 10 mg Atorvastatine, ofwel 80 mg Atorvastatine. 
Inttavasculaire echografie onderzoeken zouden gedaan worden direct na een 
succesvolle Dotterbehandeling en/ of stentplaatsing en na 1 jaar follow-up. 
Zowel de behandelde arteria iliaca communis als de onbehandelde arteria iliaca 
externa zouden met IVUS worden onderzocht. Onderzoek van de arteria iliaca 
communis zou het dosis-afhankelijke effect van statine behandeling ter 
preventie van restenose onthullen. Onderzoek van de arteria iliaca externa zou 
het dosis-afhankelijke effect van statine behandeling op de progressie van 
atherosclerose en vaatwand-remodelleren onthullen, zonder de bijeffecten van 
de vasculaire interventie. 
Samenvattend kan gesteld worden dat de IVUS-studies die in dit 
proefschrift zijn beschreven hebben bijgedragen aan de kennis van 
verschillende nieuwe behandelingsmethodes voor patienten met obstructief 
vaatlijden van de arteria femoralis superficialis. De studies tonen aan dat bij 
follow-upvaatwand-remodelleren, naastplaquegroei, een belangrijke factor 
is voor de verandering in lumen-dimensies. 
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1998- 2001 
2001- heden 
Onderwerp: lmplantatie van een ePTFE endograft in de 
arteria femoralis superficialis. 
Begeleider: Dr. E.J. Gussenhoven. 
Wetenschappelijk onderzoeker Afdeling Experimentele 
Echocardiografie, Erasmus Universiteit Rotterdam. 
Onderwerp: Vaatwandremodelleren na endovasculaire 
behandeling van perifeer vaatlijden. 
Begeleider: Dr. E.]. Gussenhoven. 
Co-assistentschappen geneeskunde. 
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